Therapeutic agents and methods of use
A gene therapy system with multiple therapeutic agents and tailored delivery mechanisms addresses the challenges of treatment-resistant cancers by modulating the tumor microenvironment and enhancing immune response and tumor lysis, improving treatment efficacy.
Patent Information
- Application Number
- PCT/US2026/028518
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-15
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
Current cancer treatments, particularly for resistant types such as pancreatic, head and neck, breast, melanoma, and prostate cancer, face challenges in achieving optimal clinical outcomes due to heterogeneous tumor microenvironments and treatment resistance, necessitating improved multimodal therapies.
A gene therapy system comprising multiple therapeutic agents, including immune checkpoint blockers, antigen release agents, dendritic cell recruiters, and tumor lysis agents, is delivered using various vectors to target distinct anti-tumor activities through a combination of immediate and delayed promoters and non-native secretory signal peptides to enhance tumor-specific expression and secretion.
The system effectively modulates the tumor microenvironment, enhancing immune response and tumor lysis, thereby improving treatment efficacy against treatment-resistant cancers.
Smart Images

Figure US2026028518_19112026_PF_FP_ABST
Abstract
Description
[0001] Attorney Docket No: FTE-00125
[0002] THERAPEUTIC AGENTS AND METHODS OF USE
[0003] CROSS-REFERENCE TO RELATED APPLICATIONS
[0004] This application claims the benefit of U. S. Provisional Application No. 63 / 806,542, filed on May 15, 2025, and of U. S. Provisional Application No. 64 / 067,090, filed on May 15, 2026, the entire contents of each of which are incorporated by reference herein in their entirety.
[0005] REFERENCE TO ELECTRONIC SEQUENCE LISTING
[0006] The application contains a Sequence Listing which has been submitted electronically in. XML format and is hereby incorporated by reference in its entirety. Said. XML copy, created on May 14, 2026, is named “FTE00125_SL” and is 1,573,134 bytes in size. The sequence listing contained in this. XML file is part of the specification and is hereby incorporated by reference herein in its entirety.
[0007] BACKGROUND
[0008] Cancer is a complex and multifaceted disease which can impact almost any tissue in the body. The heterogeneous tumor microenvironment complicates the treatment options available for therapy. Combating primary localized disease may also require different treatment regimens than metastatic or recurrent cancer which develops resistance to available therapies.
[0009] Multimodal therapies are used in cancer treatments by combining one or more treatment options. This can include combinations of chemotherapy, radiation, and surgery. Physicians also attempt to combine treatments to target different pathways and facets of the tumor microenvironment to achieve synergistic effects for better outcomes. There remains a need for optimized cancer treatments and multimodal treatment regimens to achieve best clinical outcomes. Even more, certain cancer types such as pancreatic, head and neck, breast, melanoma, and prostate cancer are particularly resistant to multimodal approaches leading to poor survival rates for patients. There remains a need for cancer treatments targeting treatment-resistant cancers.
[0010] BRIEF SUMMARY OF THE INVENTION
[0011] 1
[0012] FH30035011.1
[0013] Attorney Docket No: FTE-00125
[0014] In some aspects, provided herein is a gene therapy (or a vector system) comprising one or more isolated nucleic acid molecules encoding two or more therapeutic agents, wherein the two or more therapeutic agents are selected from the two or more of:
[0015] (i) an immune checkpoint blocker agent;
[0016] (ii) an agent facilitating antigen release and / or tumor lysis;
[0017] (iii) an agent facilitating recruitment of dendritic cells;
[0018] (iv) an agent facilitating recruitment of T cells and / or NK cells;
[0019] (v) an agent facilitating expansion and / or activation of antigen-presenting cells;
[0020] (vi) an agent facilitating expansion, activation, survival, and / or anti-exhaustion signaling of T cells and / or NK cells;
[0021] (vii) an agent facilitating co-stimulatory receptor agonism;
[0022] (viii) an agent facilitating depletion and / or functional attenuation of regulatory T cells;
[0023] (ix) an agent facilitating neutralization of TGF-P and / or reversal of stromal immune exclusion; and
[0024] (x) an agent facilitating induction of tertiary lymphoid structures and / or high endothelial venules;
[0025] wherein one or more, or each, of the two or more therapeutic agents is capable of being secreted from a target cell, optionally wherein one or more of the two or more therapeutic agents comprises a non-native secretory signal peptide; and / or
[0026] wherein at least one of the therapeutic agents is a fusion protein comprising two or more therapeutic proteins, optionally, each separated by a protease cleavage site; and / or
[0027] wherein one or more of the two or more therapeutic agents is expressed under the control of an immediate promoter (such as a tumor- specific promoter or a constitutive or ubiquitous promoter) and one or more of the two or more therapeutic agents is expressed under the control of a delayed promoter (such as a promoter that does not become active immediately upon administration of the gene therapy or becomes active after the expression and secretion of the one or more therapeutic agents under the control of the immediate promoter).
[0028] In some aspects, provided herein is a gene therapy or vector system for treating cancer or inhibiting tumor growth, comprising one or more delivery vehicles comprising one or more polynucleotides, wherein the one or more delivery vehicles comprise a DNA plasmid, linear DNA, electroporated DNA, a lipid nanoparticle-encapsulated DNA or RNA, a viral vector, a
[0029] 2
[0030] FH30035011.1
[0031] Attorney Docket No: FTE-00125 replication-competent viral vector, a non-replicating viral vector, a helper-dependent adenoviral vector, a self- amplifying RNA, a nucleoside-modified RNA, or any combination thereof; wherein the one or more polynucleotides comprise one or more transcriptional control regions selected from tumor- selective promoters or enhancers, immune-activation-responsive promoters or enhancers, and constitutive or ubiquitous promoters or enhancers, operably linked to one or more coding regions encoding at least four therapeutic agents;
[0032] wherein the at least three or four therapeutic agents collectively provide at least three or four distinct anti-tumor activities selected from:
[0033] (i) immune checkpoint blockade;
[0034] (ii) antigen release and / or tumor lysis;
[0035] (iii) recruitment of dendritic cells or other antigen-presenting cells;
[0036] (iv) recruitment of T cells and / or NK cells;
[0037] (v) expansion and / or activation of antigen-presenting cells;
[0038] (vi) expansion, activation, survival, and / or anti-exhaustion signaling of T cells and / or NK cells;
[0039] (vii) co- stimulatory receptor agonism;
[0040] (viii) depletion and / or functional attenuation of regulatory T cells;
[0041] (ix) neutralization of TGFp and / or reversal of stromal immune exclusion; and
[0042] (x) induction of tertiary lymphoid structures and / or high endothelial venules;
[0043] wherein at least three of the therapeutic agents are engineered for secretion from a tumor cell or a cell in the tumor microenvironment;
[0044] wherein at least one of the therapeutic agents comprises a non-native secretory signal peptide; and
[0045] wherein the coding regions are arranged as one or more individual open reading frames, one or more fusion open reading frames, one or more polycistronic cassettes comprising coding sequences separated by a ribosome-skipping peptide, an internal ribosome entry site, or both, or any combination thereof.
[0046] In some embodiments, one of the at least three or four distinct anti-tumor activities is antigen release and / or tumor lysis, and wherein at least one of the therapeutic agents is a tumor lysis agent engineered to be secreted from a tumor cell or a cell in the tumor microenvironment.
[0047] In some embodiments, the one or more polynucleotides are comprised in 1, 2, 3, or 4 delivery vehicles. In some embodiments, the one or more polynucleotides are comprised in no
[0048] 3
[0049] FH30035011.1
[0050] Attorney Docket No: FTE-00125 more than 2 delivery vehicles. In some embodiments, the one or more polynucleotides comprise 1, 2, 3, or 4 transcriptional control regions in a single vector. In some embodiments, the one or more polynucleotides comprise no more than 3 transcriptional control regions in a single vector.
[0051] In some aspects, provided herein is a gene therapy or vector system comprising one or more polynucleotides comprising:
[0052] (a) a first expression cassette comprising an immediate transcriptional control region operably linked to a nucleic acid sequence encoding one or more early therapeutic agents, wherein the immediate transcriptional control region comprises a tumor- selective promoter, a tumor- selective enhancer, a constitutive promoter, or a ubiquitous promoter; and
[0053] (b) a second expression cassette comprising a delayed transcriptional control region operably linked to a nucleic acid sequence encoding one or more delayed therapeutic agents, wherein the delayed transcriptional control region comprises an immune-activation-responsive promoter or enhancer that is activated following immune activation, interferon signaling, STAT1 signaling, IRF1 signaling, NF-KB signaling, or infiltration of immune effector cells in a tumor microenvironment;
[0054] wherein the one or more early therapeutic agents comprise one or more agents that recruit or activate antigen-presenting cells, recruit T cells or NK cells, reverse immunosuppression, neutralize TGFp, inhibit CTLA4, induce tertiary lymphoid structures or high endothelial venules, or activate IL-12 signaling; and
[0055] wherein the one or more delayed therapeutic agents comprise one or more agents that inhibit PD-1 or PD-L1, agonize CD40, 4- IBB, 0X40, GITR, or CD27, promote T-cell or NK-cell survival, promote IL-15, IL-21, IL-7, or IL-18 signaling, or induce tumor lysis or tumor antigen release.
[0056] In some embodiments, the first expression cassette is controlled by a promoter comprising an Androgen Response element containing promoter and / or enhancer, such as that of PSA or PSMA, an Estrogen Response Element containing promoter, a C-Myc containing promoter, a HER2 promoter, an EGFR promoter, CMV promoter, SV40 promoter, or an EFla promoter. In some embodiments the second expression cassette is controlled by a promoter comprising elements responsive to STAT1, STAT2, or STAT3, optionally a synthetic GAS element containing promoter, such as pGAS, CIITA pIV, wild type or modified PDL1 promoter, or CXCL10 promoter.
[0057] 4
[0058] FH30035011.1
[0059] Attorney Docket No: FTE-00125
[0060] In some embodiments, the first expression cassette is controlled by PSAEnhl promoter described herein. In some embodiments the second expression cassette is controlled by a pGAS promoter or a GAS-element-containing promoter, e.g., pGAS promoter or CIITA pIV promoter.
[0061] In some embodiments, the gene therapy or vector system further comprises a third expression cassette comprising a second delayed transcriptional control region operably linked to a nucleic acid sequence encoding one or more therapeutic agents, wherein:
[0062] (i) the first expression cassette is controlled by a tumor- selective or ubiquitous promoter, optionally wherein the first expression cassette is controlled by Androgen Response element containing promoter, such as PSA or PSMA, an Estrogen Response Element containing promoter, a C-Myc containing promoter, a HER2 promoter, an EGFR promoter, CMV promoter, SV40 promoter, or EFla promoter;
[0063] (ii) the second expression cassette is controlled by promoter containing elements responsive to STAT1, STAT2, or STAT3, optionally a synthetic GAS element containing promoter; and
[0064] (iii) the third expression cassette is controlled by a leaky promoter or a promoter that further delays the expression relation to the promoter in (i) and (ii), optionally CIITA pIV promoter; wherein the second and third expression cassettes are activated at different stages of immune activation in the tumor microenvironment.
[0065] In some embodiments, the first expression cassette is controlled by PSA Enhl promoter. In some embodiments the second expression cassette is controlled by a pGAS promoter or a GAS-element-containing promoter, e.g., pGAS promoter. In some embodiments, the third expression cassette is controlled by CIITA pIV promoter.
[0066] In some embodiments, (a) the first expression cassette encodes one or more of XCL1, FLT3L, CXCL9, IL- 12, anti-CTLA4 scFv-Fc, a TGFp trap, sctriLIGHT, sctriGITRL, sctriOX40L, IL-7, or a fusion thereof;
[0067] (b) the second expression cassette encodes one or more of a tumor lysis agent, anti-PD-1 blockade, anti-PD-Ll blockade, a CD40 agonist, IL- 12, IL-7, or a fusion thereof; and
[0068] (c) the third expression cassette encodes one or more of IL-15, IL-21, IL-7, a 4-1BB agonist, an 0X40 agonist, a tumor lysis agent, anti-PD-1 blockade, anti-PD-Ll blockade, or a fusion thereof.
[0069] In some embodiments, the immediate transcriptional control region comprises PSAEnhl and / or the delayed transcriptional control region comprises pGAS or CIITA pIV.
[0070] 5
[0071] FH30035011.1
[0072] Attorney Docket No: FTE-00125
[0073] In some embodiments, the immediate promoter drives expression of XCL1-FLT3L, anti-CTLA4-Fc, TGFp trap-sctriLIGHT, and CXCL9-IL12V4, and / or the delayed promoter drives expression of anti-PD-L1-Hinge-CH3-sctriCD40L, IL21-furin-sIL15, and a tumor lysis agent.
[0074] In some aspects, provided herein is a gene therapy or vector system for inducing tumor antigen release from a tumor, comprising one or more polynucleotides encoding a tumor lysis agent, wherein the tumor lysis agent is engineered for secretion from a tumor cell or a cell in a tumor microenvironment following intratumoral, peritumoral, or local administration of the gene therapy, and wherein the secreted tumor lysis agent induces pore formation, antibody-dependent cellular cytotoxicity, complement activation, opsonization, apoptosis, tumor cell lysis, immunogenic cell death, release of tumor antigens, or any combination thereof;
[0075] optionally, wherein expression, secretion, or activity of the tumor lysis agent is tuned by one or more of: promoter selection, delayed promoter activation, cassette order, placement downstream of a 2A peptide, placement downstream of an internal ribosome entry site, replacement of a native secretory signal peptide with a non-native secretory signal peptide, use of a TPA signal peptide, use of a PSA signal peptide, or use of a protease- activation sequence.
[0076] In some embodiments, the tumor lysis agent is or comprises a pore-forming protein, a protease- activated pore-forming protein, a toxin, a protease- activated toxin, a tumor-targeting antibody or antigen-binding fragment fused to an Fc domain, a tumor-targeting scFv-Fc, a bispecific tumor-targeting T-cell engager, a complement-activating molecule, or an apoptosisinducing molecule. In some embodiments, the tumor lysis agent is or comprises PRX302, a PRX302 variant, a protease-activated pore-forming toxin, a parasporin, a Clostridium perfringens enterotoxin or fragment thereof, a tumor-targeting scFv-Fc, an anti-B7-H3 scFv-Fc, an anti-PSMA scFv-Fc, an anti-HER2 scFv-Fc, an anti-EGFR scFv-Fc, an anti-STEAPl scFV-Fc, an anti-KEK2 scFV-Fc, or a variant thereof. In some embodiments, the tumor lysis agent is activated by a tumor-associated protease or tumor-enriched protease. In some embodiments, the tumor lysis agent comprises a non-native secretory signal peptide, optionally wherein the nonnative secretory signal is PSA or tissue plasminogen activator signal peptide (TPA). In some embodiments, the tumor lysis agent is positioned downstream of IRES or T2A (optionally wherein the tumor lysis agent is or comprises PRX302 or anti-B7-H3 scFv-Fc). In some embodiments, the tumor lysis agent is positioned downstream of T2A. In some embodiments, the coding region encoding the tumor lysis agent is operably linked to a delayed promoter, optionally
[0077] 6
[0078] FH30035011.1
[0079] Attorney Docket No: FTE-00125 wherein the delayed promoter is a synthetic promoter containing at least one GAS response element, such as pGAS, CIITA pIV, PDL1 promoter, or CXCL10 promoter. In some embodiments, the coding region encoding the tumor lysis agent is operably linked to a delayed promoter, optionally wherein the delayed promoter is pGAS or CIITA pIV.
[0080] In some embodiments, the one or more polynucleotides are configured to cause a transfected or transduced tumor cell to secrete one or more immunomodulatory therapeutic agents before producing, secreting, activating, or expressing a tumor lysis agent. In some embodiments, the delayed expression or attenuated expression of the tumor lysis agent preserves the transfected or transduced tumor cell as a local producer of one or more immunomodulatory therapeutic agents before tumor lysis or antigen release.
[0081] In some embodiments, the gene therapy comprises a non-replicating or helper-dependent viral vector configured to express the therapeutic agents without requiring viral replication-mediated lysis of the transduced tumor cell.
[0082] In some aspects, provided herein is a gene therapy comprising a polynucleotide encoding an engineered therapeutic protein, wherein the engineered therapeutic protein comprises a nonnative secretory signal peptide that replaces a native secretory signal peptide or is added to a protein that does not naturally comprise a secretory signal peptide, wherein the non-native secretory signal peptide is configured to increase expression, secretion, or both, of the engineered therapeutic protein from a tumor cell or a cell in a tumor microenvironment. In some aspects, provided herein is a gene therapy comprising a nucleic acid sequence encoding an engineered therapeutic protein, wherein the engineered therapeutic protein is engineered to be secreted from a target cell or cells, wherein the engineered therapeutic protein comprises a non-native secretory signal peptide processed and cleaved by the endoplasmic reticulum, and wherein the non-native secretory signal peptide is (i) a TPA signal peptide or (ii) a native secretory signal peptide of an endogenous protein expressed by and secreted from the target cell or cells, optionally wherein the endogenous protein is specifically expressed by the target cell or cells and not substantially expressed by or secreted from other, non-target cell or cells. In some embodiments, the non-native secretory signal peptide is or comprises a TPA signal peptide, a modified TPA signal peptide, an IGK signal peptide, an IL2 signal peptide, a PSA signal peptide, an HSA signal peptide, a Gaussia luciferase signal peptide, or a variant thereof. In some embodiments, the non-native secretory signal peptide is or comprises a TPA signal peptide or a modified TPA signal
[0083] 7
[0084] FH30035011.1
[0085] Attorney Docket No: FTE-00125 peptide. In some embodiments, the engineered therapeutic protein is an antibody, antibody fragment, scFv-Fc, cytokine, chemokine, TNFSF ligand, TGFp trap, tumor lysis agent, poreforming protein, protease-activated toxin, single-chain IL- 12, IL- 15 fusion, or any fusion thereof. In some embodiments, the gene therapy encodes two or more therapeutic agents comprising the same secretory signal peptide amino acid sequence encoded by different nucleic acid sequences to reduce homologous recombination.
[0086] In some aspects, provided herein is a gene therapy comprising one or more isolated nucleic acid molecules encoding two or more therapeutic agents, wherein the two or more therapeutic agents are selected from at least two of the following:
[0087] (i) an immune checkpoint inhibitor;
[0088] (ii) a chemokine;
[0089] (iii) a cytokine;
[0090] (iv) a co-stimulatory ligand (optionally, a TNFSF protein or a variant thereof or a TNFRSF agonist);
[0091] (v) a TGF-P trap; and
[0092] (vi) a tumor antigen release or tumor lysis agent;
[0093] wherein the at least one of the therapeutic agents is expressed under the control of an immediate promoter and at least one of the therapeutic agents is expressed under the control of a delayed promoter; and / or
[0094] wherein at least one of the therapeutic agents is a fusion protein comprising two or more therapeutic proteins, optionally, each separated by a proteolytic cleavage site; and / or wherein one or more, or each, of the two or more therapeutic agents is capable of being secreted from a target cell, optionally wherein one or more of the two or more therapeutic agents comprises a non-native secretory signal peptide. In some embodiments, the two or more therapeutic agents are at least three, four, five or six therapeutic agents selected from three, four, five or six of items (i) to (vi). In some embodiments, the two or more therapeutic agents comprise therapeutic agents (i), (ii), (iii) and (iv), and optionally further comprises the tumor antigen release or tumor lysis agent. In some embodiments, the tumor antigen release or tumor lysis agent comprises a non-native secretory signal peptide, optionally wherein the non-native secretory signal peptide is a TPA secretory signal peptide, PSA secretory signal peptide, or a variant of any thereof.
[0095] 8
[0096] FH30035011.1
[0097] Attorney Docket No: FTE-00125
[0098] In some aspects, provided herein is a gene therapy comprising one or more isolated nucleic acid molecules encoding two or more therapeutic agents, wherein the two or more therapeutic agents are selected from at least two of the following:
[0099] (i) an immune checkpoint inhibitor molecule, optionally wherein the immune checkpoint inhibitor molecule comprises an antibody antigen binding fragment or scFv that specifically binds to PD-1 or PD-L1, and further optionally wherein the immune checkpoint inhibitor molecule is a fusion protein comprising an immune checkpoint inhibitor fused to a TNFSF protein or a variant thereof or a TNFRSF agonist;
[0100] (ii) a TNFSF protein or a variant thereof or a TNFRSF agonist that optionally agonizes CD40, 0X40, 4- IBB, GITR, LIGHT, or CD27;
[0101] (iii) a toxin, an antibody antigen binding fragment or an scFv that specifically binds to a tumor antigen fused to an IgG Fc domain or a variant thereof, a fusion protein comprising an antibody antigen binding fragment or an scFv that specifically binds to a tumor antigen fused to an antigen binding fragment or an scFv that specifically binds to CD3, a transmembrane IgG, or another agent mediating tumor lysis;
[0102] (iv) an antibody antigen binding fragment or an scFv that specifically binds to CTLA4 fused to an IgG Fc domain or a variant thereof, or a fusion protein comprising an antigen binding fragment or an scFv that specifically binds to CTLA4 fused to a TGF-beta trap protein;
[0103] (v) a TGF-beta trapping domain, optionally a fusion protein comprising the TGF- beta trapping domain fused to a TNFSF protein or a variant thereof or a TNFRSF agonist;
[0104] (vi) an IL 12 or a variant thereof, optionally a single chain fusion protein comprising alpha chain of IL 12 fused to a truncated variant of beta chain of IL 12, further optionally comprising a fusion protein comprising an IL 12 or a variant thereof fused to a CXCR3 agonist chemokine, optionally wherein the CXCR3 agonist chemokine is CXCL9, CXCL10 or CXCL11;
[0105] (vii) a CXCR3 agonist chemokine, optionally wherein the CXCR3 agonist chemokine is CXCL9, CXCL10 or CXCL11;
[0106] 9
[0107] FH30035011.1
[0108] Attorney Docket No: FTE-00125
[0109] (viii) at least one of an FLT3 ligand and / or an XCL1 protein, optionally a fusion protein comprising FLT3 ligand fused to XCL1 protein, or a fusion protein comprising at least one of an FLT3 ligand and an XCL1 protein fused to IFN- gamma or TGF-beta trap protein; and
[0110] (ix) a cytokine selected from IL 15 or a variant thereof, IL21, IL7, and IL 18, optionally a fusion protein comprising the cytokine fused to a TNFSF protein or a variant thereof or a TNFRSF agonist;
[0111] wherein the at least one of the therapeutic agents is expressed under the control of an immediate promoter at least one of the therapeutic agents is expressed under the control of a delayed promoter; and / or
[0112] wherein at least one of the therapeutic agents is a fusion protein comprising two or more therapeutic proteins, optionally, each separated by a proteolytic cleavage site; and / or wherein one or more, or each, of the two or more therapeutic agents is capable of being secreted from a target cell, optionally wherein one or more of the two or more therapeutic agents comprises a non-native secretory signal peptide. In some embodiments, the gene therapy comprises three or more therapeutic agents selected from at least three of items (i)-(ix). In some embodiments, the gene therapy comprises four or more therapeutic agents selected from at least four of items (i)-(ix). In some embodiments, the gene therapy comprises five or more therapeutic agents selected from at least five of items (i)-(ix). In some embodiments, the gene therapy comprises six or more therapeutic agents selected from at least six of items (i)-(ix). In some embodiments, the gene therapy comprises seven or more therapeutic agents selected from at least seven, eight or nine of items (i)-(ix).
[0113] In some embodiments, the at least one of the therapeutic agents is expressed under the control of an immediate promoter and at least one of the therapeutic agents is expressed under the control of a delayed promoter; optionally wherein the immediate promoter is a tumor- specific or a ubiquitous promoter, and the delayed promoter is an immune activation sensing promoter (optionally, a pGAS promoter or a CIITA pIV promoter or a variant thereof).
[0114] In some embodiments, at least one of the therapeutic agents is a fusion protein comprising two or more therapeutic proteins, optionally, each separated by a proteolytic cleavage site; wherein the proteolytic cleavage site is a furin cleavage site, a variant thereof, or a site cleaved by a tumor-enriched protease. In some embodiments, one or more, or each, of the two or more therapeutic
[0115] 10
[0116] FH30035011.1
[0117] Attorney Docket No: FTE-00125 agents is engineered to be secreted from a target cell, wherein said engineered therapeutic agent comprises a non-native secretory signal peptide. In some embodiments, the non-native secretory signal peptide is selected from TPA, IGK, IL2, PSA and HSA secretory signal peptides and variants thereof. In some embodiments, the non-native secretory signal peptide is a TPA secretory signal peptide or a variant thereof, optionally wherein the variant is selected from spTPAvA, spTPAvG, spTPAvS, spTPAvAA, spTPAvGA, spTPA2, spTPA3, spTPA4, spTPA5, and spTPA6 as set forth in any of amino acid SEQ ID NOs: 62-68, or the secretory signal peptide is encoded by a nucleic acid sequence set forth in any of SEQ ID NOs: 69-75, or a variant thereof.
[0118] In some embodiments, at least one of the therapeutic agents is an immune checkpoint inhibitor molecule that specifically binds PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, TIGIT, CD47, B7-H3, or EGFR, optionally wherein the immune checkpoint inhibitor molecule comprises an antibody antigen binding fragment or an scFv. In some embodiments, the immune checkpoint inhibitor molecule comprises an antibody antigen binding fragment or scFv that specifically binds to PD-1 or PD-L1.
[0119] In some embodiments, at least one of the therapeutic agents is an immune checkpoint inhibitor molecule that is a fusion protein comprising an immune checkpoint inhibitor fused to a TNFSF protein or a variant thereof or a TNFRSF agonist that agonizes CD40, 0X40, 4- IBB, GITR, or CD27. In some embodiments, the fusion protein comprises an anti-PD-1 scFv or an anti-PD-Ll scFv fused to a CD40 agonist selected from: an agonist anti-CD40 scFv, monomeric CD40L, and single-chain trimeric CD40L, optionally wherein the anti-CD40 scFv comprises the amino acid sequence set forth in SEQ ID NO: 225, the monomeric CD40L comprises the amino acid sequence set forth in SEQ ID NO: 223, and / or the single-chain trimeric CD40L comprises the sequence set forth in SEQ ID NO: 224, or variants thereof. In some embodiments, the fusion protein comprises an anti-PD-1 scFv or an anti-PD-Ll scFv fused to a single-chain trimeric OX40L and / or a single-chain trimeric 4-1BBL, optionally wherein the single-chain trimeric OX40L comprises the amino acid sequence set forth in SEQ ID NO: 253, and / or the single-chain trimeric 4-1BBL comprises the amino acid sequence set forth in SEQ ID NO: 252, or variants thereof.
[0120] In some embodiments, at least one of the therapeutic agents is or comprises a TNFSF protein or a variant thereof or a TNFRSF agonist that agonizes CD40, 0X40, 4- IBB, GITR, or
[0121] 11
[0122] FH30035011.1
[0123] Attorney Docket No: FTE-00125
[0124] CD27. In some embodiments, TNFRSF agonist is an agonistic antibody, antigen binding fragment or scFv that specifically binds CD40, 0X40, 4- IBB, GITR, or CD27; and a TNFSF protein or a variant thereof is an extracellular domain of CD40 ligand, 0X40 ligand, 4- IBB ligand, GITR ligand, or LIGHT ligand. In some embodiments, the TNFSF protein or a variant thereof is an extracellular domain of the TNFSF protein in a single-chain trimeric format selected from sctriCD40L, sctriOX40L, sctri4-lBBL, sctriGITRL, and sctriLIGHT, optionally wherein the TNFSF protein is selected from an amino acid sequence set forth in any one of SEQ ID NOs: 224 and 256-259, and variants thereof.
[0125] In some embodiments, at least one of the therapeutic agents is or comprises an antibody antigen binding fragment or an scFv that specifically binds to CTLA-4 (anti-CTLA4) fused to an IgG Fc domain, optionally wherein the anti-CTLA4 comprises the amino acid sequence set forth in SEQ ID NO: 226 or 227, or a variant thereof. In some embodiments, at least one of the therapeutic agents is a fusion protein comprising the anti-CTLA-4 fused to an IgG Fc domain and further fused to a TGF-P trapping domain, optionally wherein the anti-CTLA-4 fused to an IgG Fc domain and further fused to a TGF-P trapping domain comprises the amino acid sequence set forth in SEQ ID NO: 374 or is encoded by the nucleic acid set forth in SEQ ID NO: 375, or a variant thereof.
[0126] In some embodiments, at least one of the therapeutic agents is or comprises XCL1 and / or FLT3L, optionally wherein at least one of the therapeutic agents is a fusion protein comprising XCL1 fused to FLT3L, optionally wherein the fusion protein further comprises a CD40 agonist, optionally wherein the fusion protein comprises the amino acid sequence set forth in any one of SEQ ID NO: 478, 480, 482, 484, 513, 515, and 517 or a variant thereof, or is encoded by the nucleic acid set forth in any one of SEQ ID NO: 479, 481, 483, 485, 514, 516, and 518, or a variant thereof.
[0127] In some embodiments, at least one of the therapeutic agents is or comprises a singlechain IL- 12 fusion, optionally wherein the single-chain IL- 12 fusion comprises a truncated IL- 12 p40 (P) subunit and an IL- 12 p35 (a) subunit, optionally wherein the single-chain IL- 12 fusion is selected from IL12V2, IL12V3, IL12V3_2Ct2S, and IL12V4, optionally wherein the IL-12 fusion comprises an amino set forth in any one of SEQ ID NOs: 237-241 and 245, or a variant thereof.
[0128] 12
[0129] FH30035011.1
[0130] Attorney Docket No: FTE-00125
[0131] In some embodiments, at least one of the therapeutic agents is or comprises a CXCR3 agonist chemokine selected from CXCL9, CXCL10, and CXCL11.
[0132] In some embodiments, at least one of the therapeutic agents is or comprises a singlechain IL- 12 fusion fused to the CXCR3 agonist chemokine, optionally wherein the CXCR3 agonist chemokine comprises an amino acid sequence set forth in any one of SEQ ID NOs: 206, 208, 210, 213, and 214, or a variant thereof.
[0133] In some embodiments, at least one of the therapeutic agents is or comprises a TGF-P trapping domain comprising TGF-P receptor II extracellular domain (TGFpRII ECD) or a variant thereof that binds TGF-P, optionally wherein the TGF-P trapping domain comprises the amino acid sequence set forth in SEQ ID NO: 263, or a variant thereof.
[0134] In some embodiments, at least one of the therapeutic agents is or comprises a cytokine, wherein the cytokine is selected from: IL-15, an IL-15 variant, IL-7, IL-21, or IL-18, optionally wherein the cytokine comprises an amino acid sequence selected from any one of SEQ ID NOs: 260-262, or a variant thereof. In some embodiments, an IL- 15 variant comprises an IL- 15 receptor alpha sushi domain, optionally wherein the IL- 15 receptor alpha sushi domain comprises the amino acid sequence set forth in SEQ ID NO: 683, or a variant thereof.
[0135] In some embodiments, the cytokine is a fusion protein comprising IL- 15 fused to IL-21, IL- 15 fused to IL-7, or IL-21 fused to IL-7, optionally wherein the fusion protein comprises any amino acid sequence set forth in any one of SEQ ID NO: 638, 640, 642, 644, 646, 648, 650, 652, 654, and 656, or a variant thereof.
[0136] In some embodiments, at least one of the therapeutic agents is a fusion protein comprising the cytokine fused to a TNFSF protein or a variant thereof or a TNFRSF agonist that agonizes CD40, 0X40, 4- IBB, GITR, or CD27, optionally which is a single-chain trimeric OX40L or a single-chain trimeric 4-1BBL, optionally wherein the TNFSF protein is selected from an amino acid sequence set forth in any one of SEQ ID NOs: 223, 224, 252-259, and variants thereof.
[0137] In some embodiments, at least one of the therapeutic agents is an agent that mediates tumor lysis selected from: (i) a cytotoxic polypeptide; (ii) a pore-forming polypeptide; (iii) a tumor- specific protease-gated cytotoxic polypeptide; (iv) an oncolysis-inducing factor; (v) a tumor-targeting antibody antigen binding fragment or scFv, optionally comprising an Fc that enables immune-mediated killing of tumor cells, or (vi) a transmembrane IgG molecule. In some
[0138] 13
[0139] FH30035011.1
[0140] Attorney Docket No: FTE-00125 embodiments, at least one of the therapeutic agents is a tumor- selective protease-gated cytotoxic or pore-forming polypeptide, wherein the tumor- selective protease-gated cytotoxic or poreforming polypeptide comprises: (i) a tumor-enriched protease-cleavable inhibitory domain fused to a masking domain; and (ii) a cytotoxic or pore-forming effector domain, wherein cleavage of the inhibitory domain by a tumor-enriched protease activates the cytotoxic or pore-forming effector domain. In some embodiments, at least one of the therapeutic agents is a tumor-targeting scFv fused to an IgG Fc domain, optionally targeting PSMA, EGFR, HER2, B7-H3, or SIRPa / CD47, optionally wherein the tumor- targeting scFv comprises the amino acid sequence set forth in any one of SEQ ID NOs: 228-234, or a variant thereof. In some embodiments, at least one of the therapeutic agents is a tumor-targeting antibody antigen binding fragment or scFv fused to an anti-CD3 antibody antigen binding fragment or scFv, optionally wherein the anti-CD3 antibody antigen binding fragment or scFv comprises the amino acid sequence set forth in SEQ ID NO: 273, or a variant thereof.
[0141] In some embodiments, any one or more of the therapeutic agents comprises a multimerization domain, wherein the multimerization domain is a silenced Fc domain (optionally an IgGl comprising LALA-PG mutations), a hinge-CH3 domain that lacks a CH2 domain, an IgG4 Fc domain, a leucine zipper, a collagen-like trimerization domain, or a MATN 1 trimerization domain.
[0142] In some embodiments, any one or more of the therapeutic agents is a fusion protein comprising a linker between the components of the fusion protein selected from: a flexible glycine- serine linker, a rigid alpha-helical linker, a hybrid flexible-rigid linker comprising one or more (GGGGS)n segments, and one or more (EAAAK)n segments.
[0143] In some embodiments, any one or more of the therapeutic agents comprises a tumor retention domain fused to a C-terminus of the therapeutic agent, wherein the tumor retention domain is a decorin-derived peptide, a collagen-binding peptide, a glycosaminoglycan-binding peptide, an extracellular matrix-binding domain, or any combination thereof. In some embodiments, the tumor retention domain is fused to a therapeutic agent selected from: IL- 12, IL-15, IL-15 / IL-15Ra sushi, IL-21, IL-7, IL-18, a co-stimulatory TNFSF ligand, and an immune checkpoint binding domain, optionally wherein the therapeutic agent comprises an amino acid sequence selected from any one of SEQ ID NOs: 223-234, 236-246, 250-259, 260-262, and 683, and variants thereof.
[0144] 14
[0145] FH30035011.1
[0146] Attorney Docket No: FTE-00125
[0147] In some embodiments, at least one of the two or more therapeutic agents is expressed under the control of an immediate promoter, wherein the immediate promoter is a tumor- specific promoter or a ubiquitous promoter; wherein the at least one therapeutic agent under the control of the immediate promoter comprises: (i) CXCL9, CXCL10, CXCL11, and / or XCL1, (ii) FLT3L, (iii) LIGHT and / or TGF beta trap, (iv) anti-CTLA4 scFv, (v) IL12, and / or (vi) GITRL. In some embodiments, at least one of the two or more therapeutic agents is expressed under the control of a delayed promoter configured as an immune-activation-responsive transcriptional control region (optionally activated after infiltration of immune effector cells and / or after induction of interferon-responsive transcription factors in the tumor microenvironment); and / or under the control of a constitutively active low-expressing promoter leading to continuous low-level expression of a therapeutic agent. In some embodiments, the therapeutic agent expressed under the control of the delayed promoter or the constitutively active low-expressing promoter is an agent promoting tumor lysis. In some embodiments, the immediate promoter and / or the delayed promoter are in the forward orientation (non-reverse complement) or reverse complement orientation; optionally the immediate promoter is in the forward orientation and the delayed promoter is in the reverse complement orientation, or the immediate promoter is in the reverse complement orientation and the delayed promoter is in the forward orientation.
[0148] In some embodiments, the tumor- specific promoter is a prostate cancer-specific promoter, wherein the prostate cancer-specific promoter comprises a PSA promoter, a PSA enhancer, a PSMA promoter, a KLK2 promoter, or an androgen receptor (AR) response elementcontaining promoter, or any combination thereof, optionally comprising the nucleic acid sequence set forth in any one of SEQ ID NOs: 6-12 and 19, or a variant thereof. In some embodiments, the tumor- specific promoter is or comprises a sequence of Pc_FIG_Pmtl, Pc_FIG_enhl, Pc_FIG_enh2, FIG_PSA Enh wl, or FIG_PSA Enh w2, or any combination thereof, optionally comprising the nucleic acid sequence set forth in any of SEQ ID NOs: 6-9 and 19, or a variant thereof. In some embodiments, the tumor- specific promoter is a survivin promoter, an hTERT promoter, an AFP promoter, an EPCAM promoter, a HER2 promoter, an EGFR promoter, or an MSLN promoter. In some embodiments, the tumor- specific promoter comprises a synthetic promoter comprising two or more transcription factor response elements for transcription factors enriched in tumor cells relative to normal tissue. In some embodiments, the transcription factor response elements are selected from androgen receptor (AR) response
[0149] 15
[0150] FH30035011.1
[0151] Attorney Docket No: FTE-00125 elements, c-Myc response elements, hypoxia response elements (HREs), or NF-KB response elements, or any combination combinations thereof, optionally comprising a nucleic acid sequence selected from any of SEQ ID NOs: 28-30, and variants thereof. In some embodiments, the ubiquitous promoter comprises an EFla promoter, optionally comprising the nucleic acid sequence set forth in SEQ ID NO: 18, or a variant thereof. In some embodiments, the immediate promoter comprises PSAEnh. In some embodiments, the immediate promoter drives expression of XCL1-FLT3L, anti-CTLA4-Fc, TGFp trap-sctriLIGHT, and / or CXCL9-IL12V4.
[0152] In some embodiments, at least one of the two or more therapeutic agents is expressed under the control of a delayed promoter configured as an immune-activation-responsive transcriptional control region (optionally activated after infiltration of immune effector cells and / or after induction of interferon-responsive transcription factors in the tumor microenvironment). In some embodiments, at least one of the two or more therapeutic agents is expressed under the control of a constitutively active low-expressing promoter leading to continuous low-level expression of a therapeutic agent. In some embodiments, at least one of the two or more therapeutic agents is expressed under the control of a at least one therapeutic agent under the control of the delayed promoter or constitutively active low-expressing promoter comprises: (i) a tumor lysis agent, (ii) anti-PDLl scFv and / or anti-PD-1 scFv, (iii) IL21 and / or IL15, or (iv) 4-1BBL and / or OX40L. In some embodiments, the delayed promoter is operably linked to a nucleic acid sequence encoding one or more of: (i) an agent mediating tumor lysis; (ii) an immune checkpoint inhibitor molecule; (iii) a TNFSF protein or a variant thereof or a TNFRSF agonist optionally agonizing CD40, 0X40, 4- IBB, GITR, or CD27; and (iv) a cytokine selected from IL 15 or a variant thereof, IL21, IL7, and IL18.
[0153] In some embodiments, the delayed promoter is or comprises a CIITA pIV promoter, a synthetic GAS promoter, a synthetic ISRE promoter, a modified PD-L1 promoter, a CXCL10 promoter, an IDO1 promoter, a GBP1 promoter, an NF-KB-responsive promoter, or any combination thereof, optionally comprising a nucleic acid sequence set forth in any one of SEQ ID NOs: 15-17, 20, 21, and 23, and variants thereof. In some embodiments, the delayed promoter is an interferon-responsive promoter and / or a promoter comprising one or more Gamma Interferon Activation Site (GAS) elements, optionally comprising the nucleic acid sequence of SEQ ID NO: 14, or a variant thereof. In some embodiments, the delayed promoter is or comprises a CIITA pIV promoter, optionally comprising the nucleic acid sequence set forth in
[0154] 16
[0155] FH30035011.1
[0156] Attorney Docket No: FTE-00125
[0157] SEQ ID NO: 20, or a variant thereof. In some embodiments, the delayed promoter comprises a synthetic 3xGAS promoter and a minimal promoter, optionally a minimal CMV promoter or a minimal EFla promoter, optionally wherein the CMV promoter comprises the nucleic acid sequence of SEQ ID NO: 22, optionally wherein the EFla promoter comprises the nucleic acid sequence of SEQ ID NO: 18, and variants thereof. In some embodiments, the delayed promoter is or comprises a synthetic 5XNF-KB promoter and a minimal promoter, optionally a minimal CMV promoter, optionally comprising the nucleic acid sequence set forth in SEQ ID NO: 22, or a variant thereof. In some embodiments, the delayed promoter comprises pGAS or CIITA pIV. In some embodiments, the delayed promoter drives expression of anti-PD-Ll-Hinge-CH3-sctriCD40L, IL21-furin-sIL15, and / or a tumor lysis agent.
[0158] In some embodiments, the one or more nucleic acids are comprised in one polycistronic vector. In some embodiments, the immediate promoter and the delayed promoter (or a low expressing promoter) in the polycistronic vector are oriented to drive transcription in opposite directions. In some embodiments, the polycistronic vector further comprises an insulator sequence positioned between the immediate promoter and the delayed promoter in the polycistronic vector, optionally wherein the insulator sequence comprises a cHS4 insulator or a core cHS4 insulator, optionally comprising the nucleic acid sequence set forth in SEQ ID NO: 25 or 26, or a variant thereof. In some embodiments, the immediate promoter and the delayed promoters in the polycistronic vector are separated by 50 bp to 2000 bp.
[0159] In some embodiments, one or more nucleic acids are comprised in two or more vectors, optionally wherein at least one of the two or more vectors is a polycistronic vector.
[0160] In some embodiments, the one or more nucleic acids are comprised in one polycistronic cassette within a vector. In some embodiments, the polycistronic cassette encodes at least two therapeutic agents separated by one or more ribosome skipping sequences and / or internal ribosome entry sites (IRESs). In some embodiments, the polycistronic cassette encodes at least two therapeutic agents separated by one or more ribosome skipping sequences, wherein the ribosome skipping sequence comprises a 2A peptide selected from P2A, T2A, E2A, F2A and nucleic acid variants encoding an identical amino acid 2A peptide sequence but having reduced nucleotide homology to one another, optionally wherein the 2A peptide comprises an amino acid sequence selected from any one of SEQ ID NOs: 144-146, and variants thereof. In some embodiments, at least one 2A peptide is immediately preceded by a short flexible linker that
[0161] 17
[0162] FH30035011.1
[0163] Attorney Docket No: FTE-00125 improves cleavage efficiency, optionally a GSG linker, and wherein a furin cleavage site is positioned to remove a C-terminal 2A peptide-derived remnant from an upstream polypeptide after translation, optionally comprising an amino acid sequence selected from an amino acid sequence set forth in any of SEQ ID NOs: 148, 150, 152, 153, 155, 157, 159, and 162, and variants thereof.
[0164] In some embodiments, a tumor lysis agent is positioned downstream of a ribosomeskipping peptide or an internal ribosome entry site to tune expression of the tumor lysis agent relative to one or more upstream immunomodulatory therapeutic agents. In some embodiments, the tumor lysis agent is positioned immediately downstream of a T2A peptide, P2A peptide, E2A peptide, or F2A peptide to increase expression of the tumor lysis agent relative to expression from an internal ribosome entry site. In some embodiments, the tumor lysis agent is positioned downstream of an internal ribosome entry site to attenuate expression of the tumor lysis agent relative to expression from a 2A peptide.
[0165] In some embodiments, the vector is a plasmid vector. In some embodiments, the vector is a viral vector. In some embodiments, the viral vector is selected from: adenovirus, helperdependent adenovirus, adeno-associated virus, herpes simplex virus, lentivirus, vaccinia virus, and poxvirus, optionally the viral vector is from a helper-dependent adenovirus. In some embodiments, the viral vector is a helper-dependent adenoviral vector configured to express at least four therapeutic agents from one or more expression cassettes without expressing adenoviral genes required for viral replication in the transduced tumor cell. In some embodiments, the vector is comprised in a lipid nanoparticle or a phospholipid liposome.
[0166] In some aspects, provided here is a gene therapy comprising a nucleic acid sequence encoding a protein comprising a single-chain IL- 12 fusion, wherein the single-chain IL- 12 fusion comprises an IL- 12 p35 (a) subunit and an IL- 12 p40 (0) subunit, wherein the 0 subunit is truncated at residue S295 removing amino acid sequence SWSEWASVPCS, and variants thereof. In some embodiments, the single-chain IL- 12 fusion is selected from IL12V2 of SEQ ID NO: 237, IL12V3 of SEQ ID NO: 239, IL12V3_2Ct2S of SEQ ID NO: 238, and IL12V4 of SEQ ID NO: 245, or a variant having at least 85%, 90%, 95%, or 98% sequence identity to any of SEQ ID NOs: 237, 238, 239, and 245. In some embodiments, the protein is a fusion protein comprising the single-chain IL- 12 fusion and a CXCR3 agonist chemokine, optionally wherein the CXCR3 agonist chemokine is CXCL9, CXCL10 or CXCL11, optionally wherein the fusion
[0167] 18
[0168] FH30035011.1
[0169] Attorney Docket No: FTE-00125 polypeptide comprises a protease cleavage site between the IL- 12 domain and the chemokine domain, optionally wherein the protein further comprises a tumor retention domain, optionally wherein the fusion polypeptide comprises an amino acid sequence set forth in any of SEQ ID NOs: 454, 456, 458, and 460, or a variant having at least 85%, 90%, 95%, or 98% sequence identity to any of SEQ ID NOs: 454, 456, 458, and 460.
[0170] In some aspects, provided herein is a gene therapy comprising a nucleic acid sequence encoding a fusion protein comprising a transmembrane domain from a first protein covalently linked to an extracellular domain from a second protein, wherein the extracellular domain comprises an immuno stimulatory molecule, and wherein the immuno stimulatory molecule is exposed extracellularly upon expression in a target cell, wherein the immuno stimulatory molecule is an IgG Fc or a fragment thereof, a Toll like receptor agonist, a complement protein, a phagocytosis stimulating factor, or an antigen specific to a chimeric T cell (optionally, wherein the immuno stimulatory molecule is an IgG Fc). In some embodiments, the IgG comprises an amino acid sequence set forth in SEQ ID NO 180, 181, or 182, or a variant thereof. In some embodiments, the immuno stimulatory molecule is an IgG Fc or a fragment thereof, and wherein the transmembrane domain is PSMA transmembrane domain, EGFR transmembrane domain or HER2 transmembrane domain, optionally wherein the transmembrane domain comprises an amino acid sequence set forth in any one of SEQ ID NOs: 177-179, or a variant having at least 85%, 90%, 95%, or 98% sequence identity thereto.
[0171] In some aspects, provided herein is a gene therapy comprising a nucleic acid sequence encoding a fusion protein comprising: (a) an antibody antigen binding fragment or scFv that specifically binds to PD-1 or PD-L1; and (b) a single-chain trimeric TNFSF ligand, optionally wherein the TNFSF ligand is a CD40 ligand, 0X40 ligand, 4- IBB ligand, GITR ligand, or CD27 ligand, optionally wherein the fusion protein comprises an amino acid sequence selected from SEQ ID NOs: 346, 348, 350, 352, 330, 332, and 334, or a variant having at least 85%, 90%, 95%, or 98% sequence identity thereto. In some embodiments, the fusion protein comprises an anti-PDl scFv or anti-PD-Ll scFv fused to a single-chain trimeric CD40L, single-chain trimeric OX40L, or single-chain trimeric 4-1BBL, optionally wherein the fusion protein comprises an amino acid sequence selected from SEQ ID NOs: 346, 348, 350, 352, 330, 332, and 334, or a variant having at least 85%, 90%, 95%, or 98% sequence identity thereto. In some embodiments, the gene therapy further comprises a multimerization domain, optionally wherein the
[0172] 19
[0173] FH30035011.1
[0174] Attorney Docket No: FTE-00125 multimerization domain comprises a hinge-CH3 domain or an effector- silenced Fc domain, optionally wherein the multimerization domain comprises an amino acid sequence selected from any one of SEQ ID NOs: 127, 129, 131, 133, and 181, or a variant having at least 85%, 90%, 95%, or 98% sequence identity thereto.
[0175] In some aspects, provided herein is a gene therapy comprising a nucleic acid sequence encoding a fusion protein comprising an XCL1 domain and a FLT3L domain, optionally further comprising a multimerization domain and / or a CD40 agonist domain, optionally wherein the fusion protein comprises an amino acid sequence set forth in any one of SEQ ID NOs: 478, 480, 482, 484, 513, 515, and 517, or a variant having at least 85%, 90%, 95%, or 98% sequence identity thereto.
[0176] In some aspects, provided herein is a gene therapy comprising a nucleic acid sequence encoding a fusion protein comprising an antibody antigen binding fragment or an scFv that specifically binds to CTLA4 fused to a TGF-beta trapping domain, optionally comprising the amino acid sequence set forth in SEQ ID NO: 374 or SEQ ID NO: 376, or a variant having at least 85%, 90%, 95%, or 98% sequence identity thereto.
[0177] In some aspects, provided herein is a gene therapy comprising a nucleic acid sequence encoding a fusion protein comprising a TGF-beta trapping domain fused to a TNFSF protein or a variant thereof or a TNFRSF agonist, (optionally, wherein TNFSF protein is LIGHT, and wherein the TGF-beta trapping domain is fused to any LIGHT agonist described herein), optionally comprising the amino acid sequence set forth in any one of SEQ ID NOs: 547, 548, 550, and 552, or a variant having at least 85%, 90%, 95%, or 98% sequence identity thereto.
[0178] In some aspects, provided herein is a gene therapy comprising a nucleic acid sequence encoding a fusion protein comprising IL 15 or a variant thereof, fused to a collagen-binding peptide, and optionally fused to one or more of: IL21, IL7, or a TNFSF protein or a variant thereof or a TNFRSF agonist (optionally, fused to any 4- IBB agonist described herein), optionally comprising the amino acid sequence set forth in any one of SEQ ID NOs: 638, 640, 642, 644, 646, 648, 650, 652, 658, 660, 662, 664, 666, 668, 670, 672, 684, 685, and 703, or a variant having at least 85%, 90%, 95%, or 98% sequence identity thereto.
[0179] In some embodiments, provided herein is a gene therapy comprising an expression cassette as set forth in c06t3, c06i3, g06i3, g06t73, g05t73, or g04t73 (see, e.g., figures).
[0180] 20
[0181] FH30035011.1
[0182] Attorney Docket No: FTE-00125
[0183] In some aspects, provided herein is a pharmaceutical composition comprising a gene therapy or vector system described herein and a pharmaceutically acceptable carrier. In some embodiments, the gene therapy is in a lipid nanoparticle formulation. In some embodiments, the gene therapy is in a viral vector formulation.
[0184] In some aspects, provided herein is an isolated fusion protein, such as any fusion protein described herein (optionally for use alone or as a protein cocktail for administration to a subject). In some aspects, provided herein is an isolated fusion polypeptide comprising two or more therapeutic domains selected from: an immune checkpoint binding domain, a TNFSF ligand domain, a TNFRSF agonist domain, a TGFp trapping domain, a CXCR3 agonist chemokine domain, a single-chain IL- 12 domain, an XCL1 domain, an FLT3L domain, an IL- 15 domain, an IL-15Ra sushi domain, an IL-21 domain, an IL-7 domain, a collagen-binding domain, a tumorretention domain, and a tumor-targeting antibody or antigen-binding fragment. In some embodiments, provided herein is an isolated fusion protein comprising an anti-CTLA4 scFv-Fc fused to a TGFp trapping domain. In some embodiments, provided herein is an isolated fusion protein comprising an anti-PD-1 or anti-PD-Ll binding domain fused to a CD40, 0X40, 4-1BB, GITR, or CD27 agonist domain. In some embodiments, provided herein is an isolated fusion protein comprising a TGFp trapping domain fused to sctriLIGHT. In some embodiments, provided herein is an isolated fusion protein comprising IL- 15 or IL-15 / IL-15Ra sushi fused to a collagen-binding peptide, IL-21, IL-7, a 4- IBB agonist, or any combination thereof. In some embodiments, provided herein is an isolated fusion protein comprising CXCL9, CXCL10, or CXCL11 fused to a single-chain IL- 12 variant. In some embodiments, provided herein is an isolated fusion protein comprising XCL1 fused to FLT3L, optionally further comprising a multimerization domain, Hinge-CH3 domain, silenced Fc domain, IgG4 Fc domain, CD40 agonist, or TGFp trapping domain.
[0185] In some aspects, provided herein is a pharmaceutical composition comprising an isolated fusion polypeptide described herein, and a pharmaceutically acceptable carrier.
[0186] In some aspects, provided herein is a method of treating cancer, inhibiting tumor growth, inhibiting one or more symptoms of cancer, inducing tumor antigen release, or preventing recurrence or progression of cancer in a subject (e.g., a human) in need thereof, comprising administering to a subject an effective amount of a gene therapy or vector system described herein or a pharmaceutical composition thereof. In some aspects, provided herein is a method of 21
[0187] FH30035011.1
[0188] Attorney Docket No: FTE-00125 treating cancer, inhibiting tumor growth, inhibiting one or more symptoms of cancer, inducing tumor antigen release, or preventing recurrence or progression of cancer in a subject (e.g., a human) in need thereof, comprising administering to a subject an effective amount of an isolated fusion polypeptide or protein described herein or a pharmaceutical composition thereof. In some embodiments, administering is local, regional, systemic, intravenous, intraperitoneal, or subcutaneous. In some embodiments, administering is intratumoral. In some embodiments, administering is to a tumor or tissue surrounding a tumor of a subject. In some embodiments, administering comprises intratumoral injection, peritumoral injection, electroporation into the tumor or surrounding tissue, image-guided injection, lipid nanoparticle delivery, viral vector delivery, or any combination thereof. In some embodiments, administering is by injection into the tumor and / or the tissue surrounding the tumor, optionally electroporation into the tumor. In some embodiments, administering is by electroporation into the tumor and / or the tissue surrounding the tumor, optionally electroporation into the tumor. In some embodiments, the gene therapy is delivered in a lipid nanoparticle. In some embodiments, the method is performed as a neoadjuvant therapy before surgical resection of the tumor. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is characterized by an immunosuppressive tumor microenvironment and / or low tumor mutational burden. In some embodiments, the cancer is prostate cancer, pancreatic cancer, ovarian cancer, breast cancer, lung cancer, melanoma, colorectal cancer, head and neck cancer, or glioblastoma. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a breast cancer. In some embodiments, the gene therapy is administered in two or more doses, optionally separated by 1 day to 6 weeks.
[0189] In some aspects, provided is a kit comprising: (a) any gene therapy or vector system provided herein, any pharmaceutical composition provided herein, or any isolated fusion polypeptide or protein provided herein; and (b) instructions for intratumoral administration to treat cancer.
[0190] In some aspects, provided herein is a method of treating cancer, inhibiting tumor growth, or preventing recurrence or progression of cancer in a subject (such as a human) in need thereof, comprising intratumorally administering to a subject an effective amount of a gene therapy (or one or more vectors), wherein the gene therapy comprises one or more vectors, wherein at least one of the one or more vectors is a polycistronic vector or a vector comprising a polycistronic
[0191] 22
[0192] FH30035011.1
[0193] Attorney Docket No: FTE-00125 cassette, wherein the one or more vectors encode at least 2, 3, 4, 5, or 6 therapeutic agents selected from at least two the following:
[0194] (i) an immune checkpoint blocker agent;
[0195] (ii) an agent facilitating antigen release and / or tumor lysis;
[0196] (iii) an agent facilitating recruitment of dendritic cells;
[0197] (iv) an agent facilitating recruitment of T cells and / or NK cells;
[0198] (v) an agent facilitating expansion and / or activation of antigen-presenting cells;
[0199] (vi) an agent facilitating expansion, activation, survival, and / or anti-exhaustion signaling of T cells and / or NK cells;
[0200] (vii) an agent facilitating co-stimulatory receptor agonism;
[0201] (viii) an agent facilitating depletion and / or functional attenuation of regulatory T cells;
[0202] (ix) an agent facilitating neutralization of TGF-P and / or reversal of stromal immune exclusion; and
[0203] (x) an agent facilitating induction of tertiary lymphoid structures and / or high endothelial venules;
[0204] wherein the at least 2, 3, 4, 5, 6, or 7 of the therapeutic agents is secreted from the tumor upon expression in the tumor, optionally wherein at least 1, 2, 3, 4, 5, 6, or 7 of the therapeutic agents comprise a non-native secretory signal peptide; and / or
[0205] wherein one or more of the two or more therapeutic agents is expressed under the control of an immediate promoter (such as a tumor- specific promoter or a constitutive or ubiquitous promoter) and one or more of the two or more therapeutic agents is expressed under the control of a delayed promoter (such as a promoter that does not become active immediately upon administration of the gene therapy or becomes active after the expression and secretion of the one or more therapeutic agents under the control of the immediate promoter).
[0206] In some aspects, provided herein is a method of treating cancer, inhibiting tumor growth, or preventing recurrence or progression of cancer in a subject (such as a human) in need thereof, comprising intratumorally administering to a subject an effective amount of a gene therapy (or one or more vectors), wherein the gene therapy comprises one or more vectors, wherein at least one of the one or more vectors is a polycistronic vector or a vector comprising a polycistronic cassette, wherein the one or more vectors encode at least 2, 3, 4, 5, or 6 therapeutic agents selected from at least two the following:
[0207] 23
[0208] FH30035011.1
[0209] Attorney Docket No: FTE-00125
[0210] (i) an immune checkpoint inhibitor;
[0211] (ii) a chemokine;
[0212] (iii) a cytokine;
[0213] (iv) a co-stimulatory ligand (optionally, a TNFSF protein or a variant thereof or a TNFRSF agonist);
[0214] (v) a TGF-P trap; and
[0215] (vi) a tumor antigen release or tumor lysis agent;
[0216] wherein the at least 2, 3, 4, 5, 6, or 7 of the therapeutic agents is secreted from the tumor upon expression in the tumor, optionally wherein at least 1, 2, 3, 4, 5, 6, or 7 of the therapeutic agents comprise a non-native secretory signal peptide; and / or
[0217] wherein one or more of the two or more therapeutic agents is expressed under the control of an immediate promoter (such as a tumor- specific promoter or a constitutive or ubiquitous promoter) and one or more of the two or more therapeutic agents is expressed under the control of a delayed promoter (such as a promoter that does not become active immediately upon administration of the gene therapy or becomes active after the expression and secretion of the one or more therapeutic agents under the control of the immediate promoter).
[0218] In some aspects, provided herein is a method of treating cancer, inhibiting tumor growth, or preventing recurrence or progression of cancer in a subject (such as a human) in need thereof, comprising intratumorally administering to a subject an effective amount of a gene therapy (or one or more vectors), wherein the gene therapy comprises one or more vectors, wherein at least one of the one or more vectors is a polycistronic vector or a vector comprising a polycistronic cassette, wherein the one or more vectors encode at least 2, 3, 4, 5, 6, or 7 therapeutic agents selected from at least two of the following:
[0219] (i) an immune checkpoint inhibitor molecule, optionally wherein the immune checkpoint inhibitor molecule comprises an antibody antigen binding fragment or scFv that specifically binds to PD-1 or PD-L1, and further optionally wherein the immune checkpoint inhibitor molecule is a fusion protein comprising an immune checkpoint inhibitor fused to a TNFSF protein or a variant thereof or a TNFRSF agonist;
[0220] (ii) a TNFSF protein or a variant thereof or a TNFRSF agonist that optionally agonizes CD40, 0X40, 4- IBB, GITR, LIGHT, or CD27;
[0221] 24
[0222] FH30035011.1
[0223] Attorney Docket No: FTE-00125
[0224] (iii) a toxin, an antibody antigen binding fragment or an scFv that specifically binds to a tumor antigen fused to an IgG Fc domain or a variant thereof, a fusion protein comprising an antibody antigen binding fragment or an scFv that specifically binds to a tumor antigen fused to an antigen binding fragment or an scFv that specifically binds to CD3, a transmembrane IgG, or another agent mediating tumor lysis;
[0225] (iv) an antibody antigen binding fragment or an scFv that specifically binds to CTLA4 fused to an IgG Fc domain or a variant thereof, or a fusion protein comprising an antigen binding fragment or an scFv that specifically binds to CTLA4 fused to a TGF-beta trap protein;
[0226] (v) a TGF-beta trapping domain, optionally a fusion protein comprising the TGF- beta trapping domain fused to a TNFSF protein or a variant thereof or a TNFRSF agonist;
[0227] (vi) an IL 12 or a variant thereof, optionally a single chain fusion protein comprising alpha chain of IL 12 fused to a truncated variant of beta chain of IL 12, further optionally comprising a fusion protein comprising an IL 12 or a variant thereof fused to a CXCR3 agonist chemokine, optionally wherein the CXCR3 agonist chemokine is CXCL9, CXCL10 or CXCL11;
[0228] (vii) a CXCR3 agonist chemokine, optionally wherein the CXCR3 agonist chemokine is CXCL9, CXCL10 or CXCL11;
[0229] (viii) at least one of an FLT3 ligand and / or an XCL1 protein, optionally a fusion protein comprising FLT3 ligand fused to XCL1 protein, or a fusion protein comprising at least one of an FLT3 ligand and an XCL1 protein fused to IFN- gamma or TGF-beta trap protein; and
[0230] (ix) a cytokine selected from IL 15 or a variant thereof, IL21, IL7, and IL 18, optionally a fusion protein comprising the cytokine fused to a TNFSF protein or a variant thereof or a TNFRSF agonist;
[0231] wherein the at least 2, 3, 4, 5, 6, or 7 of the therapeutic agents is secreted from the tumor upon expression in the tumor, optionally wherein at least 1, 2, 3, 4, 5, 6, or 7 of the therapeutic agents comprise a non-native secretory signal peptide; and / or
[0232] 25
[0233] FH30035011.1
[0234] Attorney Docket No: FTE-00125 wherein one or more of the two or more therapeutic agents is expressed under the control of an immediate promoter (such as a tumor- specific promoter or a constitutive or ubiquitous promoter) and one or more of the two or more therapeutic agents is expressed under the control of a delayed promoter (such as a promoter that does not become active immediately upon administration of the gene therapy or becomes active after the expression and secretion of the one or more therapeutic agents under the control of the immediate promoter).
[0235] Also provided herein are means for achieving any function described herein (e.g., means for binding any antigen, or means for achieving a functional outcome) using any structure described herein that performs said function.
[0236] BRIEF DESCRIPTION OF THE DRAWINGS
[0237] FIG. 1 provides a schematic of a gene therapy backbone with custom multiple cloning sites comprising an Ampicillin resistance gene (AmpR) promoter, an AmpT, an Ori site, and a BGH PolyA sequence.
[0238] FIG. 2 provides a schematic of a gene therapy backbone designed and manufactured for multi-modal therapy comprising an Ampicillin resistance gene (AmpR) promoter, an AmpT, an Ori site, a BGH PolyA sequence, a PSA promoter, and a PSA enhancer core +CAMP Response Element Binding Protein (CREB).
[0239] FIG. 3 provides a schematic of a gene therapy backbone designed and manufactured for multi-modal therapy comprising an Ampicillin resistance gene (AmpR) promoter, an AmpT, an Ori site, and a BGH PolyA sequence, a PSA promoter, and an androgen response element (ARE) enhancer.
[0240] FIG. 4 provides a schematic of a bicistronic vector encoding IL12-V1-CXCL10 fusion and FLT3L-IFNa fusion. A gene therapy vector designed and manufactured for multi-modal therapy for the expression of an IL12-V1-CXCL10 fusion protein (IL12 fusion protein linking full length IL12a and a truncated IL12P (IL12_V1) and a CXCL10 protein) and an FLT3L-IFNa fusion protein, comprising the backbone of FIG. 1 and comprising from 5’ to 3’ order a CMV promoter, a CMV enhancer, a nucleic acid encoding an IL12-V1-CXCL10 fusion protein and a nucleic acid encoding an FLT3L-IFNa fusion protein.
[0241] FIG. 5 provides a schematic of a tricistronic vector encoding IFNg and IL12-V1-CXCL10 fusion and FLT3L-IFNa fusion. A gene therapy vector designed and manufactured for
[0242] 26
[0243] FH30035011.1
[0244] Attorney Docket No: FTE-00125 multi-modal therapy for the expression of IFNy, an IL12-V1-CXCL10 fusion protein, and a FLT3L-IFNa fusion protein, comprising the backbone of FIG. 1 and comprising from 5’ to 3’ order a CMV promoter, a CMV enhancer, a nucleic acid encoding an IFNy, a nucleic acid encoding an IL12-V1-CXCL10 fusion protein and a nucleic acid encoding an FLT3L-IFNa fusion protein.
[0245] FIG. 6 provides a schematic of a bicistronic vector encoding Anti-CTLA4-Fc fusion and IL12_V1. A gene therapy vector designed and manufactured for multi-modal therapy for the expression of an anti-CTLA4-Fc fusion protein and an IL12 fusion protein linking full length IL12a and a truncated IL12P (IL12_V1) protein, comprising the backbone of FIG. 1 and comprising from 5’ to 3’ order a CMV promoter, a CMV enhancer, a nucleic acid encoding anti-CTLA4-Fc fusion protein, and a nucleic acid encoding IL12_V1.
[0246] FIG. 7 provides a schematic of a bicistronic vector encoding IFNg and FLT3L-CXCL10 fusion. A gene therapy vector designed and manufactured for multi-modal therapy for the expression of an IFNy and an FLT3L-CXCL10 fusion protein, comprising the backbone of FIG.
[0247] 1 and comprising from 5’ to 3’ order a CMV promoter, a CMV enhancer, a nucleic acid encoding an IFNy and a nucleic acid encoding an FLT3L-CXCL10 fusion protein.
[0248] FIG. 8 provides a schematic of a bicistronic vector encoding Anti-PD1_CD4OL bispecific and IL12_V1. A gene therapy vector designed and manufactured for multi-modal therapy for the expression of a bispecific PD1 and CD40L antibody and IL12_V1, comprising the backbone of FIG.l and comprising from 5’ to 3’ order a CMV promoter, a CMV enhancer, a nucleic acid encoding a bispecific PD1-CD40L antibody, and a nucleic acid encoding a IL12_V1.
[0249] FIG. 9 provides a schematic of a quatracistronic vector encoding IFNg and anti-CTLA4-Fc fusion and IL12-V1 and FLT3L-CXCL10 fusion. A gene therapy vector designed and manufactured for multi-modal therapy for the expression of an IFNy, an anti-CTLA4-Fc fusion, an IL12-V1 protein, and an FLT3L-CXCL10 fusion protein, comprising the backbone of FIG.l and comprising from 5’ to 3’ order a CMV promoter, a CMV enhancer, a nucleic acid encoding an IFNy, a nucleic acid encoding a CTLA4-Fc fusion protein, a nucleic acid encoding an IL 12-VI protein, and a nucleic acid encoding an FLT3L-CXCL10 fusion protein.
[0250] FIG. 10 provides a schematic of a quatracistronic vector encoding IFNg and anti-PDl-CD40L bispecific and IL 12- VI and FLT3L-CXCL10 fusion. A gene therapy vector designed and
[0251] 27
[0252] FH30035011.1
[0253] Attorney Docket No: FTE-00125 manufactured for multi-modal therapy for the expression of an IFNy, an anti-PDl-CD40L bispecific antibody, an IL12-V1 protein, and an FLT3L-CXCL10 fusion protein, comprising the backbone of FIG.l and comprising from 5’ to 3’ order a CMV promoter, a CMV enhancer, a nucleic acid encoding an IFNy, a nucleic acid encoding an anti-PDl-CD40L bispecific antibody, a nucleic acid encoding an IL 12- VI protein, and a nucleic acid encoding an FLT3L-CXCL10 fusion protein.
[0254] FIG. 11 provides a schematic of quatracistronic vector encoding anti-CTLA4-Fc fusion and IL12-V1-CXCL10 and FLT3L-IFNa fusion and IgGlFcJmPSMA. A gene therapy vector designed and manufactured for multi-modal therapy for the expression of an anti-CTLA4-Fc fusion, an IL12-V1-CXL10 fusion, an IFNa fusion protein, and an IgGlFcJmPSMA fusion protein, comprising the backbone of FIG.l and comprising from 5’ to 3’ order a CMV promoter, a CMV enhancer, a nucleic acid encoding an anti-CTLA4-Fc fusion, a nucleic acid encoding an IL12-V1-CXL10 fusion, a nucleic acid encoding an IFNa fusion protein, and a nucleic acid encoding an IgGlFc mPSMA fusion protein.
[0255] FIG. 12 provides a schematic of a quatracistronic vector encoding anti-PDl-CD40L bispecific antibody and IL12-V1-CXCL10 and FLT3L-IFNa fusion and IgGlFcJmPSMA. A gene therapy vector designed and manufactured for multi-modal therapy for the expression of an anti-PDl-CD40L bispecific antibody, an IL12-V1-CXCL10 fusion protein, an FLT3L-IFNa fusion protein, and an IgGlFcJmPSMA fusion protein comprising the backbone of FIG.l and comprising from 5 Jo 3’ order a CMV promoter, a CMV enhancer, a nucleic acid encoding an anti-PDl-CD40L bispecific antibody, a nucleic acid encoding an IL12-V1-CXCL10 fusion protein, a nucleic acid encoding an FLT3L-IFNa fusion protein, and a nucleic acid encoding an IgGlFcJmPSMA fusion protein.
[0256] FIG. 13 provides a schematic of a quatracistronic vector encoding anti-PDl-CD40L bispecific antibody, anti-CTLA4-Fc fusion, IL12-V1 protein, and an FLT3L-CXCL10 fusion protein. A gene therapy vector designed and manufactured for multi-modal therapy for the expression of an anti-PDl-CD40L bispecific antibody, anti-CTLA4-Fc fusion, an IL12-V 1 protein, and an FLT3L-CXCL10 fusion protein, comprising the backbone of FIG.l and comprising from 5 Jo 3’ order a CMV promoter, a CMV enhancer, a nucleic acid encoding an anti-PDl-CD40L bispecific antibody, a nucleic acid encoding an anti-CTLA4-Fc fusion protein,
[0257] 28
[0258] FH30035011.1
[0259] Attorney Docket No: FTE-00125 a nucleic acid encoding an IL 12- VI protein, and a nucleic acid encoding an FLT3L-CXCL10 fusion protein.
[0260] FIG. 14 provides results of an experiment measuring IL 12 activity in Promega IL- 12 Bioassay.
[0261] FIGs. 15A-15B provide results of an experiment measuring IFNy (IFNg) expression under control of different promoters and enhancers.
[0262] FIGs. 16A-16D provides results of an experiment measuring IFNy (IFNg) expression / secretion using IFNg fused to various secretory signal peptides.
[0263] FIG. 17 provides a schematic of a therapy in accordance with the invention.
[0264] FIGs. 18 to 23 provide schematics of a dual-promoter gene therapy construct comprising an immediate PSAEnhl promoter / enhancer driving expression of early payloads and a delayed (pGAS or CIITA pIV) immune-activation-responsive promoter driving expression of delayed payloads, wherein coding sequences are separated by furin-GSG-2A peptide or IRES elements as indicated, and wherein the delayed cassette comprises as a tumor lysis or tumor antigen release module (PRX302 or anti-B7-H3 scFv-Fc).
[0265] FIG. 18 provides a schematic of the AY23ins_PSAEnhl_XCL-FL3_CTLA4-Fc_TGFbt-Hin-DP-striLIGHT_CX9-IL12V4_pCIITA_PDLl-Hin-striCD40L_IL21-furin-sIL15_T2A_PRX302. It consists of a custom bacterial cloning vector backbone (AY23) and serves as a template for cloning into helper- dependent adenovirus vectors, which in this representation contains the insert for pGLAd-FIG-c06t3 (see description in FIG. 29). (This is c06t3 expression construct: CIITA pIV + T2A_PRX302).
[0266] FIG. 19 provides a schematic of the vector AY23ins_PSAEnh 1_XCL-FL3_CTLA4-Fc_TGFbt-Hin-DP-striLIGHT_CX9-IL12V4_pCIITA_PDLl-Hin-striCD40L_IL21-furin-sIL15_IRES_PRX302. It consists of a custom bacterial cloning vector backbone (AY23) and serves as a template for cloning into helper- dependent adenovirus vectors, which in this representation contains the insert for pGLAd-FIG-c06i3 (see description in FIG. 32). (This is c06i3 expression construct: CIITA pIV + IRES_PRX302).
[0267] FIG. 20 provides a schematic of the vectorAY23ins_PSAEnhl_XCL-FL3_CTLA4-Fc_TGFbt-Hin-DP-striLIGHT_CX9-IL12V4_pGASc_PDLl-Hin-striCD40L_IL21-furin-sIL15_T2A_B7H3-Fc. It consists of a custom bacterial cloning vector backbone (AY23) and serves as a template for cloning into helper- dependent adenovirus vectors, which in this
[0268] 29
[0269] FH30035011.1
[0270] Attorney Docket No: FTE-00125 representation contains the insert for pGLAd-FIG-g06t73 (see description in FIG. 27). (This is g06t73 expression construct: pGAS + T2A_B7-H3-Fc.)
[0271] FIG. 21 provides a schematic of the vectorAY23ins_PSAEnhl_XCL-FL3_CTLA4-Fc_TGFbt-Hin-DP-striLIGHT_CX9-IL12V4_pGASc_PDLl-Hin-striCD40L_IL21-furin-sIL15_IRES_PRX302. It consists of a custom bacterial cloning vector backbone (AY23) and serves as a template for cloning into helper- dependent adenovirus vectors, which in this representation contains the insert for pGLAd-FIG-g06i3 (see description in FIG. 30). (This is g06i3 expression construct: pGAS + IRES_PRX302).
[0272] FIG. 22 provides a schematic of the vector AY23ins_PSAEnh 1_XCL-FL3_CTLA4-Fc_TGFbt-Hin-DP-striLIGHT_CX9-IL12V4_pGASc_PDLl-Hin-striCD40L_T2A_B7H3-Fc. It consists of a custom bacterial cloning vector backbone (AY23) and serves as a template for cloning into helper- dependent adenovirus vectors, which in this representation contains the insert for pGLAd-FIG-g05t73 (see description in FIG. 28). (This is g05t73 expression construct: pGAS + T2A_B7-H3-Fc.)
[0273] FIG. 23 provides a schematic of the vector AY23ins_PSAEnhl_XCL-FL3_CTLA4-Fc_CX9-IL12V4_pGASc_PDLl-Hin-striCD40L_T2A_B7H3-Fc. It consists of a custom bacterial cloning vector backbone (AY23) and serves as a template for cloning into helperdependent adenovirus vectors, which in this representation contains the insert for pGLAd-FIG-g04t73 (see description in FIG 31). (This is g04t73 expression construct: pGAS + T2A_B7-H3-Fc.)
[0274] FIG. 24 provides a schematic of an AY23 backbone comprising a PSAEnhl_XCL-FL3_CTLA4-Fc_Hinge-CH3_sctriCD40L_CX9-IL12V4_pGASc_PDLl_IgG4-Fc_IL21-furin-sIL15_IRES_PRX302.
[0275] FIG. 25 provides a schematic of an AY23 backbone comprising a PSAEnhl_XCL-FL3_CTLA4-Fc_CD40L_M ATN_LIGHT _CX9-IL 12 V4_pGASc_PDL l_IgG4-Fc_IL21 -furin-sIL15_IRES_PRX302.
[0276] FIG. 26 provides a schematic of an AY23 backbone comprising a PSAEnhl_XCL-FL3_CTLA4-Fc-TGFbt_Hinge-CH3_sctriCD40L_CX9-IL12V4_pGASc_PDLl_IgG4-Fc_IL21-furin-sIL15_IRES_PRX302.
[0277] FIG. 27 provides a schematic of an Ad5 / F35 Helper-Dependent Adenovirus vector (pGLAd) harboring the tumor- specific (“initial”) promoter and enhancer PSAEnhl controlling
[0278] 30
[0279] FH30035011.1
[0280] Attorney Docket No: FTE-00125
[0281] XCLl_furin_FLT3L_spTPA in the first cassette, followed by a furin_GSG_P2A self-cleaving peptide site,anti-CTLA4 scFVFc_spTPA in the third cassette, followed by a furin_GSG_T2A self-cleaving peptide site, TGF beta trap_Hinge-CH3-DP_furin_sctriLIGHT_spTPA as the third cassette, followed by a furin2_GSG_P2A2 self- cleaving peptide site (same protein sequence as furin and P2A cleavage sites, but with different, codon-optimized, DNA sequences to prevent homologous recombination), and CXCL9_furin_IL12V4-DP_spTPA as the fourth cassette, followed by a BGH poly A site. Upstream from the PSA-promoter is the GASc IFN gammasensitive (“delayed”) promoter (“pGASc”), with an cHS4 insulator sequence in between to prevent crosstalk, that is in the reverse complement to facilitate transcription in the opposite direction of the components of the initial promoter. Under the control of the delayed promoter (all in reverse complement) is anti-PDLl scFV_Hinge-CH3_sctriCD40L_spTPA, followed by a furin3_GSG_P3A3 self-cleaving peptide site (same protein sequence as furin and P2A cleavage sites, but with different, codon-optimized, DNA sequences from furin_GSG_P2A and furin2_GSG_P2A2 to prevent homologous recombination), IL21_furin_sIL15-DP_spTPA as the second cassette, followed by a furin2_GSG_T2A2 self-cleaving peptide site, and anti-B7 H3 scFV-Fc_spTPA as the third cassette, followed by a SV40 late poly A site. - This vector is also represented by the name pGLAd_PSAEnhl_XCL-FL3_CTLA4-Fc_Hin-DP-striLIGHT_CX9-IL12V4_pGASc_PDLl-Hin-striCD40L_IL21-furin-sIL15_T2A_B7H3-Fc. In the in vivo studies described in the examples, this is referred to with the following naming conventions: as the first letter represents the delayed promoter used (“c” for CIITA pIV or “g” for GAS), the number afterward represents the number of non-tumor lysis cassettes in the vector, the letter after represents the site immediately upstream the tumor-lyser (“i” for IRES or “t” for T2A), and the last number represents which lyser (“3” for “PRX302” or “73” for “anti-B7 H3 scFV-Fc). As such, this viral vector is also named pGLAd-FIG-g06t73.
[0282] FIG. 28 provides a schematic of pGLAd_PSAEnhl_XCL-FL3_CTLA4-Fc_TGFbt-Hin-DP-striLIGHT_CX9-IL12V4_pGASc_PDLl-Hin-striCD40L_T2A_B7H3-Fc, also referred to herein as pGLAd-FIG-g05t73. This is identical to the vector in FIG 33, but with the removal of the IL21_furin_sIL15-DP_spTPA cassette and the furin3_GSG_P3A3 site.
[0283] FIG. 29 provides a schematic of pGLAd_PSAEnhl_XCL-FL3_CTLA4-Fc_TGFbt-Hin-DP-striLIGHT_CX9-IL12V4_pCIITA_PDLl-Hin-striCD40L_IL21-furin-sIL15_T2A_PRX302, also referred to herein as pGLAd-FIG-c06t3. This is identical to the vector in FIG 33, but with
[0284] 31
[0285] FH30035011.1
[0286] Attorney Docket No: FTE-00125 the replacement of GASc promoter for the CIITA pIV promoter (“pCIITA pIV”) as well as replacement of the anti-B7 H3 scFV-Fc_spTPA for PRX302_spPSA.
[0287] FIG. 30 provides a schematic of pGLAd_PSAEnhl_XCL-FL3_CTLA4-Fc_TGFbt-Hin-DP-striLIGHT_CX9-IL12V4_pGASc_PDLl-Hin-striCD40L_IL21-furin-sIL15_IRES_PRX302, also referred to herein as pGLAd-FIG-g06i3. This is identical to the vector in FIG 33, but with the replacement of the furin2_GSG_T2A site for an IRES element as well as replacement of the anti-B7 H3 scFV-Fc_spTPA for PRX302_spPSA.
[0288] FIG. 31 provides a schematic of pGLAd_PSAEnhl_XCL-FL3_CTLA4-Fc_CX9-IL12V4_pGASc_PDLl-Hin-striCD40L_T2A_B7H3-Fc, also referred to herein as pGLAd-FIG-g04t73. This is identical to the vector in FIG 34, but with the further removal of the TGF beta trap_Hinge-CH3-DP_furin_sctriLIGHT_spTPA cassette and the furin_GSG-T2A site.
[0289] FIG. 32 provides a schematic of pGLAd_PSAEnhl_XCL-FL3_CTLA4-Fc_TGFbt-Hin-DP-striLIGHT_CX9-IL12V4_pCIITA_PDLl-Hin-striCD40L_IL21-furin-sIL15_IRES_PRX302, also referred to herein as pGLAd-FIG-c06i3. This is identical to the vector in FIG 35, but with the replacement of pGASc promoter for the CIITA pIV promoter (“pCIITA pIV”).
[0290] FIG. 33 provides a schematic of AY23ins_PSAEnhl_XCL-FL3_CTLA4-Fc_TGFbt_hin-DP-sctriLIGHT_CX9-ILl 2V4_pGAS_PDL 1 -Hin-sctri-CD40L_IL21 -furin-sIL15_T2A_PRX302. This consists of a custom bacterial cloning vector backbone (AY23) and serves as a template for incorporation into a helper- dependent adenovirus vector (i.e. pGLAd). This embodiment is identical to c06t3 (FIG. 35), but with the replacement of the CIITA pIV promoter (pCIITA pIV) for a GAS promoter (pGASc). When incorporated into a viral vector, it is known as FIG-g06t3.
[0291] FIG. 34 provides a schematic of AY23ins_PSAEnhl_XCL-FL3_CTLA4-Fc_TGFbt_CD40 scFv_Hin_sctriLIGHT_CX9-IL12V4_pGAS_PDLl scFv-IgGl Fc_IL21-furin-sIL15_T2A_PRX302, which serves as a template for incorporation into a helper- dependent adenovirus vector (i.e. pGLAd). This embodiment is identical to g06t3, but with the replacement of the anti-CTLA4 scFV-Fc_spTPA cassette for anti-CTLA4 scFV-Fc_TGFbt_spTPA, the replacement of TGFbt_Hinge-CH3-DP_sctriLIGHT-spTPA for CD40 agonist scFV_Hinge-CH3_sctriLIGHT, and with the replacement of anti-PDLl scFV_Hinge-CH3_sctriCD40L for anti-PDLl scFV-IgGl -Fc. When incorporated into a viral vector, it is known as pGLAd_g06t3_
[0292] 32
[0293] FH30035011.1
[0294] Attorney Docket No: FTE-00125
[0295] PSAEnhl_CTLA4-Fc_TGFbt_CD40 scFv_Hin_sctriLIGHT_pGAS_PDLl scFv-IgGl Fc (only naming the changes from unmodified pGEAd-g06t3)
[0296] FIG. 35 provides a schematic of AY23ins_PSAEnhl_XCE-FE3_CTEA4-Fc_TGFbt_CD40 scFv_Hin_sctriEIGHT_CX9-IE12V4_pGAS_PDEl scFv-IgGl Fc_IL21-furin-sIE15_T2A_B7H3-Fc, which serves as a template for incorporation into a helperdependent adenovirus vector (i.e. pGEAd). This embodiment is identical to pGEAd_g06t3_ PSAEnhl_CTLA4-Fc-TGFbt_CD40 scFv-Hin-sctriEIGHT_pGAS_PDEl scFv-IgGl Fc (FIG
[0297] 40), but with the replacement of PRX302 for anti-B7 H3 scFV-Fc_spTPA. When incorporated into a viral vector, it is known as pGEAd_g06t73_ PSAEnhl_CTEA4-Fc-TGFbt_CD40 scFv-Hin-sctriEIGHT _pGAS_PDEl scFv-IgGl Fc (t3 changed to t73).
[0298] FIG. 36 provides a schematic of AY23ins_PSAEnhl_XCE-FE3_CTEA4-Fc_TGFbt_CD40 scFv_Hin_sctriLIGHT_CX9-IL12V4_pGAS_PDLl_Hin_sctriBlBBL_IL21-furin-sIE15_T2A_B7H3-Fc. which serves as a template for incorporation into a helperdependent adenovirus vector (i.e. pGEAd). This embodiment is identical to pGEAd_g06t73_ PSAEnhl_CTLA4-Fc-TGFbt_CD40 scFv_Hin_sctriEIGHT_pGAS_PDEl scFv-IgGl Fc (FIG
[0299] 41), but with the replacement of anti-PDEl scFv-IgGl Fc_spTPA for anti-PDEl scFv_Hinge-CH3_sctri4-lBBE. When incorporated into a viral vector, it is known as pGEAd_g06t73_ PSAEnhl_CTLA4-Fc-TGFbt_CD40 scFv-Hin-sctriEIGHT_pGAS_PDEl-Hin-sctri4-lBBE.
[0300] FIG. 37 Provides a graph showing XCE1 concentrations in conditioned media from 22Rvl cells transfected with the indicated constructs comprising XCE1 -containing payloads, including constructs encoding XCEl-furin-FET3E, XCE-FE3 linked to CXCE9-IE12V4 by P2A or T2A elements, and a multimodal PSAEnhl -driven construct. XCE1 was quantified by R& D Systems DuoSet EEISA. Negative-control conditioned medium was included as a background control.
[0301] FIG. 38 shows FLT3E concentrations in conditioned media from 22Rvl cells transfected with a PSAEnhl -driven multimodal construct comprising XCE1-FLT3E together with additional immunotherapeutic payloads. FLT3E was quantified by R& D Systems DuoSet ELISA.
[0302] Negative-control conditioned medium was included as background control.
[0303] FIG. 39 provides a graph showing IL-12-dependent reporter activation measured using a Promega IL- 12 Bioassay. Conditioned medium from 22Rvl cells transfected with a PSAEnhl -driven multimodal construct comprising CXCL9-IL12V4 was compared with an IL- 12 standard
[0304] 33
[0305] FH30035011.1
[0306] Attorney Docket No: FTE-00125 curve and negative-control conditioned medium. Reporter activity is plotted as relative luminescence units (RLU).
[0307] FIG. 40 provides a graph showing IL- 12 concentrations in conditioned media from 22Rvl cells transfected with the indicated IL12V4-containing constructs, including CXCL9-IL12V4, XCL-FL3 / CXCL9-IL12V4, P2A-linked and T2A-linked formats, and a multimodal PSAEnhl -driven construct. IL- 12 was quantified by R& D Systems DuoSet ELISA. Naive 22Rvl medium and negative-control samples were included as background controls.
[0308] FIG. 41 provides a graph of CXCL9 concentrations in conditioned media from cells transfected with the indicated CXCL9-IL12V4-containing constructs. Constructs included a full multimodal PSAEnhl -driven cassette and smaller CXCL9-IL12V4 formats linked to XCL-FL3 by P2A, T2A, or related 2A elements. CXCL9 was quantified by R& D Systems DuoSet ELISA. Negative-control conditioned medium was included as a background control.
[0309] FIG. 42 provides a graph showing detection of TGFp-trap / TGFBRII-containing payloads in conditioned media from 22Rvl cells transfected with the indicated constructs, including TGFp-trap-Hinge, TGFP-trap-Hinge-sctriLIGHT, TGFP-trap-Hinge-DP-sctriLIGHT, anti-CTLA4-Fc-TGFP-trap, TGFP-trap-Fc-CTLA4, and a full multimodal PSAEnhl construct.
[0310] TGFp-trap-related protein was quantified by R& D Systems DuoSet ELISA. Negative-control conditioned medium was included as background.
[0311] FIG. 43 provides a graph showing LIGHT concentrations in conditioned media from 22Rvl cells transfected with a multimodal construct comprising a TGFP-trap-Hinge-DP-sctriLIGHT module. LIGHT was quantified by R& D Systems DuoSet ELISA. Negative-control conditioned medium was included as background control.
[0312] FIG. 44 provides a graph showing CD40L concentrations in conditioned media from 22Rvl cells transfected with the indicated CD40L-containing constructs, including sctriCD40L, Hinge-sctriCD40L, PD-Ll-Hinge-CH3-sctriCD40L, and a multimodal EFl-driven construct comprising PD-L1 -Hinge- sctriCD40L with additional payloads. CD40L was quantified by R& D Systems DuoSet ELISA. Negative-control conditioned medium was included as background.
[0313] FIG. 45 provides a graph showing functional PD-1 / PD-L1 blockade activity in conditioned medium from 22Rvl cells transfected with an anti-PD-Ll scFv-Hinge-CH3-sctriCD40L-containing construct. Activity was measured using a Promega PD-1 / PD-L1
[0314] 34
[0315] FH30035011.1
[0316] Attorney Docket No: FTE-00125
[0317] Blockade Bioassay and is plotted as relative luminescence units (RLU). A positive-control antibody and negative-control conditioned medium were included for comparison.
[0318] FIG. 46 provides a graph showing IL- 15 concentrations in conditioned media from 22Rvl cells transfected with constructs comprising IL21-furin-sIL15, including a PSAEnhl-driven IL21 -furin- sIL 15 construct and a larger EFl -driven multimodal construct comprising PD-Ll-Hinge-sctriCD40L, IL21-furin-sIL15, and additional payloads. IL-15 was quantified by R& D Systems DuoSet Human IL-15 / IL-15Ra Complex ELISA. Negative-control conditioned medium was included as background.
[0319] FIG. 47 provides a graph showing Kaplan-Meier survival of 22Rvl xenograft-bearing HLA-matched CD34+ humanized SGM3-IL15 mice treated with a single dose of HD-Ad stuffer control or the indicated FIG helper-dependent adenoviral constructs. Experimental constructs included promoter / lyser matrix variants differing in delayed promoter identity, lyser identity, and translational linkage immediately upstream of the tumor-lysis module.
[0320] FIG. 48 provides a graph showing primary / injected tumor volumes over time in 22Rvl xenograft-bearing HLA-matched CD34+ humanized SGM3-IL15 mice treated with a single dose of HD-Ad stuffer control or the indicated FIG helper- dependent adenoviral constructs. The experimental matrix compared constructs differing in delayed promoter identity (pGASc versus OITA pIV), tumor-lysis module (PRX302 versus anti-B7-H3 scFv-Fc), translational linkage immediately upstream of the lyser cassette (T2A versus IRES), and inclusion or removal of selected non-lyser payload cassettes.
[0321] FIG. 49 provides a graph showing primary / injected tumor volumes over time in 22Rvl xenograft-bearing HLA-matched CD34+ humanized SGM3-IL15 mice treated with a single dose of HD-Ad stuffer control or the indicated FIG helper- dependent adenoviral constructs. The experimental matrix compared constructs differing in delayed promoter identity (pGASc versus CIITA pIV), tumor-lysis module (PRX302 versus anti-B7-H3 scFv-Fc), translational linkage immediately upstream of the lyser cassette (T2A versus IRES), and inclusion or removal of selected non-lyser payload cassettes.
[0322] FIG. 50 provides a graph showing contralateral / non-injected abscopal tumor volumes over time in 22Rvl xenograft-bearing HLA-matched CD34+ humanized SGM3-IL15 mice treated with a single dose of HD-Ad stuffer control or the indicated FIG helper-dependent
[0323] 35
[0324] FH30035011.1
[0325] Attorney Docket No: FTE-00125 adenoviral constructs. The experimental matrix compared delayed promoter identity, tumor-lysis module, lyser-linkage strategy, and non-lyser payload composition.
[0326] FIG. 51 provides a graph showing Promega CTLA4 blockade bioassay measuring functional CTLA4-blocking activity in conditioned medium from 22Rvl cells transfected with a plasmid encoding PSAEnhl_XCL-FL3_CTLA4-Fc_TGFpt-Hin-DP-sctriLIGHT_CX9-IL12. Conditioned medium from transfected cells was compared with an ipilimumab positive-control curve and a 22Rvl negative-control sample. Increased relative luminescence units (RLU) indicate CTLA4 pathway blockade. The anti-CTLA4-containing construct produced dose-responsive CTLA4 blockade activity above the negative control.
[0327] FIG. 52 provides a graph showing IL 15 expression in conditioned media from 22Rvl cells transfected with a reverse-complement, IFN-gamma-inducible pCIITA delayed-promoter multicistronic vector encoding anti-PD-Ll -Hinge- sctriCD40L, IL21-furin-sIL15, and PRX302, with T2A positioned immediately upstream of PRX302. Cells were cultured in the presence of 1 ng / mL IFN-gamma following transfection. IL15 concentration was measured in conditioned medium by DuoSet Human IL-15 / IL-15Ra Complex ELISA and compared with a negativecontrol transfection. Bars show mean signal with error bars as plotted.
[0328] FIG. 53 provides a graph showing CD40L expression in conditioned media from 22Rvl cells transfected with a reverse-complement, IFN-gamma-inducible pCIITA delayed-promoter multicistronic vector encoding anti-PD-Ll -Hinge- sctriCD40L, IL21-furin-sIL15, and PRX302, with T2A positioned immediately upstream of PRX302. Cells were cultured in the presence of 1 ng / mL IFN-gamma following transfection. CD40L concentration was measured in conditioned medium by DuoSet ELISA and compared with a negative-control transfection. Bars show mean signal with error bars as plotted.
[0329] FIG. 54 provides a graph showing IL 15 expression in conditioned media from 22Rvl cells transfected with a reverse-complement pGAS delayed-promoter vector encoding IL21-furin-sIL15-DP. Cells were cultured in the presence of 1 ng / mL IFN-gamma following transfection. IL15 concentration was measured in conditioned medium by DuoSet Human IL-15 / IL-15Ra Complex ELISA and compared with a negative-control transfection. Bars show mean signal with error bars as plotted.
[0330] DETAILED DESCRIPTION OF THE INVENTION
[0331] 36
[0332] FH30035011.1
[0333] Attorney Docket No: FTE-00125
[0334] In some embodiments, the present technology relates to therapeutic agents, nucleic acid constructs encoding such therapeutic agents, and methods for their use in, e.g., cancer treatment. In particular, in some embodiments, provided herein are compositions and methods for multicomponent cancer immunotherapy. In some embodiments, the cancer treatment is by local injection (in and around the tumor tissue) of vectors or expression cassettes comprising nucleic acids encoding therapeutic agents and / or polypeptide-based therapeutic agents. In some embodiments, the cancer treatment is by intratumoral injection of vectors comprising expression cassettes comprising nucleic acids encoding therapeutic agents. The vectors and expression cassettes can be polycistronic, e.g., bicistronic, tricistronic or quadricistronic. The intratumoral injection may target the cancer cells, but may also or predominantly target the surrounding tissue of the tumor microenvironment, e.g., the surrounding stromal cells. In some embodiments, the vectors comprising an expression cassette provided herein are in the form of RNA, e.g., selfamplifying RNA, circular RNA, and / or mRNA (e.g., encapsulated within a lipid nanoparticle). In some embodiments, the vectors comprising an expression cassette provided herein are in the form of DNA, e.g., plasmid or circular DNA, linear DNA, poxvirus DNA, or helper-dependent adenovirus DNA. In some embodiments, the DNA-based expression cassettes comprise promoter, enhancer and / or transcription factor responsive element(s) that are specific to the cells being targeted (such as a promoter driven by one or more transcription factor overexpressed in the target cancer cell). In some embodiments, one or more of the expression cassettes are under the control of an immediate promoter, and one or more of the expression cassettes are under the control of a delayed promoter (activated after the expression of the gene product(s) under the control of the immediate promoter) as described herein. Examples of suitable promoters, including immediate and delayed promoters, are described herein. In alternative embodiments, protein cocktails of therapeutic agents are also contemplated herein in lieu of one or more therapeutic agents delivered via nucleic acid-based delivery.
[0335] Examples of therapeutic agents provided for use in the compositions and methods of the invention are described in detail herein. In some embodiments, specific fusion proteins are used in the described cancer therapies, which are described in detail and exemplary sequences of which are provided herein.
[0336] In some embodiments, provided herein are optimized compositions and therapies suitable for multimodal approach to immunotherapy. For example, described herein are polycistronic
[0337] 37
[0338] FH30035011.1
[0339] Attorney Docket No: FTE-00125 expression cassettes or polycistronic vectors that are capable of simultaneous delivery of multiple therapeutic agents to elicit maximum effect.
[0340] The multimodal approach provided herein addresses the deficiencies that exist in the art. For example, although CTLA4 inhibition allows for signal 2 activation through improving interaction between CD28 on CD8+ T cells and CD80 / 86 on APCs, it does not address the heavy suppression of signal 1 in the majority of tumors via MHC Class I downregulation. Additionally, although anti-PDLl / anti-PDl inhibition prevents T cell exhaustion, it does not address the multiple other immunosuppressive mechanisms within the tumor microenvironment that inhibit T cell activation in the first place. In addition, toxicity has been a recurrent problem with systemic administration of cytokines that have powerful effects on reversing the immunosuppressive mechanisms, such as IL 12 and IFN gamma. The advantage of the therapies provided herein is that it results in a lasting therapeutic effect and addresses multiple immune evasion mechanisms at once. The therapies provided herein allows to optimally address multiple immune evasion mechanisms.
[0341] “Gene therapy,” as discussed herein, encompasses administration of one or more isolated nucleic acids or vectors, including two, three or more vectors, as described herein.
[0342] Provided herein are multiple therapeutic agents characterized, inter alia, by their amino acid sequences. Variants thereof having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99% amino acid sequence identity thereto are also encompassed herein. Also provided herein are nucleic acid sequences encoding certain therapeutic agents. Variants of such nucleic acid sequences having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity are also encompassed herein. In some embodiments, variants contemplated herein have mutations, amino acid substitutions or truncations (e.g., conservative amino acid substitutions), that preserve the original functionality of the therapeutic agent. The reference in the disclosure and claims to variant or variants encompasses variants that have at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99% sequence identity to the stated sequences.
[0343] In some embodiments, the gene therapies described herein are configured to use transfected or transduced tumor cells or tumor microenvironment cells as local producers of one or more immunomodulatory agents before induction of tumor lysis or tumor antigen release. In certain embodiments, expression of a tumor lysis agent is delayed, attenuated, protease-gated, or 38
[0344] FH30035011.1
[0345] Attorney Docket No: FTE-00125 otherwise tuned relative to expression of one or more upstream immunomodulatory agents, thereby permitting local production and secretion of one or more therapeutic agents prior to substantial lysis of the producer cell. In some embodiments, this temporal separation is achieved by use of an immediate promoter and a delayed immune-activation-responsive promoter, by use of IRES or 2A elements to tune relative expression, by use of different secretory signal peptides, by cassette order, or by combinations thereof, as described herein.
[0346] Terminology
[0347] Unless defined otherwise, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures utilized in connection with, and techniques of, chemistry, biochemistry, molecular biology, pharmacology and toxicology are those well-known and commonly used in the art.
[0348] The articles “a” and “an,” as used herein, refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.
[0349] The term “about,” when used to modify a numeric value herein, indicate that deviations of up to 10% above and below the numeric value remain within the intended meaning of the recited value.
[0350] A “subject,” as used herein, is a human or a non-human animal. This term includes mammals, such as humans, primates, livestock animals, companion animals and animal models of disease.
[0351] In general, the term “antibody” refers to an antibody (an immunoglobulin molecule) comprising two light chain polypeptides and two heavy chain polypeptides. As used herein, the term antibody may encompass an antigen-binding fragment of an antibody. Whole antibodies (immunoglobulin molecules) include different antibody isotypes including IgM, IgG, IgA, IgD, and IgE antibodies. The term “antibody” includes a polyclonal antibody, a monoclonal antibody, a chimerized or chimeric antibody, a humanized antibody, a primatized antibody, a deimmunized antibody, and a fully human antibody. The antibody can be made in or derived from any of a
[0352] 39
[0353] FH30035011.1
[0354] Attorney Docket No: FTE-00125 variety of species, e.g., mammals such as humans, non-human primates, horses, cattle, pigs, sheep, goats, dogs, cats, rabbits, guinea pigs, gerbils, hamsters, rats and mice. The antibody can be a purified or recombinant antibody.
[0355] The term "monoclonal antibody," as used herein, refers to an antibody member of a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible mutations, e.g., naturally occurring mutations, that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. A monoclonal antibody can be produced by any techniques including non-hybridoma techniques, e.g., by recombinant techniques.
[0356] The term “antigen-binding fragment,” as used herein, refers to a fragment of an antibody that retains the antibody’s ability to bind a target antigen. Such fragments include, without limitation, a single chain antibody, a single chain Fv fragment (scFv), an Fd fragment, a Fab fragment, a Fab’ fragment, or an F(ab’)2 fragment. An scFv fragment is a single polypeptide chain that includes both the heavy and light chain variable regions of the antibody from which the scFv is derived. Intrabodies, nanobodies, minibodies, triabodies, and diabodies are also included in the definition of antigen-binding fragment. In some embodiments, an antigen-binding fragment described herein comprises the CDRs of the light chain and / or heavy chain polypeptide of an antibody, e.g., three CDRs of the light chain and three CDRs of the heavy chain.
[0357] The term “VL,” as used herein, refers to the light chain variable domain or region of an antibody.
[0358] The term “VH,” as used herein, refers to the heavy chain variable domain or region of an antibody.
[0359] The term “LC,” as used herein, refers to the light chain of an antibody.
[0360] The term “HC,” as used herein, refers to the heavy chain of an antibody.
[0361] The term “percent (%) amino acid sequence identity” or “percent (%) sequence identity,” as used herein, with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary,
[0362] 40
[0363] FH30035011.1
[0364] Attorney Docket No: FTE-00125 to achieve the maximum percent sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are known in the art, for instance, using publicly available computer software such as BLASTp, BLAST-2, ALIGN, ALIGN-2, or Megalign (DNASTAR) software.
[0365] The term “percent (%) nucleic acid sequence identity” or “percent (%) sequence identity,” as used herein, with respect to a reference nucleic acid sequence is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity.
[0366] “Administering” or “administration of’ to a subject can be carried out using one of a variety of methods known to those skilled in the art. In some embodiments, the administration is parenteral. For example, an antibody or fragment can be administered, intravenously or intramuscularly. Administering can also be performed, for example, once, a plurality of times, and / or over one or more extended periods.
[0367] The term an “effective amount” or a “therapeutically effective amount,” as used herein, is an amount that, when administered to a subject will have or expected to have a therapeutic effect. A therapeutically effective amount may be administered in one or more administrations. The precise effective amount needed for a subject will depend upon, for example, the subject’s size, health and age, and the nature and extent of the condition being treated.
[0368] The term “treating,” as used herein, refers to administering a therapy to a subject having or suspected of having a disorder or disease (i.e., after the onset of the disorder or disease), such that at least one symptom of the disorder or disease is decreased or prevented from worsening. Desirable effects of treatment include decreasing the rate of progression, ameliorating or palliating the pathological state, and remission or improved prognosis of the disorder or disease. An individual is successfully “treated,” for example, if one or more symptoms associated with a disorder or disease are mitigated or eliminated.
[0369] The term “preventing,” as used herein, refers to administering a therapy to a subject prior to the onset of the disorder or disease, when administration of the therapy to a statistical sample prior to the onset of the disorder or disease reduces the occurrence of the disorder or disease in the treated sample relative to an untreated control sample, or delays the onset or reduces the
[0370] 41
[0371] FH30035011.1
[0372] Attorney Docket No: FTE-00125 occurrence or severity of one or more symptoms of the disorder or disease relative to the untreated control sample.
[0373] The term “cassette,” or “expression cassette,” or “expression unit,” as used herein, refers to a functional unit of DNA (or RNA) comprising one or more regulatory elements sufficient to drive expression of an operably linked coding sequence (encoding one or more gene products) in a host cell. In some embodiments, the one or more regulatory elements comprise at least a promoter, which is operably linked to a coding sequence encoding one or more gene products (such as any agent or multiple agents described herein). In some embodiments, the gene product is a protein (e.g., a fusion protein). The “cassette” or “expression cassette” may encode one gene product (e.g., a protein) or multiple (two or more) gene products (e.g., two or more proteins).
[0374] The term “polycistronic cassette,” as used herein, refers to a cassette that encodes more than one (two or more) gene products. In some embodiments, two or more gene products can be separated from each other by, for example, a cleavage site.
[0375] The term “polycistronic vector,” as used herein, refers to a vector comprising one or more cassettes together encoding more than one (i.e., two or more) gene products. A polycistronic vector may have one cassette encoding two or more gene products. A polycistronic cassette may also have two or more cassettes, where each of the two or more cassettes encodes one or more gene products.
[0376] The term “multi-cassette vector,” as used herein, refers to a vector comprising more than one (i.e., two or more) cassettes.
[0377] Therapeutic Agents
[0378] In some embodiments, provided herein is an expression cassette comprising a polynucleotide sequence encoding one or more gene products (e.g., proteins), wherein the one or more gene products target immunosuppressive tumor microenvironment or an immune evasion mechanism, such as any of those described herein. Provided herein is an expression cassette comprising a polynucleotide sequence responsive to a transcription factor (e.g., a promoter and / or enhancer) overexpressed in a target cell or tissue (e.g., in a tumor or a cancer), operably linked to a polynucleotide sequence encoding one or more gene products. In some embodiments, the target cell or tissue is a cell or tissue affected by a disease or disorder, and the one or more gene products may treat, inhibit the development of, or alleviate the disease or disorder.
[0379] 42
[0380] FH30035011.1
[0381] Attorney Docket No: FTE-00125
[0382] In some embodiments, provided herein is a nucleic acid therapy agent. A nucleic acid therapy agent provided herein can be any agent that upon expression (e.g., the expression into a protein inside a target cell) may have a therapeutic effect, such as any agent described herein or known in the art. In some embodiments, the agent is an agent that has a therapeutic effect when expressed in, or secreted from, a target cell or population of target cells (targeted by nucleic acid therapy using the compositions and methods described herein).
[0383] In some embodiments, provided herein is a nucleic acid therapy agent which encodes any agent described herein. In some embodiments, the nucleic acid therapy agent is delivered via a DNA- or RNA-based polynucleotide cassette (e.g., a DNA plasmid, linear DNA, mRNA, selfamplifying RNA, circular RNA, etc.).
[0384] In some embodiments, provided herein is a nucleic acid therapy which, in one, two, three or more DNA- or RNA-based polynucleotide cassettes, encodes multiple (e.g., 2, 3, 4, 5, 6, 7, 8 or more) agents described herein. In some embodiments, provided herein is a nucleic acid therapy which comprises administration of one, two, three or more DNA- or RNA-based cassettes encoding multiple (e.g., 2, 3, 4, 5, 6, 7, 8 or more) agents described herein (e.g., simultaneously, concurrently or sequentially). In some embodiments, a nucleic acid therapy encodes at least 4, 5, 6, 7, or 8 agents. In some embodiments, a nucleic acid therapy results in the expression of at least 4, 5, 6, 7, or 8 agents in the target cells and / or in the tissue surrounding the target cells.
[0385] In other embodiments, the agent described herein is provided in a peptide or polypeptide form. In some embodiments, the peptide or polypeptide is delivered in a form of a protein cocktail. In some embodiments, the protein cocktail comprises multiple (e.g., 2, 3, 4, 5, 6, 7, 8 or more) agents described herein. In some embodiments, the protein-based agents described herein are administered simultaneously (in one protein cocktail composition), concurrently or sequentially. In some embodiments, provided herein is a therapy with a combination of proteinbased agents comprising at least 4, 5, 6, 7, or 8 agents. In some embodiments, such agents are delivered into the target cells or the tissue comprising and / or surrounding the target cells.
[0386] In some embodiments, the agent is a cytotoxin, a tumor suppressor, a cytokine, a chemokine, an immuno stimulatory gene, an agent that modulates the tumor microenvironment by recruiting cells of the innate or adaptive immune system, or an agent that silences an anti-apoptotic gene or an immunosuppressive gene.
[0387] 43
[0388] FH30035011.1
[0389] Attorney Docket No: FTE-00125
[0390] In some embodiments, the agent is an immune response stimulator. In some embodiments, the agent is an activator of, or upregulates, MHC Class I expression. In some embodiments, the agent is IFN gamma (IFNg). In some embodiments, the agent is an immune checkpoint inhibitor. In some embodiments, the agent is an inhibitory antibody binding to CTLA4, PD1 or PDL1 (e.g., an antibody interfering with the PD1 / PDL1 interaction). In some embodiments, the agent is a cytokine, e.g., an immuno stimulatory cytokine. In some embodiments, the agent is IL- 12 or GM-CSF. In some embodiments, the agent is a dendritic cell activator. In some embodiments, the agent is FLT3 Ligand (FLT3L) or IFN alpha (IFN alpha 2B). In some embodiments, the agent is a chemokine. In some embodiments, the agent is a C-X-C motif chemokine ligand (CXCL). In some embodiments, the agent is CXCL9. In some embodiments, the agent is CXCL 10. In some embodiments, the agent is a member of the tumor necrosis factor superfamily (TNFSF) or a variant thereof. In some embodiments, the agent is or comprises an extracellular domain of a TNFSF protein. In some embodiments, the agent is a CD40 ligand (CD40L), a 4- IBB ligand (4-1BBL), an 0X40 ligand (OX40-L), LIGHT (also known as Tumor Necrosis Factor Superfamily member 14 or TNFSF14), or GITRL (also known as Glucocorticoid-Induced TNF Receptor Ligand or TNFSF18). In some embodiments, the agent is an inhibitor of M2 macrophages and / or myeloid derived stem cells (MDSCs). The molecules and antibodies described herein can be any of those known in the art or described herein, or a variant thereof (e.g., comprising, e.g., the CDRs of the antibodies known in the art, or comprising an active region or antigen-binding fragment thereof, but including conservative modifications or truncations).
[0391] In some embodiments, the agent is a therapeutic fusion protein (e.g., a fusion between two immunotherapeutic proteins). In some embodiments, the agent is a fusion protein between (i) a PD1 antigen-binding fragment described herein or known in the art and (ii) CD40 or a variant thereof. In some embodiments, the agent is a fusion protein between (i) a CTLA-4 or PD1 antigen-binding fragment described herein or known in the art and (ii) an IgG Fc region.
[0392] In some embodiments, any agent described herein is a secretory protein (e.g., a protein comprising a native secretory signal or modified to comprise a heterologous secretory signal). In some embodiments, the secretory protein (e.g., protein that does not have a native secretory signal) comprises a heterologous secretory signal from a protein known to be secreted (e.g., known to be secreted at a high level). In some embodiments, the secretory protein comprises a 44
[0393] FH30035011.1
[0394] Attorney Docket No: FTE-00125 heterologous secretory signal from a protein expressed at a high level in a target cell (e.g., a secretory signal from PSA for an agent to be expressed in prostate cancer cells, or a secretory signal from CA19 for an agent to be expressed in pancreatic cancer cells). In some embodiments, the secretory protein comprises a heterologous secretory signal from a cytokine (e.g., a TPA secretory signal). In some embodiments, at least one, two, three or more agents in the multimodal therapy provided herein comprise a non-native secretory signal, which can be the same or different. In some embodiments, at least one, two, three or more agents in the multi-modal therapy provided herein comprise a TPA secretory signal peptide (e.g., the same TPA secretory signal peptide, each of which can be encoded by a different nucleic acid sequence to minimize homologous recombination risks).
[0395] In some embodiments, an agent described herein can be engineered to comprise a homodimerization domain, such as any described herein. In some embodiments, an agent described herein can be engineered to comprise a Hinge-CH3 domain described herein. In some embodiments, a homodimerization domain or a Hinge-CH3 domain is fused to the C-terminal of a protein, or between two proteins forming a fusion protein. Where a homodimerization (e.g., Hinge-CH3) domain is present between two proteins forming a fusion protein as described herein, a linker (such as a flexible linker or any linker described herein) can be further present between any protein and the homodimerization domain.
[0396] In some embodiments, an agent described herein can be engineered to comprise a decorin peptide, as described herein. In some embodiments, a decorin peptide is fused to the C-terminal of a protein. A linker (such as a flexible linker or any linker described herein) can be further present between any protein and the decorin peptide.
[0397] In some embodiments, the agents described herein comprise a peptide-based nuclear localization sequence. In some embodiments, the nuclear localization sequence comprises the amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the nuclear localization sequence comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 98% amino acid sequence identity to SEQ ID NO: 52.
[0398] In some embodiments, the agent comprises a transmembrane protein domain fused to an extracellular protein domain, wherein the extracellular protein domain is effective to tag cells for destruction (such as by phagocytosis, cytotoxicity, or immune-mediated attack, e.g., by attracting ADCC- or complement). In some embodiments, the agent comprises a transmembrane protein
[0399] 45
[0400] FH30035011.1
[0401] Attorney Docket No: FTE-00125 domain fused to an extracellular domain comprising an IgG Fc region (e.g., CH2 and CH3 domains of IgGl Fc).
[0402] In some embodiments, a multi-modal therapy is provided herein, e.g., such that at least or mor than 2, 3, 4, 5, 6, 7, or 8 of the proteins in any of the categories described herein are expressed following administration of one or more polynucleotide cassettes described herein, administered simultaneously or as part of the combination therapy. In some embodiments, a multi-modal therapy is provided herein, e.g., such that at least or more than 2, 3, 4, 5, 6, 7, or 8 of the proteins in any of the categories described herein are combined in a pharmaceutical composition or formulation or administered simultaneously or as part of the combination therapy. In some embodiments, a multi-modal therapy combines administration of polynucleotide cassette(s) and protein-based therapeutic agent(s).
[0403] In some embodiments, a multi-modal therapy comprises one or more immune checkpoint inhibitor (e.g., an anti-PDl antigen binding fragment and / or an anti-CTLA4 antigen binding fragment), one or more cytokine (e.g., IL-12), and one or more dendritic cell activator (e.g., FLT3L). In some embodiments, the multi-modal therapy further comprises any one, two or all three selected from: an MHC Class I expression activator (e.g., IFNg), a chemokine (e.g., CXCL10) and a membrane-bound cell destruction activator (e.g., IgG Fc fused to a transmembrane domain). In some embodiments, at least some of the agents are fused (e.g., using a linker such as a flexible linker), e.g., into fusion proteins described herein. In some embodiments, at least two, three or four of the agents are expressed using a multicistronic cassette (such as any multicistronic cassette described herein). In some embodiments, the agents in the multicistronic cassette are separated by a cleavage site (e.g., any cleavage site described herein). In some embodiments, the delivery methods described herein result in expression or accumulation (e.g., simultaneous) of at least 3, 4, 5, 6, 7, 8 or more of the agents described herein in the target cells and / or the surrounding tissue. In some embodiments, the target cells are cancer cells.
[0404] In some embodiments, the agent is a gene silencing agent such as an shRNA or RNAi, as described herein. In some embodiments, the agent is an inhibitory RNA against PDL1 and / or PDL2 described herein.
[0405] In some embodiments, the therapeutic approach involves a therapy that leads to secretion of at least three, four or more of the following therapeutic proteins: (i) a protein that reconstitutes
[0406] 46
[0407] FH30035011.1
[0408] Attorney Docket No: FTE-00125 expression of MHC Class I and II, (ii) a protein that recruits and activates dendritic and T cells (e.g., a dendritic cell activator), (iii) a protein that blocks immunosuppression, such as by inhibiting immune checkpoints (e.g., a bispeciflc immune checkpoint antagonist and T cell agonist), (iv) a protein that reprograms immunosuppressive tumor microenvironment (“TME”) from immunosuppressive to immunostimulatory (e.g., an immuno stimulatory TME reprogramming cytokine), and (v) a protein that recruits tumor killing immune cells, such as by tagging tumors for ADCC and phagocytosis (e.g., an anti-tumor antibody). In some embodiments, the therapeutic approach involves at least three, four or more of the following: a dendritic cell activator, a bispecific immune checkpoint antagonist and T cell agonist, an immunostimulatory TME reprogramming cytokine, an anti-tumor antibody, a chemokine, and an anti-T-reg antibody. In some embodiments, TME reprogramming includes converting suppressive MDSCs and TAMs into immuno stimulatory cells and / or recruiting dendritic cells to process tumor antigens. In some embodiments, recruiting tumor-killing immune cells includes secretion of chemokines that attract T cells and NK cells to the tumor site. In some embodiments, the therapy provided herein involves or leads to two, three, four or more of the following: (i) tumor lysis and shrinkage, (ii) DC processing of tumor antigen(s), (iii) presentation of antigen(s) to T cells, (iv) secretion of anti-tumor antibodies, and (v) rejection of a metastatic tumor. In some embodiments, the therapy is one or more polynucleotides, delivered via LNP or EP, injected directly into a tumor with MRI fusion or ultrasound (US) guidance. In some embodiments, the one or more polynucleotides comprise therapeutic agents under the control of a promoter and / or enhancer responsive to cancer-causing transcription factors endogenously overexpressed in the targeted tumor. FIG. 17 provides a schematic of a therapy in accordance with the invention.
[0409] In some embodiments, specific examples of the agents described herein are provided in the Sequence Table or the Sequence Listing. In some embodiments, provided herein is any agent set forth in the Sequence Table or the Sequence Listing.
[0410] In some embodiments, nucleic acid (such as DNA) sequence for amino acid sequences described herein is generated using methods well known in the art. In some embodiments, the nucleic acid sequence is codon optimized (e.g., for expression in humans). In some embodiments, the DNA is generated by conversion of each amino acid to a codon that appears with highest frequency in homo sapiens (e.g., in accordance with the disclosure of Nakamura Y, Gojobori T, Ikemura T. Codon usage tabulated from international DNA sequence databases:
[0411] 47
[0412] FH30035011.1
[0413] Attorney Docket No: FTE-00125 status for the year 2000. Nucleic Acids Res. 2000 Jan 1;28(1):292, incorporated by reference herein in its entirety and specifically for the codon optimization disclosures). The published principles of codon optimization are to be followed, either using available tools or manually changing base pairs to optimize structure. In some embodiments, such as to avoid restriction enzyme sites appearing inside a protein described herein, a lower frequency codon may be used. In some embodiments, the nucleic acid is modified to achieve Codon Adaptation Index of at least about 0.9. In some embodiments, the nucleic acid is modified to achieve Codon Adaptation Index from 0.9 to 0.94. Without being bound by theory, lower CAI may slow translation. In some embodiments, the nucleic acid has no polyA-like sites (e.g., no AATAAAA). In some embodiments, the nucleic acid has no restriction sites. In some embodiments, the GC content of the nucleic acid is modified. In some embodiments, the nucleic acid is modified to ensure optimal GC content, e.g., to achieve the GC content from about 50% to about 70%. In some embodiments, the nucleic acid is modified to achieve the GC content from about 54% to about 66%. In some embodiments, the nucleic acid is modified to achieve the GC content of about 60%.
[0414] In some embodiments, also provided herein is an agent that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99% to the agent of any sequence described herein (e.g., amino acid sequence or nucleic acid sequence).
[0415] Immunostimulatory Agents
[0416] In some embodiments, the disclosure provides an immuno stimulatory agent, and polynucleotides expressing the immuno stimulatory agent. In some embodiments, the immuno stimulatory agent stimulates phagocytosis, cytotoxicity, or an immune-mediated attack. Exemplary agents that can be used in the multi-modal therapy of the disclosure are provided herein.
[0417] In some embodiments, the immuno stimulatory agent is an activator of MHC Class I expression. In some embodiments, the immuno stimulatory agent is a cytokine. In some embodiments, the immuno stimulatory agent is an immune checkpoint agent. In some embodiments, the immuno stimulatory agent is a dendritic cell activator. In some embodiments, the immuno stimulatory agent is an IgG Fc for stimulating ADCC response. In some embodiments, the immuno stimulatory agent is a phagocytosis stimulating factor. In some
[0418] 48
[0419] FH30035011.1
[0420] Attorney Docket No: FTE-00125 embodiments, the immuno stimulatory agent a complement receptor or component. In some embodiments, the immuno stimulatory agent is C3b. In some embodiments, the
[0421] immuno stimulatory agent is a chemotaxis activator.
[0422] In some embodiments, the nucleic acid therapy described herein comprises a nucleic acid sequence encoding an immune response stimulator (such as those described herein). The immune response stimulator can be any agent known in the art or described herein.
[0423] The immune response stimulator can be an agent capable of increasing T cell proliferation, stimulating APCs (e.g., maturation or proliferation of APCs) and / or the recruitment, release or upregulation of co- stimulatory molecules (e.g., CD80, CD86, ICAM-1, MHC molecules and CCR7) or pro-inflammatory cytokines (e.g., IL-ip, IL-6, IL-12, IL-15, and IFN-y). Immuno stimulatory agents include, without limitation, CD40 ligand (CD40L), CD28 ligand, agonistic anti-CD40 antibody, agonistic anti-CD28 antibody, a Toll-like Receptor (TLR) agonist, CD27 ligand; FLT 3 ligand; cytokines, such as IFN-a, IFN-P, IFN-y and IL-2; colonystimulating factors, such as G-CSF (granulocyte colony- stimulating factor) and GM-CSF (granulocyte-macrophage colony-stimulating factor), etc.
[0424] In some embodiments, the immuno stimulatory agent is a fusion protein designed by the inventor and described herein.
[0425] Activator of MHC Class I Expression
[0426] MHC Class I expression is downregulated in 40-90% of all tumors. MHC Class I is the protein that presents tumor antigens to T cells, which must bind to antigens in the context of MHC Class I expression to initiate an immune response. MHC Class I downregulation effectively suppresses the immune system’s ability to recognize and kill the cancer cells. In some embodiments, provided herein is a gene therapy resulting in expression or upregulation of an activator of MHC Class I molecules.
[0427] In some embodiments, the agent or one of the agents provided herein is any agent known in the art or described herein that activates MHC Class I expression. In some embodiments, the agent or one of the agents provided herein is any agent known in the art or described herein that promotes MHC Class I presentation on the cell surface.
[0428] In some embodiments, provided herein is a gene therapy resulting in expression, upregulation or increased cell surface presentation of Interferon Gamma (IFNg, IFN gamma, or
[0429] 49
[0430] FH30035011.1
[0431] Attorney Docket No: FTE-00125
[0432] IFNy), which reinstates MHC Class I expression in tumors. Clinical trials investigating systemic administration of IFN gamma has shown systemic toxicity, as well as autoimmune reactions. Accordingly, the solution provided herein is focused on a locally administered gene therapy approach.
[0433] In some embodiments, the therapeutic agent described herein is an interferon gamma (IFNy). In some embodiments, the IFNy is a homodimer comprising two identical chains. In some embodiments, the therapy described herein encodes one chain of the IFNy homodimer. In some embodiments, the IFNy is the first transgene in the nucleic acid therapy. In some embodiments, the IFNy comprises the amino acid sequence set forth in SEQ ID NO: 265. In some embodiments, the IFNy comprises an amino acid sequence comprising at least 85%, 90%, 95%, 98%, or 100% identity with the amino acid sequence set forth in SEQ ID NO: 265. In some embodiments, the IFNy comprises the amino acid sequence set forth in SEQ ID NO: 266. In some embodiments, the IFNy comprises an amino acid sequence comprising at least 85%, 90%, 95%, 98%, or 100% identity with the amino acid sequence set forth in SEQ ID NO: 266. In some embodiments, the IFNy is encoded by a nucleic acid sequence set forth in SEQ ID NO: 267. In some embodiments, the IFNy is encoded by a nucleic acid sequence comprises at least 80%, 85%, 90%, 95%, or 99% identity with the nucleic acid sequence set forth in SEQ ID NO: 267. In some embodiments, the IFNy is codon optimized and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 268. In some embodiments, the IFNy is encoded by a nucleic acid sequence comprises at least 80%, 85%, 90%, 95%, or 99% identity with the nucleic acid sequence set forth in SEQ ID NO: 268.
[0434] In some embodiments, the therapy described herein expresses an interferon gamma (IFNy) fused to an IGK signal peptide (IFNy_spIGK). In some embodiments, the IFNy_spIGK comprises the amino acid sequence set forth in SEQ ID NO: 301. In some embodiments, the IFNy_spIGK comprises an amino acid sequence comprising at least 85%, 90%, 95%, 98%, or 100% identity with the amino acid sequence set forth in SEQ ID NO: 301. In some embodiments, the IFNy_spIGK is encoded by a nucleic acid sequence set forth in SEQ ID NO: 300. In some embodiments, the IFNy_spIGK is encoded by a nucleic acid sequence comprises at least 80%, 85%, 90%, 95%, or 99% identity with the nucleic acid sequence set forth in SEQ ID NO: 300.
[0435] 50
[0436] FH30035011.1
[0437] Attorney Docket No: FTE-00125
[0438] In some embodiments, the therapy described herein expresses an interferon gamma (IFNy) fused to a TPA signal peptide (IFNy_spTPA). In some embodiments, the IFNy_spTPA comprises the amino acid sequence set forth in SEQ ID NO: 303. In some embodiments, the IFNy_spTPA comprises an amino acid sequence comprising at least 85%, 90%, 95%, 98%, or 100% identity with the amino acid sequence set forth in SEQ ID NO: 303. In some embodiments, the IFNy_spTPA is encoded by a nucleic acid sequence set forth in SEQ ID NO: 302. In some embodiments, the IFNy_spTPA is encoded by a nucleic acid sequence comprises at least 80%, 85%, 90%, 95%, or 99% identity with the nucleic acid sequence set forth in SEQ ID NO: 302. In some embodiments, the IFNy_spTPA is encoded by a nucleic acid sequence set forth in SEQ ID NO: 269. In some embodiments, the IFNy_spTPA is encoded by a nucleic acid sequence comprises at least 80%, 85%, 90%, 95%, or 99% identity with the nucleic acid sequence set forth in SEQ ID NO: 269.
[0439] In some embodiments, the therapy described herein expresses an interferon gamma (IFNy) fused to an IL2 signal peptide (IFNy_spIL2). In some embodiments, the IFNy_spIL2 comprises the amino acid sequence set forth in SEQ ID NO: 305. In some embodiments, the IFNy_spIL2 comprises an amino acid sequence comprising at least 85%, 90%, 95%, 98%, or 100% identity with the amino acid sequence set forth in SEQ ID NO: 305. In some embodiments, the IFNy_spIL2 is encoded by a nucleic acid sequence set forth in SEQ ID NO: 304. In some embodiments, the IFNy_spIL2 is encoded by a nucleic acid sequence comprises at least 75%, 80%, 85%, 90%, 95%, or 100% identity with the nucleic acid sequence set forth in SEQ ID NO: 304.
[0440] In some embodiments, the therapy described herein expresses an interferon gamma (IFNy) fused to a PSA signal peptide (IFNy_spPSA). In some embodiments, the IFNy_spPSA comprises the amino acid sequence set forth in SEQ ID NO: 307. In some embodiments, the IFNy_spPSA comprises an amino acid sequence comprising at least 85%, 90%, 95%, 98%, or 100% identity with the amino acid sequence set forth in SEQ ID NO: 307. In some embodiments, the IFNy_spPSA is encoded by a nucleic acid sequence set forth in SEQ ID NO: 306. In some embodiments, the IFNy_spPSA is encoded by a nucleic acid sequence comprises at least 75%, 80%, 85%, 90%, 95%, or 100% identity with the nucleic acid sequence set forth in SEQ ID NO: 306.
[0441] 51
[0442] FH30035011.1
[0443] Attorney Docket No: FTE-00125
[0444] In some embodiments, provided herein is a gene therapy resulting in expression, upregulation or increased cell surface presentation of Interferon Alpha (IFNa, IFN alpha or IFNa).
[0445] In some embodiments, the therapeutic agent described herein is an Interferon Alpha (IFNa). In some embodiments, the IFNa comprises the amino acid sequence set forth in SEQ ID NO: 470. In some embodiments, the IFNa comprises an amino acid sequence comprising at least 85%, 90%, 95%, 98%, or 100% identity with the amino acid sequence set forth in SEQ ID NO: 470. In some embodiments, the IFNa is encoded by a nucleic acid sequence set forth in SEQ ID NO: 471. In some embodiments, the IFNa is encoded by a nucleic acid sequence comprises at least 80%, 85%, 90%, 95%, or 99% identity with the nucleic acid sequence set forth in SEQ ID NO: 471.
[0446] Immune Checkpoint Agents
[0447] In some embodiments, the agent or one of the agents provided herein is an immune checkpoint inhibitor. In some embodiments, the agent or one of the agents provided herein is an immune cell activator.
[0448] In some embodiments, the agent or one of the agents provided herein is any immune checkpoint inhibitor known in the art or described herein.
[0449] Immune checkpoints are another mechanism within the tumor microenvironment that suppress anti-tumor immune responses. In some embodiments, the terms “checkpoint inhibitors” and “immune checkpoint inhibitors” can be used interchangeably.
[0450] PDL1 (Programmed Death Ligand 1) and PDL2 are immune checkpoints that are overexpressed on cancer cells as a strategy to suppress the immune system. They work by inducing T cell exhaustion by binding to PD1 on T cells. Anti-PDLl (e.g., Atezolizumab, Durvalumab) and anti-PDl (e.g., Nivolumab and Pembrolizumab) antibodies are an effective strategy to block this interaction and prevent T cell exhaustion. Contrary to anti-CTLA4 antibodies, the Fc region is not necessary for function and efficient PD1 or PDL1 blockade alone can be used to treat tumors.
[0451] Cytotoxic T cells require two signals for activation: the first is its receptor binding to antigen in the context of MHC class I; the second is its CD28 receptor binding to CD80 / 86 on APCs. CTLA4 (Cytotoxic T-Lymphocyte Antigen 4) is highly expressed on T regulatory cells,
[0452] 52
[0453] FH30035011.1
[0454] Attorney Docket No: FTE-00125 which accumulate in the tumor microenvironment. T reg cells are immunosuppressive and outcompete CD8+ cells for CD80 / 86 by binding to it with their overexpressed CTLA4. Antibody inhibitors of CTLA4 (e.g., Ipilimumab) block the T regs from competing for CD80 / 86 on APCs and allow the on CD8+ CD28 receptor to bind to CD80 / 86 instead, activating its second signal. Fc-mediated destruction of T Regs appears to be the main mechanism by which anti-CTLA4 antibodies work against tumors.
[0455] The issue with systemic anti-CTLA4 and anti-PDl antibody therapy is they have exhibited poor penetration in solid tumors as well as a small therapeutic window due to systemic cytotoxicity. Accordingly, described herein is intra-tumoral delivery of genes encoding antibodies (such as scFvs) targeting CTLA4, PD1, and PDL1 engineered for secretion into the tumor microenvironment. This would not only allow for continuous expression at the target site, but expression can be increased to a local intratumoral dose achieved much higher than with systemic delivery while minimizing toxicity, increasing the therapeutic window. Importantly, this would also allow for significant cost reduction as rather than manufacturing these antibodies, they could be produced in situ, essentially converting the tumor into its own biologic immunotherapy bioreactor.
[0456] In some embodiments, Fc-silent anti-PDl antibody is used. In some embodiments, provided herein is a bispecific scFv antibody, where one side blocks PD1 and the other side is an immuno stimulatory agonist (thus essentially converting an immunosuppressive receptor into an immuno stimulant). While for anti-CTLA4 antibodies the Fc-mediated ADCC serves as an advantage because CTLA4 is overexpressed on T regs and results in their preferential deletion, reducing the anti-PDl antibody size to only the antigen binding region and engineering its opposite pole to be immuno stimulant (e.g., by use of an anti-CD40 agonist), achieves the blocking of PD1, prevents destruction of effector cells by ADCC, and also converts the immunosuppressant to a potent immuno stimulant, such as a CD40 agonist that provides signal 2 to APCs.
[0457] The opposite strategy is contemplated for overexpressed immunosuppressive receptors on cells to be destroyed, such as T regs and cancer cells. For example, for PDL1, which is overexpressed on cancer cells and induces T cell exhaustion upon binding to PD1, an antibody that blocks PDL1 and has an Fc that tags it for destruction would lead to not only blockage of
[0458] 53
[0459] FH30035011.1
[0460] Attorney Docket No: FTE-00125
[0461] PDL1, but also destruction of said cancer cell. For the same reason, an anti-CTLA4 antibody comprising an Fc region is encompassed herein.
[0462] Thus, when it is desired to block an immunosuppressive receptor but preserve the cell, bispecific scFv is to be used that blocks the immunosuppressive receptor on one end (e.g., PD1) and has an immuno stimulatory agonist on the other end (e.g., an anti-CD40 agonist antibody). When it is desired to block an immunosuppressive receptor and also destroy the cell, an scFv can be used that blocks the immunosuppressive receptor on one end (e.g., PDL1 or CTLA4) and comprises an Fc domain on the other.
[0463] In some embodiments, a therapy described herein comprises an immune checkpoint inhibitor. In some embodiments, the immune checkpoint inhibitor can be any immune checkpoint inhibitor known in the art or described herein. In some embodiments, the
[0464] immune checkpoint inhibitor is an inhibitory antibody or an antigen-binding fragment thereof, inhibiting or antagonizing the activity of its target. In some embodiments, the
[0465] immune checkpoint inhibitor is capable of inhibiting the activity of an immune checkpoint pathway mediated by a protein select from, but not limited to, programmed cell death protein- 1 (PD-1), programmed death-ligand 1 (PD-L1), programmed death-ligand 2 (PD-L2), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin and mucin domain-3 (TIM-3), B7 homolog 3 protein (B7-H3), B7 homolog 4 protein (B7-H4), T cell immunoreceptor with Ig and ITIM domains (TIGIT), or combinations of any thereof. In some embodiments, the immune checkpoint inhibitor is capable of inhibiting PD-1. In some embodiments, the immune checkpoint inhibitor is capable of inhibiting PD-L1. In some embodiments, the immune checkpoint inhibitor is capable of blocking the binding of PD- 1 and PD-L1. In some embodiments, the immune checkpoint inhibitor is capable of inhibiting CTLA-4. In some embodiments, the immune checkpoint inhibitor is capable of inhibiting PD-1, PD-L1, CTLA-4, or a combination thereof.
[0466] In some aspects, the checkpoint inhibitor can be, but is not limited to, ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (trade name Libtayo), and dostarlimab (Jemperli), atezolizumab (Tecentriq), durvalumab (Imfinzi), or avelumab (Bavencio), or a combination thereof. In some aspects, the checkpoint inhibitor can be, but is not limited to, Tremelimumab, Sintilimab (formerly IB 1308; Tyvyt), Tislelizumab (formerly BGB-A317), Toripalimab (formerly JS 001), Spartalizumab (formerly PRD001); Camrelizumab
[0467] 54
[0468] FH30035011.1
[0469] Attorney Docket No: FTE-00125
[0470] (formerly SHR1210), KN035, Cosibelimab (formerly CK-301), CA-170, or BMS-986189, or a combination thereof. The sequences of these agents are known in the art.
[0471] In some embodiments, a therapy described herein comprises an immune cell activator. In some embodiments, the immune cell activator can be any known in the art or described herein. In some embodiments, the immune cell activator is an agonist antibody or an antigen-binding fragment thereof, promoting the activity of its target. In some embodiments, the immune cell activator is capable of promoting the activity of an activating immune checkpoint pathway mediated by a protein select from, but not limited to, CD40, CD28, 4- IBB, OX-40 (OX-40), OX-40 ligand (OX-40L), inducible T cell co-stimulator (ICOS), inducible T cell co-stimulator ligand (ICOS-L), glucocorticoid-induced TNFR-related protein (GITR), or combinations of any thereof. In some embodiments, the immune cell activator is an agonist of CD40. In some embodiments, the immune cell activator is an agonist of CD28. In some embodiments, the immune cell activator is an agonist of 4- IBB. In some embodiments, the immune cell activator is an agonist of OX-40. In some embodiments, the immune cell activator is an agonist of CD40, CD28 or OX-40, or a combination thereof.
[0472] In some embodiments, the immunotherapeutic comprises an antibody or antigen binding fragment thereof. In some embodiments, the immunotherapeutic comprises an antibody or antigen binding fragment thereof selected from the group consisting of: a Fab' fragments, F(ab')2 fragments, bispecific Fab dimers (Fab2), trispecific Fab trimers (Fab3), Fv, single chain Fv proteins (“scFv”), bis-scFv, (scFv)2, minibodies, diabodies, triabodies, tetrabodies, disulfide stabilized Fv proteins (“dsFv”), and single-domain antibody (sdAb, Nanobody). In some embodiments, the antibody or antigen binding fragment is a Fab' fragment. In some embodiments, the antibody or antigen binding fragment is an scFv. In some embodiments, the antibody or antigen binding fragment is a Fab fragment comprising a flexible linker which results in a single chain connecting the Fab heavy and Fab light chains (“scFab” or “single chain Fab).
[0473] In some embodiments, the immune checkpoint inhibitor (e.g., an antibody to CTLA-4 or PDL1 or a fragment thereof) comprises an Fc region, and exhibits Fc-mediated destruction of cancer cells and / or T regulatory cells. In some embodiments, the immune checkpoint inhibitor (e.g., an antibody to PDL1 or PD1) is Fc-silent.
[0474] 55
[0475] FH30035011.1
[0476] Attorney Docket No: FTE-00125
[0477] In some embodiments, the immunotherapeutic is a bispecific antibody comprising one or more of the immune checkpoint inhibitors and / or immune cell activators described herein.
[0478] In some embodiments, the antibody or antigen binding fragment comprises a variable heavy (VH) and variable light chain (VL) sequence. In some embodiments, the C terminal of the VH is linked to the N terminus of the VL chain. In some embodiments, the C terminal of the VL chain is linked to the N terminus of the VH chain.
[0479] Given the size of plasmids and nucleic acid therapies are limited, in some embodiments, the inventors utilize the antigen-binding portions (either single chain Fab or single chain fragment variable) of the immune checkpoint inhibitor antibodies described herein. In natural antibodies, the heavy chain and light chain are linked by a disulfide bond at the hinge region. This linkage can be synthetic through a flexible linker, which results in a single chain connecting the Fab heavy and Fab light chains (a “scFab”, or single chain Fab). It is also contemplated to truncate this Fab further and link the variable heavy and variable light chains (leaving out the constant regions), which would generate what is called a single chain fragment variable (scFv).
[0480] In some embodiments, the antigen-binding region of both the variable heavy (VH) and variable light chain (VL) are designed to be on the same side, with one of the known sequences of the VH or VL in a reverse orientation, and a linker sequence between them (in other words, with the C terminal of one chain linked to the N terminal of the other).
[0481] In some embodiments, an immune checkpoint inhibitor described herein may be fused with another therapeutic agent described herein.
[0482] i. PDl and PD-Ll
[0483] Programmed Death 1 (PD-1) is part of the immunoglobulin (Ig) gene superfamily and a member of the CD28 family. It is a 55 kDa type 1 transmembrane protein expressed on antigen-experienced cells (e.g., activated B cells, T cells, and myeloid cells). Generally, it acts by limiting the activity of T cells at the time of inflammatory response, thereby protecting normal tissues from destruction. Two ligands have been identified for PD-1, respectively PD-L1 (programmed death ligand 1) and PD-L2 (programmed death ligand 2). PD-L1 was identified in 20-50% of human cancers. The interaction between PD-1 and PD-L1 results in a decrease in tumor infiltrating lymphocytes, a decrease in T-cell receptor mediated proliferation, and immune evasion by cancerous cells.
[0484] 56
[0485] FH30035011.1
[0486] Attorney Docket No: FTE-00125
[0487] In some embodiments, the checkpoint inhibitor is a PD-1 inhibitor or PD-L1 inhibitor. In some embodiments, the checkpoint inhibitor is an antagonistic antibody that specifically binds PD1 or PDL1 (such as an antibody that disrupts the interaction between PD-1 and PD-11), or an antigen-binding fragment thereof, such as any known in the art or described herein. In some embodiments, a PD-1 inhibitor can be, but is not limited to, Nivolumab, Pembrolizumab, or Cemiplimab. In some aspects, a PD-L1 inhibitor can be, but is not limited to, Atezolizumab, Avelumab, or Durvalumab.
[0488] In some embodiments, the checkpoint inhibitor comprises an anti-PDl scFv. In some embodiments, the checkpoint inhibitor comprises an anti-PDl scFv with a variable heavy chain (VH) followed by a variable light chain (VL). In some embodiments, the anti-PDl molecule or antigen-binding fragment described herein comprises a light chain variable domain as set forth in SEQ ID NO: 216, or comprises a sequence having at least 85%, 90%, 95%, or 98% identity to SEQ ID NO: 216. In some embodiments, the anti-PDl molecule comprises a heavy chain variable region as set forth in SEQ ID NO: 215, or comprises a sequence having at least 85%, 90%, 95%, or 98% identity to SEQ ID NO: 215. In some embodiments, the anti-PDl scFv with a VH-VL comprises the amino acid sequence set forth in SEQ ID NO: 219. In some embodiments, the anti-PDl scFv with a VH-VL comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in SEQ ID NO: 219. In some embodiments, the checkpoint inhibitor comprises an anti-PDl scFv with a VL followed by a VH. In some embodiments, the anti-PDl scFv with a VL-VH comprises the amino acid sequence set forth in SEQ ID NO: 220. In some embodiments, the anti-PDl scFv with a VL-VH comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in SEQ ID NO: 220.
[0489] In some embodiments, the checkpoint inhibitor comprises an anti-PDLl scFv. In some embodiments, the checkpoint inhibitor comprises an anti-PDLl scFv with a variable heavy chain (VH) followed by a variable light chain (VL). In some embodiments, the anti-PDLl scFv with a VH-VL comprises the amino acid sequence set forth in SEQ ID NO: 221. In some embodiments, the anti-PDLl scFv with a VH-VL comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in SEQ ID NO: 221. In some embodiments, the checkpoint inhibitor comprises an anti-PDLl scFv with a VL followed by a VH. In some embodiments, the anti-PDLl scFv with a VL-VH comprises the
[0490] 57
[0491] FH30035011.1
[0492] Attorney Docket No: FTE-00125 amino acid sequence set forth in SEQ ID NO: 222. In some embodiments, the anti-PDLl scFv with a VL-VH comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in SEQ ID NO: 222.
[0493] In some embodiments, the anti-PDl antibody or fragment is any antibody or fragment thereof disclosed in U. S. Patent No. 8,345,509, the contents of which are incorporated by reference herein in its entirety.
[0494] In some embodiments, the anti-PDLl antibody or fragment is any antibody or fragment thereof disclosed in U. S. Patent No. 8,217,149, the contents of which are incorporated by reference herein in its entirety.
[0495] ii. CTLA4
[0496] CTLA4 or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD 152 (cluster of differentiation 152), is a protein receptor that, functioning as an immune checkpoint, downregulates immune responses. CTLA4 is constitutively expressed in regulatory T cells (Tregs), but only upregulated in conventional T cells after activation. CTLA4 acts as an "off’ switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. Blocking CTLA4 (e.g., using antagonistic antibodies against CTLA such as ipilimumab, which was FDA approved for melanoma in 2011) results in therapeutic benefit. CTLA4 blockade inhibits immune system tolerance to tumors and provides a useful immunotherapy strategy for patients with cancer.
[0497] In some embodiments, the checkpoint inhibitor is a CTLA4 inhibitor. In some embodiments, the checkpoint inhibitor is an antibody that specifically binds CTLA4, or an antigen-binding fragment thereof, such as any known in the art or described herein. Examples of CTLA4 inhibitors that can be used in accordance with the present disclosure include, but are not limited to, ipilimumab (Yervoy®), tremelimumab (ticilimumab), CBT-509, CS1002, BMS-986249, AGEN1181, AGEN1194, AGN2041, BA3071, ATOR-1015, ATOR-1144, ADV-1604 and BCD- 145.
[0498] In some embodiments, the CTLA4 inhibitor comprises a VH and VL chain, wherein the C terminus of the VH is linked to the C terminal of the VL chain. In some embodiments, the CTLA4 inhibitor comprises a VH and VL chain, wherein the C terminus of the VL is linked to the C terminal of the VH chain.
[0499] 58
[0500] FH30035011.1
[0501] Attorney Docket No: FTE-00125
[0502] In some embodiments, an anti-CTLA4 antibody comprises an Fc region (e.g., because anti-CTLA4 antibodies without Fc-mediated T reg depletion are less efficacious as a cancer immunotherapy).
[0503] In some embodiments, an anti-CTLA4 Fab does not comprise an Fc region.
[0504] In some embodiments, the checkpoint inhibitor comprises an anti-CTLA4 scFv. In some embodiments, the checkpoint inhibitor comprises an anti-CTLA4 scFv with a variable heavy chain (VH) followed by a variable light chain (VL). In some embodiments, the anti-CTLA4 scFv with a VH-VL comprises the amino acid sequence set forth in SEQ ID NO: 226. In some embodiments, the anti-CTLA4 scFv with a VH-VL comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in SEQ ID NO: 226. In some embodiments, the checkpoint inhibitor comprises an anti-CTLA4 scFv with a VL followed by a VH. In some embodiments, the anti-CTLA4 scFv with a VL- VH comprises the amino acid sequence set forth in SEQ ID NO: 227. In some embodiments, the anti-CTLA4 scFv with a VL-VH comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in SEQ ID NO: 227.
[0505] In some embodiments, the anti-CTLA4 antibody or fragment is any antibody or fragment thereof disclosed in U. S. Patent No. 7,605,238, the contents of which are incorporated by reference herein in its entirety.
[0506] iii. B7H3
[0507] B7 homolog 3 protein (B7H3) is an immune checkpoint molecule and costimulatory / coinhibitory immunoregulatory protein that plays a dual role in the immune system. This protein exists either as a transmembrane or soluble isoform, inhibitor. In some embodiments, the immunotherapeutic comprises an antibody that specifically binds B7H3, or an antigen-binding fragment thereof, such as any known in the art or described herein. In some embodiments, the antibody is an inhibitory antibody. In some embodiments, the immunotherapeutic comprises an anti-B7H3 scFv. In some embodiments, the anti-B7H3 scFv comprises an amino acid sequence set forth in SEQ ID NO: 228, or comprises a sequence having at least 85%, 90%, 95%, or 98% amino acid identity to SEQ ID NO: 228. In some embodiments, the anti-B7H3 scFv comprises an amino acid sequence set forth in SEQ ID NO: 229, or comprises a sequence having at least 85%, 90%, 95%, or 98% amino acid sequence identity to SEQ ID NO: 229.
[0508] 59
[0509] FH30035011.1
[0510] Attorney Docket No: FTE-00125
[0511] In some embodiments, the anti-B7H3 antibody or fragment is any antibody or fragment thereof disclosed in U. S. Patent No. 9,250,656, the contents of which are incorporated by reference herein in its entirety.
[0512] iv. CD47 and SIRPa
[0513] In some embodiments, the immunotherapeutic comprises an antibody that specifically binds CD47, or an antigen-binding fragment thereof, such as any known in the art or described herein. In some embodiments, the antibody is an inhibitory antibody (e.g., inhibits its binding to SIRPa). In some embodiments, the immunotherapeutic comprises an anti-CD47 scFv (such as an scFv that inhibits CD47 and, in particular, its binding to SIRPa). In some embodiments, the anti-CD47 scFv comprises an amino acid sequence set forth in SEQ ID NO: 231, or comprises a sequence having at least 85%, 90%, 95%, or 98% amino acid sequence identity to SEQ ID NO: 231.
[0514] In some embodiments, the immunotherapeutic comprises an antibody that specifically binds SIRPa (Signal Regulatory Protein Alpha), or an antigen-binding fragment thereof, such as any known in the art or described herein. In some embodiments, the antibody is an inhibitory antibody (e.g., inhibits its binding to CD47). In some embodiments, the immunotherapeutic comprises an anti- SIRPa scFv (such as an scFv that inhibits SIRPa and, in particular, its binding to CD47).
[0515] In some embodiments, the immunotherapeutic comprises a SIRPa-Fc fusion protein such as any known in the art or described herein (such as a protein that is capable of acting as a decoy receptor binding to CD47). In some embodiments, SIRPa-Fc fusion protein comprises the sequence set forth in SEQ ID NO: 232, or comprises a sequence having at least 85%, 90%, 95%, or 98% amino acid sequence identity to SEQ ID NO: 232.
[0516] Immunostimulatory Cytokines
[0517] In some embodiments, the immunotherapeutic described herein comprises an immuno stimulatory cytokine. As used herein, the term “immuno stimulatory cytokine” refers to a cytokine which has the ability to stimulate the immune system, in a specific or non-specific way. A vast number of cytokines are known in the art for their ability to exert an immuno stimulatory effect. In some embodiments, the agent or one of the agents provided herein is any
[0518] immuno stimulatory cytokine known in the art or described herein.
[0519] 60
[0520] FH30035011.1
[0521] Attorney Docket No: FTE-00125
[0522] Examples of suitable immuno stimulatory cytokines in the context of the invention include, without limitation, interleukins (e.g., IL-2, IL-6, IL-12, IL-15, IL-21, IL-24, IL-27), chemokines (e.g., CXCL10, CXCL9, CXCL11), interferons (e.g., IFNa, IFNp, IFNy), tumor necrosis factor (TNF), or colony-stimulating factors (e.g. GM-CSF, C-CSF, M-CSF). In some embodiments, the immuno stimulatory cytokine is selected from one or more of IL-2, IL-6, IL-12, IL-15, IL-21, IL-24, IL-27, CXCL10, CXCL9, CXCL11, IFNa, IFN, IFNy, TNF, GM-CSF, C-CSF, M-CSF, and derivatives thereof.
[0523] In some embodiments, the immuno stimulatory cytokine is selected from any cytokines known in the art or disclosed herein. In some embodiments, the immuno stimulatory cytokine is selected from IL12, IL2 (native or modified to avoid activating T reg cells), IL15, IL18, IL21, and IL27.
[0524] In some embodiments, the immuno stimulatory cytokine is IFNa or derivatives thereof. In some embodiments, the immuno stimulatory cytokine is IFNa 2B. In some embodiments, the immuno stimulatory cytokine is IL- 12 or derivatives thereof. In some embodiments, the immuno stimulatory cytokine is IL- 12. In some embodiments, the immuno stimulatory cytokine is IFNy or derivatives thereof. In some embodiments, the immuno stimulatory cytokine is IFNy. In some embodiments, the immuno stimulatory cytokine is GM-CSF or derivatives thereof. In some embodiments, the immuno stimulatory cytokine is GM-CSF.
[0525] Examples of cytokines that can be used in the compositions and methods described herein are provided throughout this disclosure. The sequences of exemplary cytokines, constructs comprising such cytokines, and polynucleotides encoding cytokines are provided in the Sequence Table, below.
[0526] For example, in some embodiments, the immuno stimulatory cytokine is a GM-CSF protein comprising the amino acid sequence set forth in SEQ ID NO: 680. In some embodiments, the immuno stimulatory cytokine is a GM-CSF protein comprising an amino acid sequence at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 680.
[0527] Interleukin- 15 (IL15) is an inflammatory cytokine that binds to and signals through a complex composed of IL-2 and IL- 15 receptors. IL15 can activate and drive the proliferation of NK cells and CD8+ killer T cells in cancer. In some embodiments, the immuno stimulatory cytokine is an IL 15 protein. In some embodiments, the IL 15 protein comprises the amino acid
[0528] 61
[0529] FH30035011.1
[0530] Attorney Docket No: FTE-00125 sequence set forth in SEQ ID NO: 250. In some embodiments, the IL 15 protein comprises an amino acid sequence having at least at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to SEQ ID NO: 250.
[0531] In some embodiments, the immuno stimulatory cytokine is an IL 15 protein comprising an N27D modification (referred to herein as “IL15 N27D”). The N72D modification improves affinity of the IL15 protein for its receptor. In some embodiments, a modified IL15 protein comprises the amino acid sequence set forth in SEQ ID NO: 251. In some embodiments, a modified IL15 protein comprises an amino acid sequence having at least at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to SEQ ID NO: 251.
[0532] In some embodiments, the immuno stimulatory cytokine is an IL 15 receptor alpha sushi domain (sIL15) protein. In some embodiments, the sIL15 protein comprises the amino acid sequence set forth in SEQ ID NO: 260. In some embodiments, the sIL15 protein comprises an amino acid sequence having at least at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to SEQ ID NO: 260.
[0533] In some embodiments, the immuno stimulatory cytokine is an IL 15 protein comprising an N27D modification fused to an IL15 receptor alpha sushi domain (sIL15) (referred to herein as “IL 15 N27D / Sushi”).
[0534] Interleukin 7 (IL7) is a cytokine that regulates the development and homeostasis of immune cells including T lymphocytes, B lymphocytes, and NK cells. In cancer, IL7 can act as a potent anti-tumor agent by enhancing T lymphocyte activity and preventing T cell exhaustion. In some embodiments, the immuno stimulatory cytokine is an IL7 protein. In some embodiments, the IL7 protein comprises the amino acid sequence set forth in SEQ ID NO: 262. In some embodiments, the IL7 protein comprises an amino acid sequence having at least at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to SEQ ID NO: 262.
[0535] Interleukin-21 (IL 12) is a cytokine produced by T cells that targets a broad range of lymphoid and myeloid cells to regulate the immune system. In cancer, IL21 enhances immune activity by driving prolifertation of CD8+ T cells and NK cells. In some embodiments, the immuno stimulatory cytokine is an IL21 protein. In some embodiments, the IL21 protein comprises the amino acid sequence set forth in SEQ ID NO: 261. In some embodiments, the IL21 protein comprises an amino acid sequence having at least at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to SEQ ID NO: 261.
[0536] 62
[0537] FH30035011.1
[0538] Attorney Docket No: FTE-00125
[0539] Interferon alpha-2b (IFNa2b) is a member of the interferon family and produced by leukocytes. The involvement in the innate immune response renders it a potent antitumor cytokine. In some embodiments, the immuno stimulatory cytokine is an IFNa2p protein. In some embodiments, the IFNa2b protein comprises the amino acid sequence set forth in SEQ ID NO: 249 or 470. In some embodiments, the IFNa2b protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to SEQ ID NO: 247 or 470. In some embodiments, the nucleic acid therapy comprises a nucleic acid sequence set forth in SEQ ID NO: 471. In some embodiments, the nucleic acid therapy comprises a nucleic acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% nucleic acid sequence identity to SEQ ID NO: 471.
[0540] Dendritic Cell Activators
[0541] Dendritic cells are the most potent tumor antigen presenting cells (APCs). Antigen presenting cells are the crucial first players of the immune system as they process antigen and then present those to matching cytotoxic T cells who then circulate and destroy any cells that express the same antigen presented to them by APCs in the context of MHC Class I. Thus, even if MHC Class I expression was reinstated, APCs are also necessary to process tumor antigens and present them to T cells. The down-side of immunologically “cold tumors” is not only their tumor microenvironment, but the lack of antigens that are recognized as foreign by the immune system. One contributing aspect to this is the lack of dendritic cells (the most powerful tumor antigen presenting cell) within the tumor microenvironment.
[0542] In some embodiments, the agent or one of the agents provided herein is any agent known in the art or described herein that activates dendritic cells.
[0543] In some embodiments, the nucleic acid therapy described herein results in expression of one or more dendritic cell activators. In some embodiments, the dendritic cell activator is any dendritic cell activator known in the art. In some embodiments, the dendritic cell activator is FLT3L, IFNa, or an inhibitor of VEGF, TGF-P, IL-10, PD-L1 or CXCL12.
[0544] DC activity is suppressed by the tumor microenvironment by factors such as VEGF, TGF-p, IL- 10, PD-L1 and CXCL12. Inhibiting these factors can promote dendritic cell function.
[0545] On the other hand, FLT3L (FLT3 Ligand) and IFN alpha activate dendritic cells.
[0546] Systemic administration of these agents has shown to induce toxicity. In some embodiments,
[0547] 63
[0548] FH30035011.1
[0549] Attorney Docket No: FTE-00125 provided herein is local intra-tumoral administration of genes encoding FLT3L and / or IFN alpha via gene therapy, to ensure low systemic toxicity and achieve a steady state expression at the target site. In some embodiments, provided herein is local intra-tumoral administration of genes encoding antibodies (e.g., scFvs) targeting VEGF, TGF-P, IL-10, PD-L1 and / or CXCL12. Focal intra-tumoral delivery also allows to increase expression and the therapeutic window locally within the tumor, minimizing toxicity and maximizing activation and proliferation of DCs.
[0550] In some embodiments, the agent is an FLT3L protein. In some embodiments, the FLT3L protein comprises the amino acid sequence set forth in SEQ ID NO: 248. In some embodiments, the FLT3L protein comprises an amino acid sequence having at least 85%, 90%, 95%, 98% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 248.
[0551] In some embodiments, the agent is an IFNa2B protein. In some embodiments, the agent is an IFNa2B protein comprising the amino acid sequence set forth in SEQ ID NO: 470. In some embodiments, the agent is an IFNa2B protein encoded by the nucleic acid sequence set forth in SEQ ID NO: 471. In some embodiments, the agent is an IFNa2B protein comprising an amino acid sequence at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 470. In some embodiments the agent is an IFNa2B protein encoded by a nucleic acid sequence at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the nucleic acid sequence set forth in SEQ ID NO: 471.
[0552] FLT3L is a potent activator of dendritic cells and, without being bound by theory, CXCL10 may facilitate its chemotaxis to the tumor microenvironment. Thus, also provided herein is an engineered FLT3L-CXCL10 fusion protein. Also provided herein are IFNa or GM-CSF, alone (e.g., in the event of CXCL10 being provided on another cassette), or a fusion protein between IFNa or GM-CSF and CXCL10, as described herein. Also provided herein is a fusion protein between FLT3L and IFNa (FLT3L-IFNa), e.g., for the multimodal therapy in which CXCL10 is present elsewhere (e.g., as part of the IL12-V1-CXCL10 fusion). FTL3L and IFNa each have potent dendritic cell activating properties, with IFNa also having the additional benefit of inducing MHC Class II expression. Thus, the fusion of FTL3L and IFNa can augment the impact of tumor antigen phagocytosis and antigen presentation (via MHC upregulation).
[0553] Chemokines and Chemotaxins
[0554] 64
[0555] FH30035011.1
[0556] Attorney Docket No: FTE-00125
[0557] Chemotaxis disruption is a mechanism employed by tumors. Several factors are responsible for this, one of which is ECM remodeling that makes the tumor denser creating a physical barrier to immune cell infiltration. Additionally, the tumor secretes factors that promote hypoxia which disturbs the chemokine gradient and immune cells chemotaxis. Secretion of the chemokines CCL22 and CCL5 preferentially favors the infiltrative chemotaxis of T regs (immunosuppressive immune cells).
[0558] The term "chemokine" is a generic term for any of the proteins that act on white blood cells and induce them to move and / or become activated to carry out their immune system functions. Chemokines can recruit anti-tumor immune cells. In some embodiments, the chemokine recruits one or more anti-tumor immune cells selected from CD8+ T cells, NK cells, and Thl cells. In some embodiments, the chemokine recruits CD8+ T cells. In some embodiments, the chemokine recruits NK cells. In some embodiments, the chemokine recruits Thl cells.
[0559] In some embodiments, the agent or one of the agents provided herein is any chemokine known in the art or described herein. Exemplary chemokines include, for example and without limitation, any chemokine receptor CXCR3 agonist, CXCL9, CXCL10, and CXCL 11. CXCL9 and CXCL 10 are small size and potent chemokines that specifically recruit anti-tumor immune cells, such as CD8+ T cells, NK cells, and Thl cells, and attract these cells based on a chemical gradient.
[0560] In some embodiments, CXCL9 is used as one of the therapeutic agents in the multimodal therapies described herein. In some embodiments, CXCL10 is used as one of the therapeutic agents in the multi-modal therapies described herein.
[0561] In some embodiments, provided herein is a local intra-tumoral administration of a gene therapy encoding CXCL9 or CXCL10, to achieve low systemic toxicity and a steady state expression at the target site, ensuring a gradient of CXCL9 or CXCL 10 that will localize to the tumor. In some embodiments, CXCL9 or CXCL 10 is fused to a cytokine (such as any immuno stimulatory cytokine described herein) to exert a dual effect: potently stimulating the immune system and directing immune cell homing to the tumor via gradient- dependent chemotaxis.
[0562] Additionally, intra-tumoral administration of genes encoding antibodies (or more specifically scFVs) targeting CCL22 and CCL5 can decrease the chemotaxis of T regs into the
[0563] 65
[0564] FH30035011.1
[0565] Attorney Docket No: FTE-00125 tumor microenvironment. In some embodiments, the nucleic acid therapy encodes an inhibitor of CCL22. Inhibitors of CCL22 are known in the art. In some embodiments, the nucleic acid therapy encodes an inhibitor of CCL5. Inhibitors of CCL5 are known in the art.
[0566] Chemotaxis or infiltration into the tumor microenvironment can be improved by secretion of collagenase or hyaluronidase. In some embodiments, the nucleic acid therapy described herein comprises a gene engineered for secretion of collagenase. In some embodiments, the nucleic acid therapy described herein comprises a gene engineered for secretion of a hyaluronidase. Further contemplated herein is intratumoral administration of genes engineered for secretion of collagenase and hyaluronidase enzymes.
[0567] In some embodiments, the chemokine for use in the compositions and methods provided herein is a CXCL10 protein. In some embodiments, the CXCL10 comprises a native CXCL10 signal peptide. In some embodiments, the CXCL10 does not comprise a signal peptide. In some embodiments, the chemokine is a CXCL10 protein comprising the amino acid sequence set forth in SEQ ID NO: 213. In some embodiments, the chemokine is a CXCL10 protein comprising an amino acid sequence at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 213.
[0568] In some embodiments, the chemokine for use in the compositions and methods provided herein is a CXCL9 protein. In some embodiments, the CXCL9 comprises the amino acid sequence set forth in SEQ ID NO: 206 or 212, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 206 or 212. In some embodiments, the nucleic acid therapy comprises a nucleic acid encoding a CXCL9 protein comprising the nucleic acid sequence as set forth in SEQ ID NO: 207, or a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the sequence set forth in SEQ ID NO: 207.
[0569] In some embodiments, the chemokine is a CXCL9 protein comprising two GG amino acid additions in the N-terminal domain (referred to herein as “GG-CXCL9”) to induce DDP4 resistance. In some embodiments, the GG-CXCL9 comprises the amino acid sequence set forth in SEQ ID NO: 208, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% amino acid sequence identity to the sequence set forth in SEQ ID NO: 208. In some embodiments, the nucleic acid therapy comprises a nucleic acid encoding a GG-CXCL9 protein comprising the nucleic acid sequence as set forth in SEQ ID NO: 209, or a
[0570] 66
[0571] FH30035011.1
[0572] Attorney Docket No: FTE-00125 sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the sequence set forth in SEQ ID NO: 209.
[0573] In some embodiments, the chemokine is a CXCL9 protein comprising a methionine on the N-terminus (referred to herein as “M-CXCL9”) to induce DDP4 resistance. In some embodiments, the M-CXCL9 comprises the amino acid sequence set forth in SEQ ID NO: 210, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% amino acid sequence identity to the sequence set forth in SEQ ID NO: 210. In some embodiments, the nucleic acid therapy comprises a nucleic acid encoding a M-CXCL9 protein comprising the nucleic acid sequence as set forth in SEQ ID NO: 211, or a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the sequence set forth in SEQ ID NO: 211.
[0574] In some embodiments, the chemokine is an XCL1 protein. In some embodiments, the XCL1 protein comprises the amino acid sequence set forth in SEQ ID NO: 247. In some embodiments, the XCL1 protein comprises an amino acid sequence having at least at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to SEQ ID NO: 247.
[0575] Tumor Necrosis Factors
[0576] In some embodiments, the agent is a tumor necrosis factor superfamily (TNFSF) protein or a variant thereof. The tumor necrosis factor superfamily is a protein family of type II transmembrane proteins receptors and related ligands that initiate signal transduction on cells. Such interactions are involved in numerous physiological functions for inflammatory signaling and development. In some embodiments, a therapeutic agent described herein is a TNFSF protein.
[0577] In some embodiments the TNFSF protein is any TNFSF protein known in the art or described herein. TNFSF proteins are membrane bound ligands, with the C-terminal domain being the ligand portion of the protein extending extracellularly.
[0578] In some embodiments, the TNFSF protein is a full length protein (e.g., a full length 4-1BBE, OX40E, CD40E, GITRE or LIGHT protein), or a modified version thereof (such as a modified version that preserves the function, such as a receptor binding function, thereof). In some embodiments, the TNFSF protein is a soluble ligand, such as receptor binding soluble ligand. In some embodiments, the agent is a truncated TNFSF protein. In some embodiments,
[0579] 67
[0580] FH30035011.1
[0581] Attorney Docket No: FTE-00125 the TNFSF protein is truncated by up to 5 or up to 10 amino acids. In some embodiments, a TNFSF protein truncated on its N-terminal part is used herein (e.g., by up to 5 or up to 10 amino acids). In some embodiments, the TNFSF protein has at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% amino acid sequence identity to the sequence of the full length native protein. In some embodiments, a soluble form of the TNFSF protein is used herein. In some embodiments, a form of TNFSF protein not bound to the membrane is used herein.
[0582] In some embodiment, the agent is or comprises an extracellular domain or ectodomain of a TNFSF protein, e.g., an extracellular domain of 4-1BBL, OX40L, CD40L, GITRL or LIGHT.
[0583] In some embodiments, the TNFSF protein is a 4-1BBL protein. In some embodiments, the 4-1BBL protein comprises the amino acid sequence set forth in SEQ ID NO: 252, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to the sequence set forth in SEQ ID NO: 252.
[0584] In some embodiments, the TNFSF protein is a single chain trimeric 4-1BBL protein (sctri4-lBBL). In some embodiments, the sctri4-lBBL protein comprises the amino acid sequence set forth in SEQ ID NO: 256, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to the sequence set forth in SEQ ID NO: 256.
[0585] In some embodiments, the TNFSF protein is the full soluble ligand form of 4-1BBL protein (4-lBBLfs). In some embodiments, the 4-lBBLfs comprises the amino acid sequence set forth in SEQ ID NO: 705, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to the sequence set forth in SEQ ID NO: 705.
[0586] In some embodiments, the TNFSF protein is a OX40L protein. In some embodiments, the OX40L protein comprises the amino acid sequence set forth in SEQ ID NO: 253, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to the sequence set forth in SEQ ID NO: 253.
[0587] In some embodiments, the TNFSF protein is a single chain trimeric OX40L protein (sctriOX40L). In some embodiments, the sctriOX40L protein comprises the amino acid sequence set forth in SEQ ID NO: 257, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to the sequence set forth in SEQ ID NO: 257.
[0588] 68
[0589] FH30035011.1
[0590] Attorney Docket No: FTE-00125
[0591] In some embodiments, the TNFSF protein is a GITRF protein. In some embodiments, the GITRF protein comprises the amino acid sequence set forth in SEQ ID NO: 254, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to the sequence set forth in SEQ ID NO: 254.
[0592] In some embodiments, the TNFSF protein is a single chain trimeric GITRF protein (sctriGITRL). In some embodiments, the sctriGITRL protein comprises the amino acid sequence set forth in SEQ ID NO: 258, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to the sequence set forth in SEQ ID NO:
[0593] 258.
[0594] In some embodiments, the TNFSF protein is a OX40E protein. In some embodiments, the OX40E protein comprises the amino acid sequence set forth in SEQ ID NO: 253, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to the sequence set forth in SEQ ID NO: 253.
[0595] In some embodiments, the TNFSF protein is a LIGHT protein. In some embodiments, the LIGHT protein comprises the amino acid sequence set forth in SEQ ID NO: 255, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to the sequence set forth in SEQ ID NO: 255.
[0596] In some embodiments, the TNFSF protein is a single chain trimeric LIGHT protein (sctriLIGHT). In some embodiments, the sctriLIGHT protein comprises the amino acid sequence set forth in SEQ ID NO: 259, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to the sequence set forth in SEQ ID NO:
[0597] 259.
[0598] In some embodiments, the TNFSF protein is the full soluble ligand form of LIGHT protein (LIGHTfs). In some embodiments, the LIGHTfs comprises the amino acid sequence set forth in SEQ ID NO: 706, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to the sequence set forth in SEQ ID NO: 706.
[0599] In some embodiments, the TNFSF protein is the full soluble ligand form of sctriLIGHT protein (sctriLIGHTfs). In some embodiments, the sctriLIGHTfs comprises the amino acid sequence set forth in SEQ ID NO: 708, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to the sequence set forth in SEQ ID NO: 708. In some embodiments, the agent (such as an immune response stimulator agent) is a
[0600] 69
[0601] FH30035011.1
[0602] Attorney Docket No: FTE-00125
[0603] CD40L protein. The CD40L protein is also a TNFSF protein. In some embodiments, the immune response stimulator is a CD40L protein comprising the amino acid sequence set forth in SEQ ID NO: 223. In some embodiments, the immune response stimulator is a CD40L protein comprising an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in SEQ ID NO: 223.
[0604] In some embodiments, the agent (such as an immune response stimulator agent) is a single chain trimeric CD40L protein (referred to herein as “sctriCD40L”). In some embodiments, the sctriCD40L comprises the amino acid sequence set forth in SEQ ID NO: 224. In some embodiments, the sctriCD40L comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 224.
[0605] In some embodiments, the TNFSF protein is the full soluble ligand form of CD40L protein (CD40Lfs). In some embodiments, the CD40Lfs comprises the amino acid sequence set forth in SEQ ID NO: 707, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to the sequence set forth in SEQ ID NO: 707.
[0606] In some embodiments, a TNFSF protein is incorporated into a fusion protein described herein as a C-terminal fusion. For example, in some embodiments, wherein a fusion protein comprises a Hinge-CH3 or other dimerization domain, or linker, the TNFSF protein is at the C-terminus of the fusion protein following the dimerization domain or linker.
[0607] Other Immune Response Stimulators
[0608] In some embodiments, the agent (such as an immune response stimulator agent) is a CD40 agonist, such as any known in the art or described herein. In some embodiments, the CD40 agonist is an agonistic anti-CD40 antibody. Suitable anti-CD40 agonist antibodies include antibodies that bind to CD40 on the surface of a cell and stimulate CD40 signaling as a result of the binding, and can modulate tumor-associated macrophages’ immunosuppressive effect on development of a T cell-mediated antitumor response. In some embodiments, the CD40 agonist is a CD40 ligand (e.g., a soluble CD40 ligand).
[0609] In some embodiments, the agent (such as an immune response stimulator agent) is an anti-CD40 agonist, such as any known in the art or described herein. In some embodiments, the agent (such as an immune response stimulator agent) is an agonistic anti-CD40 antibody or an
[0610] 70
[0611] FH30035011.1
[0612] Attorney Docket No: FTE-00125 antigen binding fragment thereof. In some embodiments, the agent (such as an immune response stimulator agent) is an anti-CD40 agonist scFv (referred to herein as “anti-CD40a scFv”). In some embodiments, the anti-CD40a scFv comprises the amino acid sequence set forth in SEQ ID NO: 225. In some embodiments, the anti-CD40a scFv comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 225.
[0613] In some embodiments, the agent (such as an immune response stimulator agent) is a CD28 agonist, such as any known in the art or described herein. In some embodiments, the CD28 agonist is an agonistic anti-CD28 antibody or an antigen binding fragment thereof. In some embodiments, the CD40 agonist is a CD28 ligand (e.g., a soluble CD28 ligand).
[0614] In some embodiments, the CD40 agonist is any CD40 agonist disclosed in U. S. Patent No. 7,605,238, the contents of which are incorporated by reference herein in its entirety.
[0615] In some embodiments, the agent is an anti-4- IBB agonist, such as any known in the art or described herein. In some embodiments, the agent is an anti-4- IBB agonist scFv, such as any known in the art or described herein. In some embodiments, anti-4- IBB agonist scFv comprises the amino acid sequence set forth in SEQ ID NO: 701. In some embodiments, the anti-41BB agonist scFv comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 701.
[0616] Cluster of Differentiation 3 (CD3) is a protein complex and T cell co-receptor. In some embodiments, the immune response stimulator is an anti-CD3 antibody or an antigen binding fragment thereof. In some embodiments, the immune response stimulator is an anti-CD3 scFv. In some embodiments, the anti-CD3 scFv comprises the amino acid sequence set forth in SEQ ID NO: 273 or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to the sequence set forth in SEQ ID NO: 273.
[0617] In some embodiments, the agent (such as an immune response stimulator agent) is a heat shock protein. In some embodiments, the heat shock protein is an HSP70 (e.g., HSPA1A / B), HSP90 (e.g., gp96 / HSP90Bl, and HSP90a), HSP110, or Grpl70 (e.g., HSPH2 / 4). Without wishing to be bound by theory, HSP70 and HSP 90 act as ligand for TLR2 / 4, which activate inflammatory pathway and the heat shock proteins bind to tumor- specific antigens, forming Chaperone-Peptide Complexes, and are taken up by APCs via receptors like CD91, allowing for cross-presentation to T cells. HSP70 is capable of binding a broad spectrum of tumor-associated
[0618] 71
[0619] FH30035011.1
[0620] Attorney Docket No: FTE-00125 antigens (TAAs) and delivering them to CD91 on Dendritic Cells. In some embodiments, the heat shock protein is an HSPA1A. In some embodiments, the HSPA1A comprises the amino acid sequence of SEQ ID NO: 203, In some embodiments, the HSPA1A comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% amino acid sequence identity to SEQ ID NO: 203.
[0621] In some embodiments, the agent is a Transforming growth factor beta (TGFP) trap (referred to herein as “TGFP trap”, “TGF beta trap”, or “TGFbt” ). TGFbeta isoforms are small homodimeric signaling proteins activated by multiple mechanisms. TGFbeta can promote tumor activity. A TGFbeta trap is a fusion protein capable of binding and neutralizing TGFbeta to suppress the activity of TGFbeta. In some embodiments, the agent is a TGFP trap comprising the amino acid sequence set forth in SEQ ID NO: 263 or 264. In some embodiments, the TGFP trap comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 263 or 264.
[0622] Inhibitors of M2 Macrophages and / or Myeloid Derived Stem Cells (MDSCs)
[0623] The tumor microenvironment consists of immunosuppressive cells, such as M2 macrophages and MDSCs (myeloid derived stem cells) that secrete immunosuppressive cytokines. In some embodiments, the agent or one of the agents provided herein is any agent known in the art or described herein that inhibits M2 macrophages and / or MDSCs.
[0624] IFN gamma as well as immuno stimulatory cytokines such as IE12 and GM-CSF are potent activators of the immune system and can reprogram these cells from an immunosuppressive to an immuno stimulatory phenotype (e.g., M2 converts to
[0625] immuno stimulatory Ml macrophages). In addition, antibodies against IE-4, IE-10, IL-13, CCL2, TGF-beta, and / or CSF-1, especially IL- 10 and TGF-beta, can inhibit MDSC and M2 function and even reprogram them to immuno stimulatory cells. Although systemic administration of IL-12 has shown to induce toxicity (thus limiting the dose), local intra-tumoral administration of IL-12 via gene therapy can provide for low systemic toxicity and result in a steady state expression at the target site. The same can be true by intra-tumoral administration of genes encoding antibodies (or more specifically scFvs) targeting IL-4, IL-10, IL-13, CCL2, TGF-beta, and / or CSF-1, especially IL- 10 and TGF-beta. Local intra-tumoral delivery also allows to increase
[0626] 72
[0627] FH30035011.1
[0628] Attorney Docket No: FTE-00125 expression and the therapeutic window locally within the tumor, minimizing toxicity and maximizing inhibition and reprogramming of MDSCs and M2 macrophages.
[0629] In some embodiments, the inhibitor of M2 macrophages or MDSCs is any IL-4 inhibitor known in the art. In some embodiments, the inhibitor of M2 macrophages or MDSCs is any IL-10 inhibitor known in the art. In some embodiments, the inhibitor of M2 macrophages or MDSCs is any IL- 13 inhibitor known in the art. In some embodiments, the inhibitor of M2 macrophages or MDSCs is any TGFp inhibitor known in the art. In some embodiments the inhibitor of M2 macrophages or MDSCs is any CSF-1 inhibitor known in the art.
[0630] Anti-Tumor Agents and Cytotoxic Agents
[0631] In some embodiments, the agent provided herein is a tumor lysing agent (or “tumor lyser” or “tumor lysis agent”) capable of tumor cell lysis or destruction upon expression. In some embodiments, the nucleic acid therapy of the present invention encodes a tumor lysing agent. In some embodiments, the agent provided herein is an agent that leads to tumor antigen release. In some embodiments, a tumor lysing agent is any agent known in the art or described herein. In some embodiments, a tumor lysing agent is an anti-tumor agent described herein. In some embodiments, a tumor lysing agent is a toxin or cytotoxin described herein.
[0632] In some embodiments, the agent is an anti-tumor agent. In some embodiments, the nucleic acid therapy of the present invention encodes an anti-tumor agent. In some embodiments, the anti-tumor agent is an anti-tumor antibody or an antigen-binding fragment thereof. In some embodiments, the anti-tumor agent (e.g., an anti-tumor antibody or an antigen binding fragment thereof) is a protein that binds to an antigen on a surface of a tumor cell. In some embodiments, such anti-tumor agent specifically recognizes tumor cells. In some embodiments, such anti-tumor agent preferentially binds to tumor cells relative to non-tumor cells (e.g., of the same tissue or type), for example, displays at least 2X, 3X, 4X, 5X, 10X, 15X, or 20X stronger binding to tumor cells relative to normal cells. In some embodiments, such anti-tumor agent does not bind to or substantially does not bind to normal cells. In some embodiments, the anti-tumor agent is a protein that recruits tumor killing immune cells. In some embodiments, the anti-tumor agent tags tumors for ADCC and / or phagocytosis.
[0633] In some embodiments, the anti-tumor agent (e.g., an anti-tumor antibody or an antigen binding fragment thereof) is any agent that binds to a tumor- specific antigen, such as any known
[0634] 73
[0635] FH30035011.1
[0636] Attorney Docket No: FTE-00125 in the art or described herein. In some embodiments, the tumor- specific antigen is that expressed on the surface of the tumor being treated in accordance with the disclosure provided herein. Skilled artisans would know the cell surface antigens that can be targeted depending on the tumor identity.
[0637] In some embodiments, the anti-tumor agent is a tumor-targeting antibody or antigenbinding fragment fused to an Fc domain (such as wherein the anti-tumor antibody or antigenbinding fragment binds to any tumor antigen, e.g., tumor- specific antigen, known in the art or described herein). In some embodiments, the anti-tumor agent is a tumor-targeting scFv-Fc (such as wherein the anti-tumor scFv is any scFv known in the art to bind to a tumor antigen, e.g., tumor- specific antigen, known in the art or described herein). In some embodiments, the antitumor agent is an anti-B7-H3 scFv-Fc, an anti-PSMA scFv-Fc, an anti-HER2 scFv-Fc, or an anti-EGFR scFv-Fc.
[0638] In some embodiments, the anti-tumor agent is an anti-EGFR antibody or an antigen binding fragment thereof. In some embodiments, provided herein is an anti-EGFR scFv. In some embodiments, the anti-EGFR scFv comprises the amino acid sequence as set forth in SEQ ID NO: 230, or comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% amino acid sequence identity to SEQ ID NO: 230.
[0639] In some embodiments, the anti-tumor agent is an anti-HER2 antibody or an antigen binding fragment thereof. In some embodiments, provided herein is an anti-HER2 scFv. In some embodiments, the anti-HER2 scFv comprises the amino acid sequence as set forth in SEQ ID NO: 233, or comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% amino acid identity to SEQ ID NO: 233.
[0640] In some embodiments, the anti-HER antibody or fragment is any antibody or fragment thereof disclosed in U. S. Patent No. 5,677,171, the contents of which are incorporated by reference herein in its entirety.
[0641] In some embodiments, the anti-tumor agent is an anti-PSMA antibody or an antigen binding fragment thereof. In some embodiments, provided herein is an anti-PSMA scFv. In some embodiments, the anti-PSMA scFv comprises the amino acid sequence as set forth in SEQ ID NO: 234, or comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% amino acid identity to SEQ ID NO: 234.
[0642] 74
[0643] FH30035011.1
[0644] Attorney Docket No: FTE-00125
[0645] In some embodiments, the anti-PSMA antibody or fragment is any antibody or fragment thereof disclosed in U. S. Publication No. 2010 / 0278726 or U. S. Patent No. 6,107,090, the contents of which are incorporated by reference herein in its entirety.
[0646] In some embodiments, the anti-tumor agent is an anti-B7-H3 antibody or an antigen binding fragment thereof. In some embodiments, provided herein is an anti-B7-H3 scFv. In some embodiments, the anti-B7-H3 scFv comprises the amino acid sequence as set forth in SEQ ID NO: 228, or comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% amino acid identity to SEQ ID NO: 228. In some embodiments, the anti-B7-H3 scFv comprises the amino acid sequence as set forth in SEQ ID NO: 229, or comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% amino acid identity to SEQ ID NO: 229.
[0647] In some embodiments, the agent or one of the agents provided herein is any cytotoxin known in the art or described herein. In some embodiments, the nucleic acid therapy of the present invention encodes a toxin-derived polypeptide.
[0648] In some embodiments, the toxin selected from: diphtheria toxin, Shiga toxin, ABx toxin, ribosome inactivating protein toxin, abrin, anthrax toxin, Aspf 1, bouganin, bryodin, cholix toxin, claudin, gelonin, heat-labile enterotoxin, mitogillin, pertussis toxin, pokeweed antiviral protein, pulchellin, Pseudomonas exotoxin A, restrictocin, ricin, saporin, sarcin, and subtilase cytotoxin. In some embodiments, the toxin is derived from the aerolysin family, Gasdermins (GSDME), Perforin, Diphtheria toxin, Shiga toxin, or Cytolysin A. In some embodiments, the toxin is from the aerolysin family. In some embodiments, the toxin is diphtheria toxin. In some embodiments, the toxin is a Shiga toxin. In some embodiments, the toxin is a GSDME. In some embodiments, the toxin is Perforin. In some embodiments, the toxin is Cytolysin A.
[0649] In some embodiments, the shiga toxin comprises the amino acid sequence set forth in SEQ ID NO: 674. In some embodiments, the shiga toxin comprises the an amino acid sequence at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 674. In some embodiments, the nucleic acid therapy described herein comprises the nucleic acid sequence set forth in SEQ ID NO: 675. In some embodiments, the nucleic acid therapy described herein comprises a nucleic acid sequence at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the nucleic acid sequence set forth in SEQ ID NO: 675.
[0650] In some embodiments, the diphtheria toxin comprises the amino acid sequence set forth in SEQ ID NO: 676. In some embodiments, the diphtheria toxin comprises the an amino acid
[0651] 75
[0652] FH30035011.1
[0653] Attorney Docket No: FTE-00125 sequence at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 676. In some embodiments, the nucleic acid therapy described herein comprises the nucleic acid sequence set forth in SEQ ID NO: 677. In some embodiments, the nucleic acid therapy comprises a nucleic acid sequence at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the nucleic acid sequence set forth in SEQ ID NO: 677.
[0654] In some embodiments, the toxin effector peptide is driven by a tumor- specific promoter or enhancer to drive cell death in the tumor.
[0655] In some embodiments, the tumor lysis agent is or comprises a pore-forming protein, or a protease- activated pore-forming protein. In some embodiments, the tumor lysis agent is or comprises PRX302.
[0656] In some embodiments, the tumor lysis agent is or comprises a pore-forming protein, a protease- activated pore-forming protein, a toxin, a protease- activated toxin, a tumor-targeting antibody or antigen-binding fragment fused to an Fc domain, a tumor-targeting scFv-Fc, a bispecific tumor-targeting T-cell engager, a complement-activating molecule, or an apoptosisinducing molecule. In some embodiments, the tumor lysis agent is or comprises PRX302, a PRX302 variant, a protease-activated pore-forming toxin, a parasporin, a Clostridium perfringens enterotoxin or fragment thereof, a tumor-targeting scFv-Fc, an anti-B7-H3 scFv-Fc, an anti-PSMA scFv-Fc, an anti-HER2 scFv-Fc, an anti-EGFR scFv-Fc, or a variant thereof.
[0657] In some embodiments, the tumor lysis agent is activated by a tumor-associated protease or tumor-enriched protease. In some embodiments, the tumor lysis agent comprises a non-native secretory signal peptide. In some embodiments, the tumor lysis agent comprises a TPA secretory signal peptide. In some embodiments, the tumor lysis agent comprises a PSA secretory signal peptide. In some embodiments, the tumor lysis agent is positioned downstream of IRES. In some embodiments, the tumor lysis agent is positioned downstream of T2A. In some embodiments, the coding region encoding the tumor lysis agent is operably linked to a delayed promoter. In some embodiments, the coding region encoding the tumor lysis agent is operably linked to a pGAS promoter. In some embodiments, the coding region encoding the tumor lysis agent is operably linked to a CIITA pIV promoter.
[0658] For example, the therapeutic protein encoded downstream of the cancer-causing transcription factor specific promoter / enhancer can be a protein based toxin, such as diphtheria toxin, which will result in apoptosis specifically in cancer cells. To destroy the tumor the
[0659] 76
[0660] FH30035011.1
[0661] Attorney Docket No: FTE-00125 transfection efficiency needs to be high (only the transfected cells with toxin would be killed). Studies have shown that a single molecule of diphtheria toxin can result in apoptosis. The advantage of using a protein-based toxin is not only that it can be driven by the cancer cell and lead to its own demise, but also it does not rely on the cancer cell’s apoptosis machinery. Both diphtheria and shiga toxin arrest protein synthesis and result in cell death regardless of the integrity of the apoptosis mechanisms within the cell (which are often inhibited or altered).
[0662] In some embodiments, the methods describe herein comprise a co-transfection (e.g., a 10%:90% ratio) of a tumor- specific promoter / enhancer-driven protein-based toxin (e.g., 10%) to drive tumor specific lysis and a robust polycistronic multimodal polynucleotide described herein that drives secretion of multiple proteins into the tumor microenvironment for the purpose of infiltration and activation of immune cells to train the immune system to kill cancer cells.
[0663] In some embodiments, the intracellular tumor lysing agent is operably linked to a delayed promoter. In some embodiments, the delayed promoter is configured to delay expression of the intracellular tumor lysing agent for a period sufficient to permit the tumor cell to function as a bioreactor for production of one or more additional therapeutic agents prior to tumor cell destruction. In some embodiments, the delayed promoter is selected to provide temporal control over expression of the intracellular toxin such that the tumor cell remains viable for a therapeutically useful duration before lysis occurs. In some embodiments, the delayed promoter is selected to provide temporal control over expression of the intracellular toxin such that the tumor cell remains viable for, e.g., at least 6 hours, 12 hours, 1 day, 1 week, 2 weeks or 1 month.
[0664] In some embodiments, the therapeutic agent is a secreted compound released into the tumor microenvironment. In some embodiments, the majority of therapeutic agents encoded by the engineered cell are configured for secretion into the tumor microenvironment, thereby utilizing the tumor cell as a bioreactor that produces and releases therapeutic agents extracellularly while remaining viable. In some embodiments, the engineered cell expresses a therapeutic agent configured to induce lysis or destruction of a tumor cell. In some embodiments, the tumor lysing agent comprises a transmembrane domain fused to an Fc domain, wherein expression of the transmembrane-Fc fusion on the surface of the tumor cell tags the tumor cell for immune-mediated destruction. In some embodiments, the transmembrane-Fc fusion becomes embedded in the tumor cell membrane and presents the Fc domain extracellularly, thereby marking the tumor cell for antibody-dependent cellular cytotoxicity, complement-dependent
[0665] 77
[0666] FH30035011.1
[0667] Attorney Docket No: FTE-00125 cytotoxicity, or phagocytosis by immune effector cells. In some embodiments, the transmembrane-Fc fusion is used to target tumor cells for which no suitable therapeutic antibody is available. Various transmembrane-Fc fusions are described herein, including in the next section.
[0668] In some embodiments, the tumor lysing agent comprises Gasdermin or a functional fragment thereof. In some embodiments, Gasdermin is expressed intracellularly within the tumor cell, wherein Gasdermin induces pyroptotic cell death of the tumor cell.
[0669] Transmembrane IgG
[0670] In some embodiments, a solution provided herein to trigger the immune system to attack the cancer cells (a so called “induced autoimmunity”) is intra- tumoral delivery (e.g., for expression in cancer cells) of a gene encoding a fusion protein of a transmembrane domain and an IgG (e.g., IgGl) Fc region. The endoplasmic reticulum recognizes the transmembrane domain and processes the protein to be destined for anchoring into the cell membrane of the target cell (e.g., a cancer cell). The Fc domain, which is fused to the transmembrane domain with a flexible linker, such as Glycine-Serine linker or hinge region, is thus exposed extracellularly while anchored to the cell membrane. This in essence “tags” the cancer cell for antibody-dependent cellular cytotoxicity (ADCC) by NK cells and antibody-dependent phagocytosis by macrophages, dendritic cells, and neutrophils. This promotes cell death, exposing internal tumor antigens, as well as phagocytosis, improving antigen presentation by antigen presenting cells.
[0671] Accordingly, described herein are recombinant fusion proteins comprising an immuno stimulatory domain exposed extracellularly (e.g., IgG Fc) and a membrane- anchoring (e.g., transmembrane) domain. In some embodiments, the immuno stimulatory domain and the transmembrane domain are derived from different proteins. In some embodiments, a type I or type II transmembrane protein (e.g., a protein overexpressed in a target cell) is modified in its extracellular domain to comprise a non-native immuno stimulatory domain.
[0672] In some embodiments, described herein is a recombinant fusion protein comprising an Fc region and a transmembrane domain. The Fc Receptor is a powerful activator of immune attack that bypasses many of the “self’ protections that prevent autoimmune attack. The endoplasmic reticulum recognizes the transmembrane domain and processes the protein to be destined for anchoring into the cell membrane. The Fc domain, which is fused to the transmembrane domain
[0673] 78
[0674] FH30035011.1
[0675] Attorney Docket No: FTE-00125 with a flexible linker, such as Glycine-Serine linker or hinge region, is thus exposed extracellularly while anchored to the cell membrane. This in essence “tags” the cancer cell for antibody-dependent cellular cytotoxicity (ADCC) by NK cells and antibody-dependent phagocytosis by macrophages, dendritic cells, and neutrophils. This promotes cell death, exposing internal tumor antigens, as well as phagocytosis, improving antigen presentation by antigen presenting cells.
[0676] In some embodiments, the transmembrane domain or anchor is any transmembrane domain or anchor described in Chou & Elrod, 1999, Proteins 34(1): 137-53.
[0677] In some embodiments, the transmembrane domain is from a type 2 transmembrane protein. In some embodiments, the transmembrane domain is from a type 1 transmembrane protein. The transmembrane protein signal peptide provides specific instructions to the endoplasmic reticulum to shuttle the entire protein to be anchored into the cell membrane. Type 2 transmembrane proteins are characterized by their C terminal domains being extracellular with shorter N terminals being cytosolic, and comprise a signal peptide in their anchoring transmembrane domain. Type 1 transmembrane proteins are characterized by their N terminal domains being extracellular.
[0678] In some embodiments, the disclosure provides a polynucleotide that encodes a protein comprising i) a signal peptide, ii) a domain that anchors within the cell membrane, and iii) an immuno stimulatory molecule. In some embodiments, the anchor is a transmembrane domain.
[0679] Described herein are Fc receptors tagged with a transmembrane domain, a lipid chain anchor, or a GPI anchor. In some embodiments, an Fc receptor is fused with a transmembrane domain. In some embodiments, an Fc receptor is fused with a lipid chain anchor. In some embodiments, an Fc receptor is fused with a GPI anchor. In some embodiments, the immuno stimulatory molecule is exposed extracellularly in a target cell. In some embodiments, the immuno stimulatory molecule replaced the extracellular domain of the transmembrane protein from which the transmembrane domain is derived from. In some embodiments, a fusion protein described herein comprises a flexible linker (e.g., a hinge region) between the transmembrane domain anchor and the extracellular region comprising an immuno stimulatory domain.
[0680] i. Transmembrane domains
[0681] In some embodiments, the recombinant fusion protein provided herein comprises a transmembrane domain.
[0682] 79
[0683] FH30035011.1
[0684] Attorney Docket No: FTE-00125
[0685] In some embodiments, the transmembrane domain is derived from a protein overexpressed in a target cell (e.g., cancer cell). In some embodiments, the transmembrane domain is derived from a protein overexpressed in a tumor.
[0686] A “transmembrane domain” or “TM domain” refers to a hydrophobic portion of polypeptide that anchors the polypeptide to the plasma membrane of the cell. The
[0687] TM domain may be derived either from a natural, synthetic, semi- synthetic, or recombinant source.
[0688] In some embodiments, the transmembrane domain is from a Type I transmembrane protein. As used herein, the term “Type I transmembrane protein” is used in accordance with its plain and ordinary meaning and refers to any of the recombinant or naturally- occurring forms of a membrane protein containing a single-pass transmembrane region, where the N-terminus of the protein is located on the extracellular surface. Type I transmembrane proteins are known in the art. The type I transmembrane domain may be any type I transmembrane domain known in the art or described herein.
[0689] In some embodiments, provided herein are recombinant proteins comprising
[0690] a Type I transmembrane domain and an immuno stimulatory molecule, optionally, an immunoglobulin G (IgG) Fc region. In some embodiments, the transmembrane domain is fused to the C-terminus of the IgG Fc and the recombinant protein is resistant to cleavage by a protease.
[0691] In some embodiments, the transmembrane domain is derived from a type I transmembrane protein with a cytoplasmic tail of less than 100 or less than 75 amino acids, and the N-terminal extracellular domain of the type I transmembrane protein is replaced (in whole or in part) with an immuno stimulatory molecule described herein.
[0692] In some embodiments, the Type I transmembrane domain is from one of the following proteins: VTCN1, CD276, Tomoregulin-2, MICA, EGFR, PDGFR-alpha, PDGFR-beta, HER2, HER3, HER4, FGFR1, FGFR2, FGFR3, FGFR4, VEGFR1, VEGFR2, VEGFR3, Trk-A, Trk-B, Trk-C, and insulin receptor.
[0693] In some embodiments, the transmembrane domain is from a Type II transmembrane protein. As used herein, the term “Type I transmembrane protein” is used in accordance with its plain and ordinary meaning and refers to any of the recombinant or naturally- occurring forms of a membrane protein containing a single-pass transmembrane region, where the C-terminus of the
[0694] 80
[0695] FH30035011.1
[0696] Attorney Docket No: FTE-00125 protein is located on the extracellular surface. Type II transmembrane proteins are known in the art. The type II transmembrane domain may be any type II transmembrane domain known in the art or described herein.
[0697] In some embodiments, provided herein are recombinant proteins comprising
[0698] a Type II transmembrane domain and an immuno stimulatory molecule, optionally, immunoglobulin G (IgG) Fc region. In some embodiments, the transmembrane domain is fused to the C-terminus of the IgG Fc and the recombinant protein is resistant to cleavage by a protease.
[0699] In some embodiments, the transmembrane domain is derived from a type II transmembrane protein with a cytoplasmic tail of less than 75 amino acids, or less than 50 amino acids, and the C-terminal extracellular domain of the type II transmembrane protein is replaced (in whole or in part) with an immuno stimulatory molecule described herein.
[0700] In some embodiments, the Type II transmembrane domain is from one of the following proteins: PSMA, MSRE, IEX1, NADL2, CLC9A, CL17A, C1GLC, TRHDE, ECEL1, CD72, TNFC, TM11A, CLC1B, CLC4K, H6ST1, ASGR2, and CLC1A.
[0701] In some embodiments, the cytoplasmic tail of the fusion protein provided herein has limited intracellular signaling either naturally or through incorporated mutations to or truncations of kinase domains, ITIMs / ITAMs, endocytic motifs, or nuclear-translocating fragments. In some embodiments, the cytoplasmic tail of the fusion protein provided herein has no or substantially no intracellular signaling activity.
[0702] In some embodiments, the transmembrane domain is a multipass transmembrane domain. Multipass transmembrane domains are present in proteins such as ion pumps, ion channels and transporters, and include two or more helices that span the membrane multiple times. Multipass transmembrane domain proteins and their sequences are known in the art. In some embodiments, the transmembrane domain is a multipass transmembrane domain known in the art.
[0703] In some embodiments, the transmembrane domain is a PSMA transmembrane domain. In some embodiments, the transmembrane domain is a PSMA transmembrane domain comprises the amino acid sequence set forth in SEQ ID NO: 177. In some embodiments, the transmembrane domain is a PSMA transmembrane domain comprising an amino acid sequence at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 177. In some embodiments, the transmembrane domain is an EGFR transmembrane
[0704] 81
[0705] FH30035011.1
[0706] Attorney Docket No: FTE-00125 domain. In some embodiments, the transmembrane domain is an EGFR transmembrane domain comprises the amino acid sequence set forth in SEQ ID NO: 178. In some embodiments, the transmembrane domain is an EGFR transmembrane domain comprising an amino acid sequence at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 178. In some embodiments, the transmembrane domain is a HER2 transmembrane domain. In some embodiments, the transmembrane domain is a HER2 transmembrane domain comprises the amino acid sequence set forth in SEQ ID NO: 179. In some embodiments, the transmembrane domain is a HER2 transmembrane domain comprising an amino acid sequence at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 179. In some embodiments, the transmembrane domain is a VTCN1 transmembrane domain. In some embodiments, the transmembrane domain is a VTCN 1 transmembrane domain comprises the amino acid sequence set forth in SEQ ID NO: 292. In some embodiments, the transmembrane domain is a VTCN 1 transmembrane domain comprising an amino acid sequence at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 292. In some embodiments, the transmembrane domain is a CD276 transmembrane domain. In some embodiments, the transmembrane domain is a CD276 transmembrane domain comprises the amino acid sequence set forth in SEQ ID NO: 293. In some embodiments, the transmembrane domain is a CD276 transmembrane domain comprising an amino acid sequence at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 293. In some embodiments, the transmembrane domain is a truncated CD276 transmembrane domain. In some embodiments, the transmembrane domain is a CD276 transmembrane domain comprises the amino acid sequence set forth in SEQ ID NO: 294. In some embodiments, the transmembrane domain is a CD276 transmembrane domain comprising an amino acid sequence at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 294. In some embodiments, the transmembrane domain is a Tomoregulin-2 transmembrane domain. In some embodiments, the transmembrane domain is a Tomoregulin-2 transmembrane domain comprises the amino acid sequence set forth in SEQ ID NO: 295. In some embodiments, the transmembrane domain is a Tomoregulin-2 transmembrane domain comprising an amino acid sequence at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 295. In some embodiments, the transmembrane domain is a truncated Tomoregulin-2 transmembrane domain. In some
[0707] 82
[0708] FH30035011.1
[0709] Attorney Docket No: FTE-00125 embodiments, the transmembrane domain is a Tomoregulin-2 transmembrane domain comprises the amino acid sequence set forth in SEQ ID NO: 296. In some embodiments, the transmembrane domain is a Tomoregulin-2 transmembrane domain comprising an amino acid sequence at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 296. In some embodiments, the transmembrane domain is a MICA1 transmembrane domain. In some embodiments, the transmembrane domain is a MICA1 transmembrane domain comprises the amino acid sequence set forth in SEQ ID NO: 297. In some embodiments, the transmembrane domain is a MICA1 transmembrane domain comprising an amino acid sequence at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 297.
[0710] ii. GPI Anchors
[0711] Glycosylphosphatidylinositol (GPI) Anchor Signal Sequences are responsible for attaching proteins to the outer leaflet of the plasma membrane through a glycosylphosphatidylinositol anchor. This signal sequence facilitates the secretion of GPI-anchored proteins, allowing them to be presented on the cell surface. The term “GPI-anchor” as used within this application denotes a posttranslational modification attached to a C-terminus of a polypeptide or protein. A “GPI-anchor” has a core structure comprising at least one ethanolamine phosphate residue, a trimannoside, a glucosamine residue, and an inositol phospholipid. Notwithstanding this core structure a GPI-anchor normally possesses a certain microheterogeneity and therefore a protein having a GPI-anchor normally is a mixture of proteins with homologous GPI-anchors of the same core structure having different side chain modifications. The GPI anchor may be any GPI anchor known in the art or described herein. In some embodiments, the GPI anchor is selected from Tir4, Dani, Dan4, Sagl, or Sedl.
[0712] iii. Immuno stimulatory Molecules
[0713] In some embodiments, the immuno stimulatory molecule is an Fc domain (e.g., an IgG Fc domain), a toll like receptor agonist, a complement protein, or an antigen specific to a chimeric T cell. In some embodiments, the immuno stimulatory molecule is an Fc domain (e.g., an IgG Fc domain). In some embodiments, the immuno stimulatory molecule is a toll like receptor agonist. In some embodiments, the immuno stimulatory molecule is a complement protein. In some embodiments, the immuno stimulatory molecule is an antigen specific to a chimeric T cell.
[0714] 83
[0715] FH30035011.1
[0716] Attorney Docket No: FTE-00125
[0717] The constant (Fc) regions of antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system. In some embodiments, the Fc region is a human Fc region, or a variant of a said region. The Fc region may be an IgGl, IgG2, IgG3 or IgG4 region. Variants of an Fc region, e.g., affecting the biological function relative to the native Fc region are also contemplated herein. Examples of such biological functions which may be modulated by the presence of a variant Fc region include antibody dependent cell cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complementdependent cytotoxicity (CDC), and / or apoptosis.
[0718] In some embodiments, the immuno stimulatory molecule is an IgG Fc region. In some embodiments, the recombinant protein comprises an IgG Fc region selected from IgGl, IgG2, IgG3, and IgG4. In some embodiments, the IgG is IgGl. In some embodiments, the IgG is IgG2. In some embodiments, the IgG is IgG3. In some embodiments, the IgG is IgG4.
[0719] In some embodiments, the recombinant proteins provided herein comprise an extracellular Fc region (e.g., CH2 and / or CH3) and a hinge region. In some embodiments, the recombinant proteins provided herein comprise extracellular CH2 and CH3 domains of Fc.
[0720] In some embodiments, the IgG comprises the amino acid sequence set forth in SEQ ID NO: 180. In some embodiments, the IgG comprises an amino acid sequence at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid set forth in SEQ ID NO: 180. In some embodiments, the nucleic acid therapy comprises a nucleic acid encoding a silenced IgG Fc comprising the sequence set forth in SEQ ID NO: 181. In some embodiments, the nucleic acid therapy comprises a nucleic acid encoding a silenced IgG Fc comprising a sequence at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the sequence set forth in SEQ ID NO: 181. In some embodiments, the nucleic acid therapy comprises a nucleic acid encoding an IgG4 Fc region comprising an S229P modification, wherein the nucleic acid comprises the sequence set forth in SEQ ID NO: 182. In some embodiments, the nucleic acid therapy comprises a nucleic acid encoding an IgG4 Fc region comprising an S229P modification, wherein the nucleic acid comprises a nucleic acid sequence at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the sequence set forth in SEQ ID NO: 182.
[0721] In some embodiments, the IgG comprises a modified hinge region. In some embodiments, the nucleic acid therapy comprises a nucleic acid encoding an IgG Fc with a
[0722] 84
[0723] FH30035011.1
[0724] Attorney Docket No: FTE-00125 modified hinge region comprising the amino acid sequence set forth in SEQ ID NO: 180. In some embodiments, the nucleic acid therapy comprises a nucleic acid encoding a IgG Fc with a modified hinge region comprising an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the sequence set forth in SEQ ID NO: 180.
[0725] In some embodiments, the immuno stimulatory molecule is a phagocytosis stimulating molecule. In some embodiments, the immuno stimulatory molecule is an “opsonin”, which is any molecule that is involved in opsonization and / or binds to a pathogen cell and
[0726] promotes phagocytosis. Examples of opsonins are C3b, and Immunoglobulin G, IgGl and IgG3, proteins. In some embodiments, the immuno stimulatory molecule is a pathogen-associated molecular pattern (PAMP). In some embodiments, the immuno stimulatory molecule is a complement component. In some embodiments, the complement component is Cl, C2, C3, C4, C5, C6, C7, C8, C9, or any subtype, variant, or fragment thereof. In some embodiments, complement component is a complement component known in the art or described herein.
[0727] In some embodiments, the immuno stimulatory molecule is a toll like receptor agonist. A " Toll-like receptor agonist" or " TLR agonist" refers to a moiety (e.g., compound, nucleic acid, polypeptide, antibody) that decreases, inhibits, blocks, abrogates or interferes with the activity or expression of a Toll-like receptor (e.g., TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, or TLR10), including variants, isoforms, species homologs of human TLR (e.g., mouse). In some embodiments, the toll like receptor agonist is a toll like receptor agonist known in the art or described herein.
[0728] iv. Linkers
[0729] In some embodiments, the immuno stimulatory domain is linked to a transmembrane domain described herein. In some embodiments, the immuno stimulatory domain is covalently linked to a transmembrane domain described herein. In some embodiments, an Fc domain is linked to a transmembrane domain. Linkers provide flexibility to facilitate domain motions and to regulate the inter-domain geometry between the immuno stimulatory domain and transmembrane domain. The linkage between the immuno stimulatory domain and transmembrane domain may be by direct attachment, the use of an intermediate or a spacer peptide, the use of a linker region, the use of a hinge region, or the use of both a linker and a hinge region. In some embodiments, the linker region may fall within the sequence of the hinge
[0730] 85
[0731] FH30035011.1
[0732] Attorney Docket No: FTE-00125 region, or alternatively, the hinge region may fall within the sequence of the linker region. In some embodiments, the linker is a flexible linker.
[0733] In some embodiments, the linker is a hinge region. In some embodiments, the linker is a peptide including anywhere from 1 to 40 amino acids, e.g., from 1 to 35 amino acids, from 1 to 30 amino acids, from 1 to 25 amino acids, from 1 to 20 amino acids, from 5 to 35 amino acids, from 5 to 30 amino acids, from 5 to 25 amino acids, from 5 to 20 amino acids, from 5 to 15 amino acids, from 10 to 35 amino acids, from 10 to 30 amino acids, from 10 to 25 amino acids, from 10 to 20 amino acids. In some embodiments, the linker has 3, 4, 5, 6, 7, 8, 9 or 10 amino acids. In some embodiments, the linker has fewer than 75 amino acids, fewer than 50 amino acids, or fewer than 30 amino acids. In some embodiments, the linker comprises Glycine, Serine, and / or Lysine amino acids. In some embodiments, the linker is a Glycine-Serine linker, such as any Glycine-Serine linkers described herein, e.g., having 1, 2, 3, 4, 5, 6, or more GGGGS repeats. In some embodiments, the linker is a Glycine-Serine linker having the formula ((Glycine)4Serine)n, wherein n is 1-7.
[0734] v. Exemplary Transmembrane IgG
[0735] In some embodiments, the disclosure provides a PSMA (a type 2 transmembrane protein anchored to and abundant in prostate cancer cells) transmembrane domain signal peptide fused to an IgGl Fc region (specifically CH2 and CH3, which are the motifs recognized by the Fc receptor). In some embodiments, the PSMA transmembrane domain signal peptide fused to an IgG Fc region is linked by a Glycine-Serine linker. In some embodiments, the PSMA transmembrane domain signal peptide fused to an IgG Fc region is linked by a hinge region. In some embodiments, the PSMA transmembrane domain signal peptide fused to an IgG Fc region is linked by a Glycine-Serine linker and hinge region. In some embodiments, the IgGlJmPSMA fusion comprises the amino acid sequence set forth in SEQ ID NO: 308. In some embodiments, the IgGlJmPSMA fusion comprises an amino acid sequence at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 308. In some embodiments, the nucleic acid therapy described herein comprises the nucleic acid sequence set forth in SEQ ID NO: 309. In some embodiments, the nucleic acid therapy described herein comprises a nucleic acid sequence comprising at least 75%, 80%, 85%, 90%, 95%, or 100% identity to the nucleic acid sequence set forth in SEQ ID NO: 309.
[0736] 86
[0737] FH30035011.1
[0738] Attorney Docket No: FTE-00125
[0739] In some embodiments, the disclosure provides a VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) transmembrane domain signal peptide fused to an IgGl Fc region (specifically CH2 and CH3, which are the motifs recognized by the Fc receptor). In some embodiments, the VTCN 1 transmembrane domain signal peptide fused to an IgG Fc region is linked by a Glycine- Serine linker. In some embodiments, the VTCN1 transmembrane domain signal peptide fused to an IgG Fc region is linked by a hinge region. In some embodiments, the VTCN 1 transmembrane domain signal peptide fused to an IgG Fc region is linked by a Glycine-Serine linker and hinge region. In some embodiments, the IgGlJmVTCNl fusion (with a Glycine-Serine linker) comprises the amino acid sequence set forth in SEQ ID NO: 299. In some embodiments, the IgGlJm VTCN1 fusion comprises an amino acid sequence at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 299.
[0740] Therapeutic Fusion Proteins
[0741] Generally, when cancer cells emerge, the immune system kills them before they grow into tumors. Eventually, however, a cancer cell develops several key mutations that give it a combination of immune evasion mechanisms that prevent it from being recognized by the immune system. This is the point at which it grows uncontrollably and becomes a tumor and why most solid tumors have a complex immunosuppressive tumor microenvironment. In some aspects, provided herein is gene therapy aimed to target immunosuppressive tumor microenvironment, e.g., for the treatment of solid tumors.
[0742] In some embodiments, the disclosure provides recombinant fusion proteins comprising a therapeutic agent described herein fused to one or more domains or peptides facilitating its secretion, homodimerization, Fc-mediated functionality, or another functionality described herein. Such domains or peptides include, without limitation, a secretory signal peptide, a decorin peptide, a homodimerization domain, a modified IgG Fc domain, and the like, as described herein.
[0743] In some embodiments, the disclosure provides recombinant fusion proteins comprising one or more of the therapeutic agents described herein. In some embodiments, any of the two or three agents (or active variants or fragments thereof) described herein are fused or linked into a fusion protein (e.g., using a flexible linker). Without being bound by any theory, the use of such
[0744] 87
[0745] FH30035011.1
[0746] Attorney Docket No: FTE-00125 fusion proteins facilitates co-expression, co-accumulation and / or concerted (or synergistic) action of the fused proteins in target cells or tissues.
[0747] In some embodiments, the fusion protein comprises one or more of an activator of MHC Class I expression, an immune checkpoint inhibitor, an immuno stimulatory cytokine, a dendritic cell activator, a chemotaxin, an immune response stimulator, an inhibitor of M2 macrophages, a transmembrane IgG, or a cytotoxic agent described herein.
[0748] In some embodiments, the fusion protein comprises a secretory signal peptide. In some embodiments, the fusion protein comprises a secretory signal peptide known in the art or described herein (e.g., TPA signal peptide).
[0749] In some embodiments, a homodimerization domain is incorporated between two agents of a fusion protein. In some embodiments, the homodimerization domain is selected from a humanized leucine zipper, a full IgGl Fc with a LALA-PG silencing mutation, an IgGl Hinge-CH3 domain (with CH2 effector function removed), and an IgG4 Fc domain. Exemplary homodimerization domains are described herein. In some embodiments, the homodimerization domain is a Hinge-CH3 domain as described herein. In some embodiments, the homodimerization domain is flanked by a linker (such as any linker described herein), on one or both sides. In some embodiments, the homodimerization domain is not flanked by a linker but attached directly to one or both agents forming a fusion protein.
[0750] In some embodiments, a fusion protein, such as a fusion protein described herein, comprises a decorin peptide. In some embodiments, a fusion protein comprises a decorin peptide on the C-terminus of a fusion protein. In some embodiments, a fusion protein is linked to the decorin peptide via a linker (such as any linker described herein). In some embodiments, a fusion protein is attached to the decorin peptide directly, without a linker. In some embodiments, a fusion protein comprises a homodimerization domain (e.g., Hinge-CH3 domain) and a decorin peptide.
[0751] In some embodiments, a fusion protein, such as a fusion protein described herein, comprises a protease cleavage site between the two agents in the fusion protein. In some embodiments, the protease cleavage site is not tumor- specific (can be activated not in a tumorspecific manner). In some embodiments, the protease cleavage site is tumor- specific (is activated by proteases enriched in the tumor or tumor microenvironment). Exemplary protease cleavage
[0752] 88
[0753] FH30035011.1
[0754] Attorney Docket No: FTE-00125 sites are described herein. In some embodiments, a protease cleavage site is flanked on one or both sides by a linker, e.g., a linker capable of facilitating cleavage by the protease.
[0755] In some embodiments, the fusion protein comprises a peptide-based nuclear localization sequence. In some embodiments, the nuclear localization sequence comprises the amino acid sequence set forth in SEQ ID NO: 52.
[0756] In some embodiments, the specific fusion protein exemplified herein can be modified by removing or replacing one or more features, e.g., a linker (removing a linker or replacing it by another linker), a homodimerization domain (removing the provided domain or replacing it with another domain), a therapeutic agent component (removing the provided agent or replacing it with another agent, e.g., in the same category), a cleavage site (removing the provided cleavage site or replacing it with another cleavage site), and the like.
[0757] In some embodiments, the secretory signal peptide in the fusion proteins provided herein can be replaced by another secretory signal peptide disclosed herein (or known in the art). In some embodiments, the linker in the fusion proteins provided herein can be replaced by another linker disclosed herein (or known in the art). In some embodiments, the self-cleaving peptide in the proteins provided herein can be replaced by another self-cleaving peptide disclosed herein (or known in the art). In some embodiments, the antibody VH and VL sequences in the fusion proteins provided herein can be replaced by other VH and VL sequences from known antibodies specifically binding the same target (and known to have same or similar antagonistic or agonistic functions). In some embodiments, the homodimerization domain in the fusion proteins provided herein can be replaced by another homodimerization domain disclosed herein (or known in the art). In some embodiments, the cleavage site in the fusion proteins provided herein can be replaced by another cleavage site disclosed herein (or known in the art). In some embodiments, the structure of the constructs provided herein remains the same whereas the above-referenced components can be interchangeably used in the multi-modal therapies described herein.
[0758] Linkers
[0759] In some embodiments, the fusion proteins described herein comprise one or more linkers between the covalently linked therapeutic agents. The proteins of a fusion protein described herein may be linked using methods known in the art. The linker can be any linker known in the art or described herein. In some embodiments, the linker is any flexible linker. In some
[0760] 89
[0761] FH30035011.1
[0762] Attorney Docket No: FTE-00125 embodiments, the linkage is made with a glycine, serine, threonine, or alanine. For example, in some embodiments, the linker is a gly-ser linker.
[0763] In some embodiments, a linker comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 amino acids. In some embodiments, a linker comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, or at least 40 amino acids. In some embodiments, a linker has 5 to 75 amino acids. In some embodiments, a linker has 5 to 40 amino acids. In some embodiments, a linker comprises 5-10 amino acids. In some embodiments, a linker comprises 10-15 amino acids. In some embodiments, a linker comprises 15-20 amino acids. In some embodiments, a linker comprises 20-25 amino acids. In some embodiments, a linker comprises 25-30 amino acids. In some embodiments, a linker comprises 30-35 amino acids. In some embodiments, a linker comprises 35-40 amino acids. In some embodiments, the linker has 25, 30, 35, 40, 50, 60, 75 or fewer amino acids. In some embodiments, the linker has 5, 10, 15 or more amino acids.
[0764] In some embodiments, the linker is a gly-ser polypeptide linker, i.e., a peptide that consists of glycine and serine residues. Exemplary gly-ser polypeptide linkers comprise the amino acid sequence Ser(Gly4Ser)n, as well as (Gly4Ser)n and / or (Gly4Ser3)n. In some embodiments, n=l. In some embodiments, n=2. In some embodiments, n=3, i.e., Ser(Gly4Ser)s. In some embodiments, n=4, i.e., Ser(Gly4Ser)4. In some embodiments, n=5. In some embodiments, n=6. In some embodiments, n=7. In some embodiments, n=8. In some embodiments, n=9. In some embodiments, n=10. Another exemplary gly-ser polypeptide linker comprises the amino acid sequence Ser(Gly4Ser)n. In some embodiments, n=l. In some embodiments, n=2. In some embodiments, n=3. In another embodiment, n=4. In some embodiments, n=5. In some embodiments, n=6. Another exemplary gly-ser polypeptide linker comprises (Gly4Ser)n. In some embodiments, n=l. In some embodiments, n=2. In some embodiments, n=3. In some embodiments, n=4. In some embodiments, n=5. In some embodiments, n=6. Another exemplary gly-ser polypeptide linker comprises (Gly3Ser)n. In some embodiments, n=l. In some embodiments, n=2. In some embodiments, n=3. In some
[0765] 90
[0766] FH30035011.1
[0767] Attorney Docket No: FTE-00125 embodiments, n=4. In another embodiment, n=5. In yet another embodiment, n=6.
[0768] Another exemplary gly-ser polypeptide linker comprises (Gly4Ser3)n. In some embodiments, n=l. In some embodiments, n=2. In some embodiments, n=3. In some embodiments, n=4. In some embodiments, n=5. In some embodiments, n=6. Another exemplary gly-ser polypeptide linker comprises (Gly3Ser)n. In some embodiments, n=l. In some embodiments, n=2. In some embodiments, n=3. In some embodiments, n=4. In another embodiment, n=5. In yet another embodiment, n=6.
[0769] In some embodiments, the linker is a (GGGGS)n linker, wherein n is 1-15 (SEQ ID NO: 100). In some embodiments, the linker peptide comprises, e.g., a (G4S)1 linker, a (G4S)2 linker, a (G4S)3 linker, a (G4S)4 linker, a (G4S)5 linker, (G4S)6 linker, or a (G4S)7 linker. In some embodiments, the linker peptide comprises, e.g., a (G4S)3 linker (GGGGSGGGGSGGGGS) (SEQ ID NO: 103), a (G4S)4 linker (GGGGSGGGGSGGGGSGGGGS) (SEQ ID NO: 105). In some embodiments, the linker is a (G4S)3 linker (GGGGSGGGGSGGGGS) (SEQ ID NO: 103), or a (G4S)4 linker (GGGGSGGGGSGGGGSGGGGS) (SEQ ID NO: 105). In some embodiments, the linker comprises or essentially consists of the sequence set forth in SEQ ID NO: 101. In some embodiments, the linker comprises or essentially consists of the sequence set forth in SEQ ID NO: 102. In some embodiments, the linker comprises or essentially consists of the sequence set forth in SEQ ID NO: 106. In some embodiments, the linker comprises or essentially consists of the sequence set forth in SEQ ID NO: 107. In some embodiments, the linker comprises or essentially consists of the sequence set forth in SEQ ID NO: 108. In some embodiments, the linker comprises or essentially consists of the sequence set forth in SEQ ID NO: 109. In some embodiments, the linker comprises or essentially consists of the sequence set forth in SEQ ID NO: 110.
[0770] In some embodiments, a linker can be encoded by a nucleic acid sequence comprising the sequence set forth in any of SEQ ID NOs: 104 and 111-114. In some embodiments, a linker can be encoded by a nucleic acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 97% or 98% identity to the nucleic acid sequence set forth in any one of SEQ ID NOs: 104 and 111-114.
[0771] In some embodiments, the linker is a rigid linker. (EAAAK)n linkers are known as rigid linker and form a straight arm extension via alpha helix. In some embodiments, the linker is a hybrid linker. Hybrid linkers may provide flexibility to bind to receptors and also create distance between the proteins of the fusion protein. For example, in some embodiments, the hybrid linker 91
[0772] FH30035011.1
[0773] Attorney Docket No: FTE-00125 is a (GGGGS)3(EAAAK)5(GGGGS)3 linker (SEQ ID NO: 117), providing about 100 angstroms of effective distance. This space may be needed for the receptors / clusters in between the two cells. In some embodiments, the linker is a hybrid linker of the formula (GGGGS)a(EAAAK)b(GGGGS)c, wherein a is any number 0 to 10, b is any number 0 to 15 and c is any number 0 to 10 (SEQ ID NO: 115). In some embodiments, a and c are between 2 and 4. In some embodiments, c is between 4 and 8. In some embodiments, the linker is a linker of the formula (EAAAK)n wherein n is 1-15 (SEQ ID NO: 116). In some embodiments, the linker is or comprises the sequence set forth in SEQ ID NO: 117. In some embodiments, a nucleic acid sequence comprising the sequence set forth in SEQ ID NO: 118 encodes the hybrid linker. In some embodiments, a nucleic acid sequence comprising the sequence set forth in SEQ ID NO: 119 encodes the hybrid linker. In some embodiments, a nucleic acid sequence comprising the sequence set forth in SEQ ID NO: 120 encodes the hybrid linker. Use of a nucleic acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 97% or 98% identity to the nucleic acid sequence set forth in any one of SEQ ID NOs: 117-120 is also contemplated herein. In some embodiments, hybrid flexible-rigid linkers can be used (e.g., to allow spacing for fusion proteins).
[0774] In some embodiments, the linker is any linker described in Chen et al., 2013, Adv Drug Deliv Ref. 65( 10): 1357- 1369. In some embodiments, the linker is any linker described in Klein et al., 2014, Protein Engineering Design & Selection 27(10):325-330.
[0775] When fusing two proteins described herein, in some embodiments, glycine or serine (sometimes threonine or alanine) residues native within both proteins are linked together. Since the GS linker is made up of glycine and serines, rather than abruptly connecting the tail ends by two amino acids at random, a glycine or serine residue natively present in both proteins can be used. This approach works for either orientation, whether the heavy or light chain is reversed.
[0776] Agents Engineered for Secretion
[0777] The disclosure provides therapeutic agents engineered to be secreted from a target cell or cells (e.g., a tumor or cancer cell). In some embodiments, any of the therapeutic agents described herein comprises a secretory signal peptide. In some embodiments, any of the therapeutic agents described herein comprise a secretory signal peptide facilitating extracellular secretion of the therapeutic agent upon expression in a cell. In some embodiments, the therapeutic agents of the
[0778] 92
[0779] FH30035011.1
[0780] Attorney Docket No: FTE-00125 disclosure comprise a native secretory signal peptide. In some embodiments, the therapeutic agents of the disclosure comprise a heterologous or non-native secretory signal peptide (e.g., from another protein). In some embodiments, a nucleic acid therapy described herein has a nucleic acid sequence encoding a secretory signal peptide upstream of a nucleic acid sequence encoding the therapeutic protein. In some embodiments, secretory signal sequences of naturally occurring proteins can be used in the recombinant therapeutic agents provided herein. In some embodiments, synthetic, non-naturally occurring secretory signal sequences can be used in the recombinant therapeutic agents provided herein. In some embodiments, a secretory signal peptide is added to a protein that is not a secretory protein and does not contain a native secretory signal peptide. In some embodiments, a native secretory signal peptide of a secretory protein is replaced by a non-native or synthetic secretory signal peptide as described herein.
[0781] In some embodiments, the secretory signal peptide is 5 to 40 amino acids in length, 10 to 30 amino acids in length, or 15 to 25 amino acids in length. In some embodiments, the secretory signal peptide is 18-22 amino acids in length. In some embodiments, the secretory signal peptide is 17-22 amino acids in length. In some embodiments, the secretory signal peptide is 17, 18, 19, 20, 21, or 22 nucleotides in length. In some embodiments, the secretory signal peptide is positioned at the amino terminus of a therapeutic agent described herein. In some embodiments, the secretory signal peptide is processed and cleaved by the endoplasmic reticulum.
[0782] In some embodiments, when a polycistronic vector described herein comprises two or more copies of the same secretory signal peptide, the nucleic acid sequences encoding the two or more copies of the secretory signal peptide are designed to differ (e.g., having the identical nucleotide sequence overlap of less than 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11 or 10 contiguous nucleotides), while encoding the secretory signal peptides having identical amino acid sequences. Without being bound by theory, this is done because repeat sequences in the same vector may promote homologous recombination. In some embodiments, the nucleic acid sequence of a secretory signal peptide can be codon optimized, and two or more different codon-optimized versions of the nucleic acid sequence can be used to facilitate secretion of two or more gene products, respectively. In some embodiments, a vector comprises only one copy of any one nucleic acid sequence encoding a secretory signal peptide (but it can comprise more than one non-identical nucleic acid sequences each encoding the same secretory signal peptide). In some embodiments, the nucleic acid sequences encoding the same secretory signal peptide are
[0783] 93
[0784] FH30035011.1
[0785] Attorney Docket No: FTE-00125 modified to comprise less than 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, or 50%, nucleic acid sequence identity. In some embodiments, the nucleic acid sequences encoding the same secretory signal peptide are modified to comprise less than 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, or 70% nucleic acid sequence identity (e.g., less than about 76% sequence identity). In some embodiments, the nucleic acid sequences encoding the same secretory signal peptide are modified to comprise less than 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 base pairs of contiguous identical sequence overlap (e.g., less than about 17 base pairs of contiguous identical sequence overlap).
[0786] In some embodiments, a native secretory signal peptide is replaced or a non-native secretory signal peptide is added to a synthetic or fusion protein, wherein the secretory signal peptide is derived from a secreted protein that has evolved to be rapidly and efficiently secreted, e.g., to save life within minutes. Examples of such proteins include Tissue plasminogen activator (TPA), Von willibrand factor (vWR), fibrinogen, coagulation factors (e.g., thrombin, factor VIII), complement proteins (e.g., C3a, C5a, anaphylatoxins, MAC components), and mast cell proteases (e.g., tryptase, chymase).
[0787] In some embodiments, the secretory signal peptide is a signal peptide from: TPA, vWR, fibrinogen, a coagulation factor (e.g., thrombin, factor VIII), a complement protein (e.g., C3a, C5a, anaphylatoxins, MAC components), or a mast cell protease (e.g., tryptase, chymase). In some embodiments, the secretory signal peptide is a signal peptide from: TPA, GM-CSF, IL2, IGK, PSMA, PSA, human serum albumin (HSA), or CA 19-9.
[0788] In some embodiments, the therapeutic agent comprises at least one secretory signal peptide. In some embodiments, the therapeutic agent comprises two secretory signal peptides (e.g., one native secretory signal peptide and one non-native secretory signal peptide).
[0789] In some embodiments, the secretory signal peptide is a TPA signal peptide. In some embodiments, the TPA signal peptide is expressed with complex folding proteins, e.g., an antibody or a receptor. In some embodiments, the secretory signal peptide is a TPA signal peptide comprising the amino acid sequence set forth in SEQ ID NO: 76. In some embodiments, the secretory signal peptide comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in SEQ ID NO: 76.
[0790] In some embodiments, the secretory signal peptide is a modified TPA signal peptide (such as modified relative to the TPA signal peptide of SEQ ID NO: 76). In some embodiments, the
[0791] 94
[0792] FH30035011.1
[0793] Attorney Docket No: FTE-00125
[0794] TPA signal peptide is modified by substituting any one of the three terminal residues with another residue (e.g., residues V, S, and P, at positions -3, -2, and -1, respectively). In some embodiments, the TPA signal peptide is modified by substituting residue P at position -1 and / or residue V at position -3 of the TPA signal peptide with another residue. In some embodiments, the substitution is with a small, uncharged amino acid (e.g., alanine). In some embodiments, the substitution is with A (alanine), S (serine), or G (glycine), where each of these positions can be substituted with the same or different residue. In some embodiments, the substitution is with A (alanine) residue. In some embodiments, the TPA signal peptide is modified by substituting the terminal P (proline) residue with another residue. In some embodiments, the substitution is with a small, uncharged amino acid. In some embodiments, the terminal P (proline) residue is repalced with A (alanine) residue. Without being bound by theory, such modification of the TPA signal peptide may improve signal peptidase cleavage (because of the importance of positions -1 to -3 for signal peptidase).
[0795] In some embodiments, the secretory signal peptide is a modified TPA signal peptide comprising the amino acid sequence set forth in SEQ ID NO: 63. In some embodiments, the secretory signal peptide comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in SEQ ID NO: 63. In some embodiments, the secretory signal peptide is a modified TPA signal peptide comprising the amino acid sequence set forth in SEQ ID NO: 64. In some embodiments, the secretory signal peptide comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in SEQ ID NO: 64. In some embodiments, the secretory signal peptide is a modified TPA signal peptide comprising the amino acid sequence set forth in SEQ ID NO: 65. In some embodiments, the secretory signal peptide comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in SEQ ID NO: 65. In some embodiments, the secretory signal peptide is a modified TPA signal peptide comprising the amino acid sequence set forth in SEQ ID NO: 66. In some embodiments, the secretory signal peptide comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in SEQ ID NO: 66. In some embodiments, the secretory signal peptide is a modified TPA signal peptide comprising the amino acid sequence set forth in SEQ ID NO: 67. In some embodiments, the secretory signal peptide comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in
[0796] 95
[0797] FH30035011.1
[0798] Attorney Docket No: FTE-00125
[0799] SEQ ID NO: 67. In some embodiments, the secretory signal peptide is a modified TPA signal peptide comprising the amino acid sequence set forth in SEQ ID NO: 68. In some embodiments, the secretory signal peptide comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in SEQ ID NO: 68.
[0800] In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 77. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 77.
[0801] In some embodiments, the nucleic acid encoding a TPA signal peptide is modified. In some embodiments, a vector encodes multiple agents, where more than one (e.g., 2, 3 or 4) agents comprise a TPA signal peptide (e.g., the same TPA signal peptide either unmodified or modified). In such embodiments, the vector comprises more than one nucleic acid sequences encoding the TPA signal peptide. In some embodiments, the more than one nucleic acid sequences encoding the TPA signal peptide are not identical and may comprise, e.g., less than 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, or 50% nucleic acid sequence identity. In some embodiments, the more than one nucleic acid sequences encoding the TPA signal peptide comprise less than 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, or 70% nucleic acid sequence identity (e.g., less than about 76% sequence identity). In some embodiments, the more than one nucleic acid sequences encoding the TPA signal peptide comprise less than 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, or 70% nucleic acid sequence homology (e.g., less than about 76% sequence homology). In some embodiments, the more than one nucleic acid sequences encoding the TPA signal peptide comprise less than 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 base pairs of contiguous identical sequence overlap. In some embodiments, the more than one nucleic acid sequences encoding the TPA signal peptide comprise less than about 17 base pairs of contiguous identical sequence overlap.
[0802] In some embodiments, the nucleic acid sequence encoding the TPA signal peptide is codon optimized.
[0803] In some embodiments, the GC content of the nucleic acid encoding a TPA signal peptide is modified. In some embodiments, the nucleic acid encoding a TPA signal peptide is modified to ensure optimal GC content, e.g., to achieve the GC content from about 50% to about 70%. In some embodiments, the nucleic acid encoding a TPA signal peptide is modified to achieve the
[0804] 96
[0805] FH30035011.1
[0806] Attorney Docket No: FTE-00125
[0807] GC content from about 54% to about 66%. In some embodiments, the nucleic acid encoding a TPA signal peptide is modified to achieve the GC content of about 60%.
[0808] In some embodiments, the nucleic acid encoding a TPA signal peptide is modified to achieve Codon Adaptation Index of at least about 0.9. In some embodiments, the nucleic acid encoding a TPA signal peptide is modified to achieve Codon Adaptation Index from 0.9 to 0.94. Without being bound by theory, lower CAI may slow translation.
[0809] In some embodiments, the nucleic acid encoding a TPA signal peptide has no polyA-like sites (e.g., no AATAAAA). In some embodiments, the nucleic acid encoding a TPA signal peptide has no restriction sites.
[0810] In some embodiments, the nucleic acid sequences encoding the TPA signal peptides (such as those present in one vector or in one polycistronic cassette): (i) share less than 76% sequence homology, (ii) share less than 17 base pairs of identical overlap, (iii) comprise a Codon Adaptation Indence of at least 0.9, (iv) comprise about about 50% to about 70% GC content, and / or (v) comprise no polyA-like sites. In some embodiments, the nucleic acid sequences encoding the TPA signal peptide share less than 76% sequence homology. In some embodiments, the nucleic acid sequences encoding the TPA signal peptide share less than 17 base pairs of identical overlap. In some embodiments, the nucleic acid sequences encoding the TPA signal peptide comprise a Codon Adaptation Indence of at least 0.9. In some embodiments, the nucleic acid sequences encoding the TPA signal peptide comprise about 60% + / - 6% GC content. In some embodiments, the nucleic acid sequences encoding the TPA signal peptide comprise no polyA-like sites. In some embodiments, a codon optimized secretory signal peptide sequence is used in the constructs described herein.
[0811] In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 78. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 78. In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 79. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 79. In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 80. In some 97
[0812] FH30035011.1
[0813] Attorney Docket No: FTE-00125 embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 80. In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 81. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 81. In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 69. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 69. In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 70. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 70. In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 71. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 71. In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 72. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 72. In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 73. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 73. In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 74. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 74. In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 75. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic
[0814] 98
[0815] FH30035011.1
[0816] Attorney Docket No: FTE-00125 acid sequence set forth in SEQ ID NO: 75. In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 166. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 166. In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 167. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 167. In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 168. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 168. In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 169. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 169. In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 170. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 170. In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 171. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 171. In some embodiments, the secretory signal peptide is a TPA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 172. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 172.
[0817] In some embodiments, the secretory signal peptide is a Gaussia Luciferase (GL) signal peptide (spGL). In some embodiments, the Gaussia Luciferase signal peptide can be used, e.g., with small proteins, chemokines, and cytokines. In some embodiments, the secretory signal peptide is a Gaussia Luciferase signal peptide comprising the amino acid sequence set forth in
[0818] 99
[0819] FH30035011.1
[0820] Attorney Docket No: FTE-00125 any of SEQ ID NOs: 82, 85, 87, and 89. In some embodiments, the secretory signal peptide comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in any of SEQ ID NO: 82, 85, 87, and 89. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to a nucleic acid sequence set forth in any of SEQ ID NOs: 86, 88, and 90.
[0821] In some embodiments, a protein or fusion protein described herein does not comprise a secretory signal peptide. In some embodiments, a protein or fusion protein that does comprise a secretory signal peptide is or comprises, e.g., a cytotoxic agent (e.g., a toxin). In some embodiments, a tumor lysis agent comprises a secretory signal peptide. In some embodiments, a protein or fusion protein that does not comprise a secretory signal peptide is or comprises, e.g., a cytotoxic agent (e.g., a toxin). In some embodiments, a tumor lysis agent does not comprise a secretory signal peptide. In some embodiments, a tumor lysis agent comprising a transmembrane domain fused to an Fc does not comprise a secretory signal peptide. In some embodiments the protein or fusion protein that does not comprise a secretory signal peptide is selected from diphtheria toxin, Shiga toxin, ABx toxin, ribosome inactivating protein toxin, abrin, anthrax toxin, Aspf 1, bouganin, bryodin, cholix toxin, claudin, gelonin, heat-labile enterotoxin, mitogillin, pertussis toxin, pokeweed antiviral protein, pulchellin, Pseudomonas exotoxin A, restrictocin, ricin, saporin, sarcin, and subtilase cytotoxin, a toxin derived from the aerolysin family, Gasdermins (GSDME), Perforin, or Cytolysin A. In some embodiments, an miRNA therapeutic described herein does not comprise a secretory signal peptide. In some embodiments, a tumor lysis agent is placed under the control of a delayed promoter as described elsewhere herein.
[0822] In some embodiments, a codon optimized secretory signal peptide sequence is used in combination with a nucleic acid encoding an IFNy. In some embodiments, a codon optimized signal peptide sequence is used in combination with a nucleic acid encoding a PD1-CD40 fusion protein. In some embodiments, a codon optimized signal peptide sequence is used in combination with a nucleic acid encoding an IL12 protein. In some embodiments, a codon optimized signal peptide sequence is used in combination with a nucleic acid encoding an FLT3L protein.
[0823] 100
[0824] FH30035011.1
[0825] Attorney Docket No: FTE-00125
[0826] In some embodiments, the secretory signal peptide is a PSA signal peptide. In some embodiments, the secretory signal peptide is a PSA signal peptide comprising the amino acid sequence set forth in SEQ ID NO: 58. In some embodiments, the secretory signal peptide comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in SEQ ID NO: 58. In some embodiments, the secretory signal peptide is a PSA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 61. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 61.
[0827] In some embodiments, the secretory signal peptide is an IL2 signal peptide. In some embodiments, the secretory signal peptide is an IL2 signal peptide comprising the amino acid sequence set forth in SEQ ID NO: 96. In some embodiments, the secretory signal peptide comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in SEQ ID NO: 96. In some embodiments, the secretory signal peptide is an IL2 signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 97. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 97.
[0828] In some embodiments, the secretory signal peptide is an IGK signal peptide. In some embodiments, the secretory signal peptide is an IGK signal peptide comprising the amino acid sequence set forth in any of SEQ ID NOs: 54, 55, and 98. In some embodiments, the secretory signal peptide comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino acid sequence set forth in any of SEQ ID NOs: 54, 55, and 98. In some embodiments, the secretory signal peptide is an IGK signal peptide encoded by the nucleic acid sequence set forth in any of SEQ ID NOs: 55, 57, and 99. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in any of SEQ ID NOs: 55, 57, and 99.
[0829] In some embodiments, the secretory signal peptide is an HSA signal peptide. In some embodiments, the secretory signal peptide is an HSA signal peptide comprising the amino acid sequence set forth in SEQ ID NO: 91. In some embodiments, the secretory signal peptide comprises an amino acid sequence having at least 85%, 90%, 95%, or 98% identity to the amino 101
[0830] FH30035011.1
[0831] Attorney Docket No: FTE-00125 acid sequence set forth in SEQ ID NO: 91. In some embodiments, the secretory signal peptide is an HSA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 95. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 95. In some embodiments, the secretory signal peptide is an HSA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 92. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 92. In some embodiments, the secretory signal peptide is an HSA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 93. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 93. In some embodiments, the secretory signal peptide is an HSA signal peptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 94. In some embodiments, the secretory signal peptide is encoded by a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 98% identity to the nucleic acid sequence set forth in SEQ ID NO: 94.1n some embodiments, the secretory signal peptide is a CA 19-9 signal peptide, which is known in the art. In some embodiments, the secretory signal peptide is a variant of the CA 19-9 signal peptide, e.g., having at least 85%, 90%, 95%, or 98% identity thereto.
[0832] In some embodiments, the presence of a non-native secretory signal peptide, such as any of those described herein, increases secretion of a secretory protein (relative to the native protein or the protein without the non-native secretory signal peptide) by at least or more than 2x, 5x, 10x, 50x, 100x, 500x, or 200%, 500%, or 1000%.
[0833] Fc, Dimerization and Trimerization Domains for Agents
[0834] In some embodiments, an agent provided herein comprises an IgG Fc domain or a variant of an IgG Fc domain.
[0835] In some embodiments, a fusion protein described herein comprises an IgG Fc domain. In some embodiments, the IgG is a wild- type Ig Gl, wild- type IgG4, or a silenced IgGl. In some embodiments, a fusion protein described herein comprises a Hinge and the CH3 domain of an IgG as described herein (but not CH2 or CHI domains).
[0836] 102
[0837] FH30035011.1
[0838] Attorney Docket No: FTE-00125
[0839] Without wishing to be bound by theory, a fusion protein comprising wild- type IgGl Fc triggers antibody-dependent cellular cytotoxicity (ADCC) destruction of the target (such as a tumor cell). In some embodiments, a wild-type IgG Fc (e.g., IgGl Fc) is fused to a protein or fusion protein (e.g., an antigen-binding fragment or scFv) directed against CTLA4, B7-H3, HER2, EGFR, PSMA, CD47, or PDL1.
[0840] In some embodiments, the IgG Fc domain is a native IgG Fc domain, e.g., IgGl.
[0841] In some embodiments, the therapeutic construct comprises a wild type IgGl Fc region of full length, including both the CH2 and CH3 domains and the hinge region. The wild type IgGl Fc region retains full effector function, including antibody-dependent cellular cytotoxicity (ADCC), such that binding of the construct to a target cell triggers immune-mediated destruction of that target cell. In some embodiments, the wild type IgGl Fc region is selected when the therapeutic intent is to deplete or destroy cells bearing the target antigen. Targets for which ADCC-mediated destruction is desired include, without limitation, CTLA-4, and tumor- specific or tumor-associated markers such as B7-H3, HER2, EGFR, PSMA, CD47, and PD-L1.
[0842] In some embodiments, an IgG Fc domain is a silenced IgG Fc domain (e.g., IgGl Fc with a LALA-PG silencing mutation (L234A / L235A / P329G)). In some embodiments, the homodimerization domain comprises an IgGl with a silencing mutation. A silencing mutation may include one or more mutations for increasing half-life of a protein described herein. In some embodiments, the silencing mutations prevent effector functions of the IgG domain from attacking anti-tumor immune cells. In some embodiments, the silencing mutation is a L234A / L235A / P329G group of mutations. In some embodiments, the silenced IgG comprises the sequence set forth in SEQ ID NO: 181. In some embodiments, the nucleic acid therapy comprises a nucleic acid encoding a silenced IgG Fc comprising a sequence at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the sequence set forth in SEQ ID NO: 181.
[0843] In some embodiments, IgG Fc domain is an IgG4 Fc domain. In some embodiments, the IgG4 Fc region comprises an S229P modification. In some embodiments, the IgG4 Fc region is encoded by a nucleic acid sequence comprising the sequence set forth in SEQ ID NO: 182. In some embodiments, the IgG4 Fc region comprising an S229P modification is encoded by a nucleic acid sequence comprising at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the sequence set forth in SEQ ID NO: 182.
[0844] 103
[0845] FH30035011.1
[0846] Attorney Docket No: FTE-00125
[0847] In some embodiments, an agent provided herein comprises a homodimerization domain, which promotes dimerization of an agent. In some embodiments, the homodimerization domains are selected from a humanized leucine zipper, a full IgGl Fc with a LALA-PG silencing mutation, a minimal IgGl Hinge-CH3 domain (with CH2 effector function removed), and an IgG4 Fc domain. In some embodiments, a homodimerization domain is incorporated between the two proteins of a fusion protein. In some embodiments, the homodimerization domain comprises a humanized leucine zipper. In some embodiments, the homodimerization domain comprises an IgGl Fc with a LALA-PG silencing mutation. In some embodiments, the homodimerization domain comprises a minimal IgGl Hinge-CH3 domain. In some embodiments, the homodimerization domain comprises an IgG4.
[0848] In some embodiments, the therapeutic construct comprises an Fc region selected to provide receptor blockade without triggering destruction of the target cell. This configuration is appropriate when the target antigen is expressed on immune cells whose preservation is therapeutically desirable. For example, PD-1 is expressed on T cells and other immune effector cells, and destruction of PD-1 -bearing cells would be counterproductive to the therapeutic goal of restoring anti-tumor immunity. In some embodiments, such constructs comprise a full-length wild type IgG4 Fc region. In some embodiments, such constructs comprise a silenced IgGl Fc region described herein bearing mutations that abrogate effector function. In some embodiments, such constructs comprise a truncated Fc region consisting of the hinge region and the CH3 domain without the CH2 domain (referred to herein as a " Hinge-CH3" configuration).
[0849] In some embodiments, the homodimerization domain is a Hinge-CH3 domain, which is an Fc domain (such as IgGl Fc) in which the CH2 domain has been removed. A “Hinge -CH3 domain” comprises the hinge region of an Fc and the CH3 region of an Fc, and does not comprise the CH2 region of the Fc. The Hinge-CH3 domain can be fused to the end of a protein to facilitate dimerization of a protein described herein. Removing the CH2 domain removes the effector functions of the CH2 domain. Further, and without wishing to be bound by theory, the Hinge-CH3 domain can rapidly clear from the body if there is leakage from tumors into circulation given the operational binding site for the neonatal Fc receptor (FcRn), responsible for recycling antibodies and increasing half-life, spans the interface between the CH2 and CH3 domains; eliminating the CH2 domain removes key residues (such as Ile253) needed to form the hydrophobic core required for stable binding.. In some embodiments, a Hinge-CH3 is used
[0850] 104
[0851] FH30035011.1
[0852] Attorney Docket No: FTE-00125 herein to modestly increase the half-life of an agent (e.g., a fusion protein). In some embodiments, an IgG4 Fc, IgGl Fc (wild type), or silenced IgGl Fc domain is used to substantially increase the half-life of an agent (e.g. anti-PDLl scFV).
[0853] In some embodiments, the therapeutic construct comprises the Hinge-CH3 configuration when the therapeutic intent requires both the absence of effector function and reduced serum half-life relative to a full-length Fc-containing construct. The CH2 domain contributes to extended circulatory half-life through interactions with the neonatal Fc receptor (FcRn), and removal of the CH2 domain accordingly reduces serum persistence of the construct. In some embodiments, the Hinge-CH3 configuration is selected for constructs that bind to cells whose preservation is essential to the desired immune response, such that neither ADCC-mediated destruction nor prolonged systemic exposure to the construct would be therapeutically acceptable.
[0854] In some embodiments, the construct comprising the Hinge-CH3 configuration is a costimulatory receptor agonist. Co-stimulatory receptor agonists bind to immune cells that are necessary for effective anti-tumor immunity, including dendritic cells and T cells. Exemplary costimulatory receptor agonists include, without limitation, single-chain trimeric LIGHT (sctriLIGHT), single-chain trimeric 4- IBB ligand (sctri-4-lBBL), and single-chain trimeric CD40 ligand (sctriCD40L). Because these agonists bind to cells that are essential effectors of anti-tumor immunity, the Hinge-CH3 configuration is selected to avoid targeting such cells for ADCC-mediated destruction. Furthermore, the reduced half-life conferred by the absence of the CH2 domain limits systemic exposure. For example, CD40 agonism licenses dendritic cells to mount an immune response against antigens they encounter, and prolonged systemic CD40 agonism in circulation may result in undesirable autoimmune toxicity.
[0855] In some embodiments, the co-stimulatory receptor agonist comprising the Hinge-CH3 configuration is fused to a targeting moiety that anchors the agonist activity to a desired anatomical site. In some embodiments, the targeting moiety is a single-chain variable fragment (scFv) directed against PD-L1 (an "anti-PD-Ll scFv"). By fusing a CD40 agonist to an anti-PDLl scFv, the construct anchors dendritic cell licensing activity to PD-L1 -expressing tumor cells while simultaneously blocking PD-L1 -mediated immune checkpoint signaling. The resulting construct thereby provides both localized co-stimulatory agonism and checkpoint blockade within the tumor microenvironment.
[0856] 105
[0857] FH30035011.1
[0858] Attorney Docket No: FTE-00125
[0859] In some embodiments, provided herein is a Hinge-CH3 domain comprising the amino acid sequence set forth in SEQ ID NO: 127 or a sequence having at least 85%, 90%, 95%, or 98% amino acid sequence identity to SEQ ID NO: 127. In some embodiments, a nucleic acid sequence encoding the Hinge-CH3 domain comprises the nucleic acid sequence set forth in SEQ ID NO: 128 or a sequence having at least 85%, 90%, 95%, or 98% identity to SEQ ID NO: 128.
[0860] In some embodiments, a homodimerization domain (e.g., the Hinge-CH3 domain) is flanked by a linker such as any linker described herein, e.g., a flexible linker. In some embodiments, an agent described herein comprises a homodimerization domain (e.g., the Hinge-CH3 domain) and a linker between the agent and the homodimerization domain (e.g., the Hinge-CH3 domain). In some embodiments, a homodimerization domain (e.g., the Hinge-CH3 domain) is flanked by (GGGGS)n sequences wherein n is from 1 to 15 (SEQ ID NO: 100). In some embodiments, the Hinge-CH3 domain is flanked by (GGGGS)n sequences wherein n is from 1 to 15 (SEQ ID NO: 100).
[0861] In some embodiments, provided herein is a Hinge-CH3 domain comprising the amino acid sequence set forth in SEQ ID NO: 129 or a sequence having at least 85%, 90%, 95%, or 98% amino acid sequence identity to SEQ ID NO: 129. In some embodiments, a nucleic acid sequence encoding the Hinge-CH3 domain comprises the nucleic acid sequence set forth in SEQ ID NO: 130 or a sequence having at least 85%, 90%, 95%, or 98% identity to SEQ ID NO: 130.
[0862] In some embodiments, provided herein is a Hinge-CH3 domain comprising the amino acid sequence set forth in SEQ ID NO: 131 or a sequence having at least 85%, 90%, 95%, or 98% amino acid sequence identity to SEQ ID NO: 131. In some embodiments, a nucleic acid sequence encoding the Hinge-CH3 domain comprises the nucleic acid sequence set forth in SEQ ID NO: 132 or a sequence having at least 85%, 90%, 95%, or 98% identity to SEQ ID NO: 132.
[0863] In some embodiments, provided herein is a Hinge-CH3 domain comprising the amino acid sequence set forth in SEQ ID NO: 133 or a sequence having at least 85%, 90%, 95%, or 98% amino acid sequence identity to SEQ ID NO: 133. In some embodiments, a nucleic acid sequence encoding the Hinge-CH3 domain comprises the nucleic acid sequence set forth in SEQ ID NO: 134 or a sequence having at least 85%, 90%, 95%, or 98% identity to SEQ ID NO: 134.
[0864] In other embodiments, a linker, e.g., a flexible linker, is used in homodimerization domain containing agents which differs from (GGGGS)n.
[0865] 106
[0866] FH30035011.1
[0867] Attorney Docket No: FTE-00125
[0868] In some embodiments, a homodimerization domain is fused to an scFv described herein. In some embodiments, a Hinge-CH3 domain is fused to an scFv described herein, such as in cases where there is reason to prevent increase in half-life or to eliminate effector function. In some embodiments, an scFv is fused to a Hinge-CH3 domain which is further fused to another therapeutic agent (such as to facilitate dimerization of both proteins).
[0869] In some embodiments, the therapeutic construct comprises an anti-PD-L1 scFv fused to a full length Fc region without a co-stimulatory receptor agonist. When the anti-PD-L1 scFv is not fused to a co-stimulatory receptor agonist, the extended serum half-life conferred by the full length Fc region, including the CH2 domain, is therapeutically desirable because prolonged PD-L1 blockade enhances anti-tumor immunity without the toxicity concerns associated with systemic co-stimulatory agonism. In some embodiments, the full length Fc region is a silenced IgGl Fc or a wild type IgG4 Fc. In some embodiments, the full length Fc region is a wild type IgGl Fc, depending on whether effector function against PD-L1 -expressing cells is desired.
[0870] In some embodiments, the anti-PD-Ll scFv-Fc construct is administered systemically, including in conjunction with a separate intratumoral therapy. In some embodiments, the intratumoral therapy comprises a co-stimulatory receptor agonist, such as sctriCD40L, administered directly into the tumor. In such embodiments, systemic administration of the anti-PD-Ll scFv-Fc construct with extended half-life provides sustained checkpoint blockade, while intratumoral administration of the co-stimulatory receptor agonist confines the potentially toxic agonist activity to the tumor microenvironment. In some embodiments where the CD40 agonist is not linked to a PD-L1 blocking moiety, extended serum half-life of the systemically administered checkpoint inhibitor is desirable to maintain continuous PD-L1 blockade throughout the treatment period.
[0871] In some embodiments, the humanized leucine zipper comprises a human CCAAT / Enhancer-Binding Protein (C / EBP), a CREB, or an ATF1 leucine zipper. In some embodiments, the humanized leucine zipper is a humanized version of yeast GCN4-pl. Methods of humanizing a yeast GCN4-pl are known to those of skill in the art. In some embodiments, the humanized leucine zipper comprises the amino acid sequence set forth in SEQ ID NO: 696.
[0872] In some embodiments, such as where target blockade is desired without destroying the target cell (e.g., PD-1 blockade), a fusion protein may comprise full length wild type IgG4 Fc, silenced IgGl Fc, or “Hinge-CH3” as described herein. Without wishing to be bound by theory, a
[0873] 107
[0874] FH30035011.1
[0875] Attorney Docket No: FTE-00125 fusion protein comprising a Hinge-CH3 reduces effector function and reduces the half-life of a protein or fusion protein described herein. In some embodiments, a “Hinge-CH3” can be used where it is desired to avoid effector function and to prevent long half-life. In some embodiments, an agent comprising a co-stimulatory ligand agonist (e.g., sctriLIGHT, sctri-4-lBBL, or sctriCD40L) comprises a hinge domain and a CH3 domain of IgG (e.g., IgGl), without the CH2 domain (to avoid triggering ADCC and remove CH2 effector function). In some embodiments, a Hinge-CH3 is fused to a sctriLIGHT, sctri-4-lBBL, sctriCD40L. In some embodiments, a Hinge-CH3 is fused to a sctriLIGHT, sctri-4-lBBL, sctriCD40L where the fusion protein may bind to a dendritic cell or T cell. Without being bound by theory, the CH2 domain may increase half-life, which can be toxic in circulation. Without wishing to be bound by theory, removing CH2 effector function may reduce half-life to inhibit toxic circulation. In some embodiments, where the fusion protein comprises a CD40 agonist, the CH2 domain is removed from an Fc region for the fusion protein (e.g., to reduce effector function and / or reduce half-life). In some embodiments, a Hinge-CH3 domain is used in cases where a short half-life is beneficial for therapy. In some embodiments, the fusion protein is a CD40 ligand fused to an anti-PDLl scFv as described herein, and optionally further fused to a “Hinge-CH3.” In some embodiments (e.g., such as where an increased half-life is desirable), a full length Fc (with a CH2 domain) is used in agents described herein. For example, in some embodiments, provided herein is an anti-PDLl scFv-Fc (e.g., alone, without fusion to co-stimulatory receptor agonist), and with a full length Fc, an Fc comprising a CH2 domain, or a silenced Fc. In some embodiments where the fusion protein does not comprise a CD40 agonist fused to an anti-PDLl or anti-PDl scFv, the fusion protein comprises an Fc with the CH2 domain, e.g., a full IgG Fc.
[0876] In some embodiments, an agent provided herein comprises a multimerization or a trimerization domain. In some embodiments, a multimerization domain comprises stabilizing disulfide bonds for multimerization. In some embodiments, a trimerization domain facilitates trimerization of a TNFSF monomer alone or in a fusion with a tumor or checkpoint targeting scFv. Without wishing to be bound by theory, although a TNFSF may form a trimer on its own, a trimerization domain, in fusion with an scFv, may increase the avidity of an antibody binding domain and facilitate clustering. In some embodiments, a trimerization domain is a Matrilin 1 (MATN1) disulfide stabilized homo-trimerization domain. In some embodiments, a multi-trimerization domain is a Cartilage Oligomeric Matrix Protein (COMP) domain.
[0877] 108
[0878] FH30035011.1
[0879] Attorney Docket No: FTE-00125
[0880] In some embodiments, a MATN trimerization domain comprises at least 85%, 90%, 95%, 98%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 173. In some embodiments, the MATN trimerization domain comprises at least 85%, 90%, 95%, 98%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 174. In some embodiments, the MATN trimerization domain is encoded by a nucleic acid sequence comprising at least 85%, 90%, 95%, 98%, or 100% identity to the nucleic acid sequence set forth in SEQ ID NO: 175. In some embodiments, the multi-trimerization domain is a Cartilage Oligomeric Matrix Protein (COMP). In some embodiments, a COMP trimerization domain comprises at least 85%, 90%, 95%, 98%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 176.
[0881] Collagen Peptides for Agents
[0882] In some embodiments, a collagen peptide is used to facilitate anchoring of an agent (e.g., a cytokine described herein) to the tumor microenvironment. In some embodiments, the collagen peptide is any collagen peptide known in the art or described herein (e.g., any such peptide that is capable of facilitating anchoring of an agent to the tumor microenvironment). In some embodiments, the collagen peptide is a peptide that does not cause steric hindrance. In some embodiments, the collagen peptide is selected from the A3 domain of von Willbrand Factor, Lumican, TKKTLRT (synthetic motif), or a decorin peptide. In some embodiments, the collagen peptide is an A3 domain of von Willbrand Factor. In some embodiments, the collagen peptide is a Lumican peptide. In some embodiments, the collagen peptide is a synthetic motif. In some embodiments, the collagen peptide is or comprises the sequence of TKKTLRT.
[0883] In some embodiments, the collagen peptide is fused to the agent directly or via a linker, e.g., any linker described herein. In some embodiments, the collagen peptide is fused to a protein via a flexible linker, e.g., to a C-terminal domain of the protein. In some embodiments, the collagen peptide is fused to the agent via a homodimerization domain (e.g., Hinge-CH3 domain). In some embodiments, a homodimerization domain and the collagen peptide are fused directly or via a linker, e.g., any linker described herein.
[0884] Examples of proteins that can be anchored via a collagen peptide include IL 12 and IL 15.
[0885] In some embodiments, the collagen peptide is a decorin peptide. Decorin is a small leucine-rich proteoglycan that binds to the extracellular matrix (ECM) in the tumor microenvironment, and may, inter alia, inhibit tumor cell growth. Without being bound by theory,
[0886] 109
[0887] FH30035011.1
[0888] Attorney Docket No: FTE-00125 an agent described herein (e.g., a fusion protein) can be linked to a decorin peptide to facilitate retention of the agent in the tumor microenvironment or tumor ECM.
[0889] In preferred embodiments, the decorin peptide is fused to the agent at the C-terminus. In some embodiments, the decorin is fused to the agent directly or via a linker, e.g., any linker described herein. In some embodiments, the decorin peptide is fused to the agent via a homodimerization domain (e.g., Hinge-CH3 domain). In some embodiments, a homodimerization domain and the decorin peptide are fused directly or via a linker, e.g., any linker described herein.
[0890] In some embodiments, the decorin peptide comprises the amino acid sequence set forth in SEQ ID NO: 121 or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to the sequence set forth in SEQ ID NO: 121.
[0891] In some embodiments, the decorin peptide comprises a linker, such as a linker N-terminal to the decorin peptide.
[0892] In some embodiments, the decorin peptide comprises the amino acid sequence set forth in SEQ ID NO: 122 or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity to the sequence set forth in SEQ ID NO: 122.
[0893] In some embodiments, the nucleic acid therapy comprises a nucleic acid encoding a decorin peptide wherein the nucleic acid comprises the sequence set forth in SEQ ID NO: 123, or a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to the sequence set forth in SEQ ID NO: 123. In some embodiments, the nucleic acid therapy comprises a nucleic acid encoding a decorin peptide wherein the nucleic acid comprises the sequence set forth in SEQ ID NO: 124, or a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to the sequence set forth in SEQ ID NO: 124. In some embodiments, the nucleic acid therapy comprises a nucleic acid encoding a decorin peptide wherein the nucleic acid comprises the sequence set forth in SEQ ID NO: 125, or a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to the sequence set forth in SEQ ID NO: 125. In some embodiments, the nucleic acid therapy comprises a nucleic acid encoding a decorin peptide wherein the nucleic acid comprises the sequence set forth in SEQ ID NO: 126, or a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to the sequence set forth in SEQ ID NO: 126.
[0894] 110
[0895] FH30035011.1
[0896] Attorney Docket No: FTE-00125
[0897] Protease Cleavage Sites
[0898] In some embodiments, the proteins forming part of a fusion protein are separated by a cleavage site, e.g., any cleavage site described herein. In some embodiments, a fusion protein described herein comprises a sequence recognized and cleaved by a protease (e.g., furin or another protease). In some embodiments, the cleavage site is flanked on one or both sides by a linker, e.g., a GS linker, as described herein. In some embodiments, the flanking linker is capable of facilitating the cleavage at the site. The cleavage site can be a furin cleavage site or, for example, a cleavage sequence recognized by a protease that is present or enriched with the tumor microenvironment, as described herein.
[0899] In some embodiments, the cleavage site is a furin cleavage site (an amino acid sequence recognized by furin protease). In some embodiments, the furin cleavage site comprises the amino acid sequence set forth in SEQ ID NO: 135. In some embodiments, the furin cleavage site comprises the amino acid sequence set forth in SEQ ID NO: 140. In some embodiments, a nucleic acid encoding the furin cleavage site comprises the nucleic acid sequence set forth in SEQ ID NO: 136, or a nucleic acid sequence comprising at least 80%, 85%, 90%, 95%, or 98% identity to the sequence set forth in SEQ ID NO: 136. In some embodiments, a nucleic acid encoding the furin cleavage site comprises the nucleic acid sequence set forth in SEQ ID NO: 137, or a nucleic acid sequence comprising at least 80%, 85%, 90%, 95%, or 98% identity to the sequence set forth in SEQ ID NO: 137. In some embodiments, a nucleic acid encoding the furin cleavage site comprises the nucleic acid sequence set forth in SEQ ID NO: 138, or a nucleic acid sequence comprising at least 80%, 85%, 90%, 95%, or 98% identity to the sequence set forth in SEQ ID NO: 138. In some embodiments, a nucleic acid encoding the furin cleavage site comprises the nucleic acid sequence set forth in SEQ ID NO: 139, or a nucleic acid sequence comprising at least 80%, 85%, 90%, 95%, or 98% identity to the sequence set forth in SEQ ID NO: 139. In some embodiments, a nucleic acid encoding the furin cleavage site comprises the nucleic acid sequence set forth in SEQ ID NO: 141, or a nucleic acid sequence comprising at least 80%, 85%, 90%, 95%, or 98% identity to the sequence set forth in SEQ ID NO: 141. In some embodiments, a nucleic acid encoding the furin cleavage site comprises the nucleic acid sequence set forth in SEQ ID NO: 142, or a nucleic acid sequence comprising at least 80%, 85%, 90%, 95%, or 98% identity to the sequence set forth in SEQ ID NO: 142.
[0900] Ill
[0901] FH30035011.1
[0902] Attorney Docket No: FTE-00125
[0903] In some embodiments, the cleavage site is a PSA specific cleavage site. In some embodiments, the PSA specific cleavage site comprises the amino acid sequence set forth in SEQ ID NO: 183. In some embodiments, the cleavage site is a Matrix Metalloproteinase- 9 (MMP-9) specific cleavage site. In some embodiments, the MMP-9 specific cleavage site comprises the amino acid sequence set forth in SEQ ID NO: 184. In some embodiments, the cleavage site is a Fibroblast Activation Protein (FAP) specific cleavage site. In some embodiments, the FAP specific cleavage site comprises the amino acid sequence set forth in any one of SEQ ID NOs: 185-190. In some embodiments, the FAP specific cleavage site comprises the amino acid sequence set forth in SEQ ID NO: 185. In some embodiments, the FAP specific cleavage site comprises the amino acid sequence set forth in SEQ ID NO: 186. In some embodiments, the FAP specific cleavage site comprises the amino acid sequence set forth in SEQ ID NO: 187. In some embodiments, the FAP specific cleavage site comprises the amino acid sequence set forth in SEQ ID NO: 188. In some embodiments, the FAP specific cleavage site comprises the amino acid sequence set forth in SEQ ID NO: 189. In some embodiments, the FAP specific cleavage site comprises the amino acid sequence set forth in SEQ ID NO: 190. In some embodiments, the cleavage site is a Urokinase Plasminogen Activator (uPA) specific cleavage site. In some embodiments, the uPA specific cleavage site comprises the amino acid sequence set forth in SEQ ID NO: 191. In some embodiments, the uPA specific cleavage site comprises the amino acid sequence set forth in SEQ ID NO: 192. In some embodiments, the uPA specific cleavage site comprises the amino acid sequence set forth in SEQ ID NO: 193. In some embodiments, the cleavage site is a Asparaginyl Endopeptidase (Legumain) specific cleavage site. In some embodiments, the Legumain specific cleavage site comprises the amino acid sequence set forth in SEQ ID NO: 194. In some embodiments, the Legumain specific cleavage site comprises the amino acid sequence set forth in SEQ ID NO: 195. In some embodiments, the cleavage site is a Cathepsin specific cleavage site. In some embodiments, the Cathepsin specific cleavage site comprises the amino acid sequence set forth in SEQ ID NO: 196. In some embodiments, the Cathepsin specific cleavage site comprises the amino acid sequence set forth in SEQ ID NO: 197. In some embodiments, also contemplated herein are cleavage sites that represent a variant of any of the cleavage sites described herein (e.g., having one or two or more amino acid substitutions) which preserves the function of cleaving protease recognition and cleavage.
[0904] 112
[0905] FH30035011.1
[0906] Attorney Docket No: FTE-00125
[0907] In some embodiments, the cleavage site or sites can be positioned within a polycistronic (e.g., bicistronic, tricistronic or quatracistronic) cassette to allow for cleavage between the agents in the polycistronic cassette.
[0908] Exemplary Fusion Proteins
[0909] In some embodiments, a fusion protein comprises any two or more agents (proteins) described herein. In some embodiments, a fusion protein comprises one or more proteins described herein fused via one or more linkers described herein. In some embodiments, a fusion protein described herein comprises one or more linkers between the two or more proteins, and / or one or more cleavage sites between the two or more proteins, and / or a homo dimerization domain (e.g., Hinge-CH3), and / or a decorin peptide. The exemplary fusion proteins described herein are not intended to limit the possibilities of combinations contemplated herein.
[0910] In some embodiments, a fusion protein described herein is designed according to the fusion combinations as described in Table 1. Table X shows examples of fusions exemplified by the agent category combinations, specific examples of fusion proteins with the combination category, and exemplary functions or uses of such fusion proteins.
[0911] Table 1. Exemplary fusion proteins
[0912] 113
[0913] FH30035011.1
[0914] Attorney Docket No: FTE-00125
[0915]
[0916] 114
[0917] FH30035011.1
[0918] Attorney Docket No: FTE-00125
[0919]
[0920] 115
[0921] FH30035011.1
[0922] Attorney Docket No: FTE-00125
[0923]
[0924] 116
[0925] FH30035011.1
[0926] Attorney Docket No: FTE-00125
[0927]
[0928] i. Checkpoint / Agonist Fusions
[0929] In some embodiments, a fusion protein described herein comprises one or more therapeutic agents as discussed herein.
[0930] In some embodiments, the fusion proteins described herein comprise an antigen binding fragment or a single-chain variable fragment (scFv) that blocks an immune checkpoint, e.g., PD-1, PD-L1, CD47, EGFR, LAG-3, TIM-3, or B7-H3, and converts the immune checkpoint into an immuno stimulatory signal. The fusion proteins are further in combination with a co- stimulatory ligand (e.g., a TNFSF molecule, e.g., a CD40, 0X40, GITR, or 4- IBB agonist scFv or ligand, or any other described herein), or a cytokine. In some embodiments, a checkpoint- specific scFv is fused to an scFv that agonizes a co- stimulatory ligand. In some embodiments, a checkpointspecific scFv is fused to either a monomeric co- stimulatory ligand or a single-chain trimeric costimulatory ligand (e.g., sctri-CD40L).
[0931] In some embodiments, the fusion proteins described herein comprise an antigen binding fragment or a single-chain variable fragment (scFv) that blocks an immune checkpoint, e.g., PD-1, PD-L1, CD47, EGFR, LAG-3, TIM-3, or B7-H3, and a TNFSF agonist (e.g., an agonistic
[0932] 117
[0933] FH30035011.1
[0934] Attorney Docket No: FTE-00125 antigen-binding fragment or scFV, or a ligand), optionally wherein the TNFSF agonist is an agonist of CD40, 4- IBB, 0X40, LIGHT or GITRL. In some embodiments the TNFSF agonist is CD40 ligand (CD40L), a 4- IBB ligand (4-1BBL), an 0X40 ligand (OX40-L), LIGHT, or GITRL. In some embodiments, the fusion protein comprises a secretory signal peptide described herein (e.g., TPA, IGK, or IL2). In some embodiments, the secretory signal peptide is TPA. In some embodiments, the secretory signal peptide is IGK.
[0935] In some embodiments, the fusion protein comprises an anti-PDl scFv with a variable heavy chain (VH) followed by a variable light chain (VL) (VH-VL) with a signal peptide described herein (e.g., TPA, IGK, or IL2). In some embodiments, the fusion protein comprises an anti-PDl scFv with a VH-VL with a TPA signal peptide described herein. In some embodiments, the anti-PDl scFv comprising a VH followed by a VL with a TPA signal peptide (referred to herein as “anti-PDl scFv_spTPA (VH-VL)”) comprises at least 85%, 90%, 95%, 98%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 274. In some embodiments, the anti-PDl scFv_spTPA (VH-VL) is encoded by a nucleic acid sequence comprising at least 85%, 90%, 95%, 98%, or 100% identity to the nucleic acid sequence set forth in SEQ ID NO: 275. In some embodiments, the fusion protein comprises an anti-PDl scFv with a VL followed by a VH (VL-VH) with a signal peptide described herein (e.g., TPA, IGK, or IL2). In some embodiments, the fusion protein comprises an anti-PDl scFv with a VL-VH with a TPA signal peptide described herein. In some embodiments, the anti-PDl scFv comprising a VL-VH with a TPA signal peptide (referred to herein as “anti-PDl scFv_spTPA (VL-VH)”) comprises at least 85%, 90%, 95%, 98%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 276. In some embodiments, the anti-PDl scFv_spTPA (VH-VL) is encoded by a nucleic acid sequence comprising at least 85%, 90%, 95%, 98%, or 100% identity to the nucleic acid sequence set forth in SEQ ID NO: 277.
[0936] In some embodiments, the fusion protein comprises an anti-PDl scFv with a (VH-VL), a Hinge-CH3, and a signal peptide described herein (e.g., TPA, IGK, or IL2, for example, TPA). In some embodiments, the anti-PDl scFv comprising a (VH-VL), a Hinge-CH3, and a TPA signal peptide (referred to herein as “anti-PDl scFv_Hinge-CH3_spTPA (VH-VL)”) comprises at least 85%, 90%, 95%, 98%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 278. In some embodiments, the anti-PDl scFv_Hinge-CH3_spTPA (VH-VL) is encoded by a nucleic acid ...
Claims
1. Attorney Docket No: FTE-00125What is claimed is:
1. A gene therapy or vector system for treating cancer or inhibiting tumor growth, comprising one or more delivery vehicles comprising one or more polynucleotides, wherein the one or more delivery vehicles comprise a DNA plasmid, linear DNA, electroporated DNA, a lipid nanoparticle-encapsulated DNA or RNA, a viral vector, a replication-competent viral vector, a non-replicating viral vector, a helper- dependent adenoviral vector, a self-amplifying RNA, a nucleoside-modified RNA, or any combination thereof;wherein the one or more polynucleotides comprise one or more transcriptional control regions selected from tumor- selective promoters or enhancers, immune-activation-responsive promoters or enhancers, and constitutive or ubiquitous promoters or enhancers, operably linked to one or more coding regions encoding at least four therapeutic agents;wherein the at least four therapeutic agents collectively provide at least four distinct anti-tumor activities selected from:(i) immune checkpoint blockade;(ii) antigen release and / or tumor lysis;(iii) recruitment of dendritic cells or other antigen-presenting cells;(iv) recruitment of T cells and / or NK cells;(v) expansion and / or activation of antigen-presenting cells;(vi) expansion, activation, survival, and / or anti-exhaustion signaling of T cells and / or NK cells;(vii) co- stimulatory receptor agonism;(viii) depletion and / or functional attenuation of regulatory T cells;(ix) neutralization of TGFp and / or reversal of stromal immune exclusion; and(x) induction of tertiary lymphoid structures and / or high endothelial venules;wherein at least three of the therapeutic agents are engineered for secretion from a tumor cell or a cell in the tumor microenvironment;wherein at least one of the therapeutic agents comprises a non-native secretory signal peptide; andwherein the coding regions are arranged as one or more individual open reading frames, one or more fusion open reading frames, one or more polycistronic cassettes comprising coding459FH30035011.1Attorney Docket No: FTE-00125 sequences separated by a ribosome-skipping peptide, an internal ribosome entry site, or both, or any combination thereof.
2. The gene therapy or vector system of claim 1, wherein one of the at least four distinct anti-tumor activities is antigen release and / or tumor lysis, and wherein at least one of the therapeutic agents is a tumor lysis agent engineered to be secreted from a tumor cell or a cell in the tumor microenvironment.
3. The gene therapy or vector system of claim 1 or 2, wherein the tumor lysis agent comprises a pore-forming protein, a protease- activated pore-forming protein, a toxin, a protease-activated toxin, a tumor-targeting antibody or antigen-binding fragment fused to an Fc domain, a tumor-targeting scFv-Fc, a bispecific tumor-targeting T-cell engager, a complement-activating molecule, an apoptosis-inducing molecule, or any combination thereof.
4. The gene therapy or vector system of any one of claims 1-3, wherein the one or more polynucleotides are comprised in one, two, three or four delivery vehicles, optionally in no more than two delivery vehicles.
5. The gene therapy or vector system of claim 4, wherein the one or more polynucleotides comprise one, two, three or four transcriptional control regions in a single vector, optionally no more than three transcriptional control regions in a single vector.
6. A gene therapy or vector system for inducing tumor antigen release from a tumor, comprising one or more polynucleotides encoding a tumor lysis agent, wherein the tumor lysis agent is engineered for secretion from a tumor cell or a cell in a tumor microenvironment following intratumoral, peritumoral, or local administration of the gene therapy, and wherein the secreted tumor lysis agent induces pore formation, antibody-dependent cellular cytotoxicity, complement activation, opsonization, apoptosis, tumor cell lysis, immunogenic cell death, release of tumor antigens, or any combination thereof;optionally, wherein expression, secretion, or activity of the tumor lysis agent is tuned by one or more of: promoter selection, delayed promoter activation, cassette order, placement downstream460FH30035011.1Attorney Docket No: FTE-00125 of a 2A peptide, placement downstream of an internal ribosome entry site, replacement of a native secretory signal peptide with a non-native secretory signal peptide, use of a TPA signal peptide, use of a PSA signal peptide, or use of a protease- activation sequence.
7. The gene therapy or vector system of any one of claims 2-6, wherein the tumor lysis agent comprises at least one of PRX302, a PRX302 variant, a protease- activated pore-forming toxin, a parasporin, a Clostridium perfringens enterotoxin or fragment thereof, a tumor-targeting scFv-Fc, an anti-B7-H3 scFv-Fc, an anti-PSMA scFv-Fc, an anti-HER2 scFv-Fc, an anti-EGFR scFv-Fc, an anti-STEAPl scFV-Fc, an anti-KLK2 scFV-Fc, or a variant of any of the foregoing.
8. The gene therapy or vector system of any one of claims 2-7, wherein the tumor lysis agent is activated by a tumor-associated protease or tumor-enriched protease.
9. The gene therapy or vector system of any one of claims 2-8, wherein the tumor lysis agent comprises a non-native secretory signal peptide, optionally wherein the non-native secretory signal is Prostate Specific Antigen signal peptide (PSA) or tissue plasminogen activator signal peptide (TPA).
10. The gene therapy or vector system of any one of claims 2-9, wherein the tumor lysis agent is positioned downstream of IRES or a 2A self-cleaving peptide containing domain (T2A) (optionally wherein the tumor lysis agent is or comprises PRX302, Parasporin 2, or variants thereof, Clostridium perfringens enterotoxin, or variants thereof, or a tumor-antigen binding domain operably linked to an Fc domain, such as, optionally, an anti-B7-H3 scFv-Fc); optionally positioned downstream of T2A.
11. The gene therapy or vector system of any one of claims 2-10, wherein the coding region encoding the tumor lysis agent is operably linked to a promoter whose expression is delayed relative to another promoter within the same vector or a separate co-administered vector, optionally wherein the delayed promoter is a synthetic promoter containing at least one GAS response element, optionally wherein the delayed promoter is or comprises pGAS, OITA pIV,461FH30035011.1Attorney Docket No: FTE-00125PDL1 promoter, CXCL10 promoter; optionally wherein the delayed promoter is pGAS or CIITA pIV.
12. A gene therapy or vector system comprising one or more polynucleotides comprising:(a) a first expression cassette comprising an immediate transcriptional control region operably linked to a nucleic acid sequence encoding one or more early therapeutic agents, wherein the immediate transcriptional control region comprises a tumor- selective promoter, a tumor- selective enhancer, a constitutive promoter, or a ubiquitous promoter; and(b) a second expression cassette comprising a delayed transcriptional control region operably linked to a nucleic acid sequence encoding one or more delayed therapeutic agents, wherein the delayed transcriptional control region comprises an immune-activation-responsive promoter or enhancer that is activated following immune activation, interferon signaling, STAT1 signaling, IRF1 signaling, NF-KB signaling, or infiltration of immune effector cells in a tumor microenvironment;wherein the one or more early therapeutic agents comprise one or more agents that recruit or activate antigen-presenting cells, recruit T cells or NK cells, reverse immunosuppression, neutralize TGFp, inhibit CTLA4, induce tertiary lymphoid structures or high endothelial venules, or activate IL- 12 signaling; andwherein the one or more delayed therapeutic agents comprise one or more agents that inhibit PD-1 or PD-L1, agonize CD40, 4- IBB, 0X40, GITR, or CD27, promote T-cell or NK-cell survival, promote IL-15, IL-21, IL-7, or IL-18 signaling, or induce tumor lysis or tumor antigen release.
13. The gene therapy or vector system of claim 12, further comprising a third expression cassette comprising a second delayed transcriptional control region operably linked to a nucleic acid sequence encoding one or more late therapeutic agents, wherein:(i) the first expression cassette is controlled by a tumor- selective or ubiquitous promoter, optionally wherein the first expression cassette is controlled by Androgen Response element containing promoter (optionally PSA or PSMA), an Estrogen Response Element containing promoter, a C-Myc containing promoter, a HER2 promoter, an EGFR promoter, CMV promoter, SV40 promoter, or EFla promoter; optionally controlled by PSAEnhl promoter;(ii) the second expression cassette is controlled by elements responsive to STAT1, STAT2, or462FH30035011.1Attorney Docket No: FTE-00125STAT3, optionally a synthetic GAS element containing promoter; optionally a pGAS promoter; and(iii) the third expression cassette is controlled by a promoter that harbors expression that is further delayed than the first two promoters; optionally a CIITA pIV promoter;wherein the second and third expression cassettes are activated at different stages of immune activation in the tumor microenvironment.
14. The gene therapy or vector system of claim 12 or 13, wherein:(a) the first expression cassette encodes one or more of XCL1, FLT3L, CXCL9, IL-12, anti-CTLA4 scFv-Fc, a TGFp trap, sctriLIGHT, sctriGITRL, sctriOX40L, IL-7, or a fusion thereof;(b) the second expression cassette encodes one or more of a tumor lysis agent, anti-PD-1 blockade, anti-PD-Ll blockade, a CD40 agonist, IL- 12, IL-7, or a fusion thereof; and(c) the third expression cassette encodes one or more of IL-15, IL-21, IL-7, a 4-1BB agonist, an 0X40 agonist, a tumor lysis agent, anti-PD-1 blockade, anti-PD-Ll blockade, or a fusion thereof.
15. The gene therapy or vector system of claim 12, wherein the immediate transcriptional control region comprises an Androgen Response element containing promoter and / or enhancer (optionally that of PSA or PSMA), an Estrogen Response Element containing promoter, a C-Myc containing promoter, a HER2 promoter, an EGFR promoter, CMV promoter, SV40 promoter, or an EFla promoter (optionally, PSAEnhl), and the delayed transcriptional control region comprises a promoter containing elements responsive to STAT1, STAT2, or STAT3, optionally a synthetic GAS element containing promoter, optioanlly pGAS, CIITA pIV, wild type or modified PDL1 promoter, or CXCL10 promoter (optionally, pGAS or CIITA pIV).
16. The gene therapy or vector system of claim 12 or 15, wherein the immediate promoter drives expression of XCL1-FLT3L, anti-CTLA4-Fc, TGFp trap- sctriLIGHT, and CXCL9-IL12V4, and wherein the delayed promoter drives expression of anti-PD-Ll -Hinge-CH3-sctriCD40L, IL21-furin-sIL15, and a tumor lysis agent.
17. The gene therapy or vector system of any preceding claim, wherein the one or more polynucleotides are configured to cause a transfected or transduced tumor cell to secrete one or463FH30035011.1Attorney Docket No: FTE-00125 more immunomodulatory therapeutic agents before producing, secreting, activating, or expressing a tumor lysis agent.
18. The gene therapy or vector system of claim 17, wherein delayed expression or attenuated expression of the tumor lysis agent preserves the transfected or transduced tumor cell as a local producer of one or more immunomodulatory therapeutic agents before tumor lysis or antigen release.
19. The gene therapy or vector system of any preceding claims, wherein the gene therapy comprises a non-replicating or helper- dependent viral vector configured to express the therapeutic agents without requiring viral replication-mediated lysis of the transduced tumor cell.
20. A gene therapy comprising a polynucleotide encoding an engineered therapeutic protein, wherein the engineered therapeutic protein comprises a non-native secretory signal peptide that replaces a native secretory signal peptide or is added to a protein that does not naturally comprise a secretory signal peptide, wherein the non-native secretory signal peptide is configured to increase expression, secretion, or both, of the engineered therapeutic protein from a tumor cell or a cell in a tumor microenvironment.
21. A gene therapy comprising a nucleic acid sequence encoding an engineered therapeutic protein, wherein the engineered therapeutic protein is engineered to be secreted from a target cell or cells, wherein the engineered therapeutic protein comprises a non-native secretory signal peptide processed and cleaved by the endoplasmic reticulum, and wherein the non-native secretory signal peptide is (i) a TPA signal peptide or (ii) a native secretory signal peptide of an endogenous protein expressed by and secreted from the target cell or cells, optionally wherein the endogenous protein is specifically expressed by the target cell or cells and not substantially expressed by or secreted from other, non-target cell or cells.
22. The gene therapy of claim 20 or claim 21, wherein the non-native secretory signal peptide comprises a TPA signal peptide, a modified TPA signal peptide, an IGK signal peptide,464FH30035011.1Attorney Docket No: FTE-00125 an IL2 signal peptide, a PSA signal peptide, an HSA signal peptide, a Gaussia luciferase signal peptide, or a variant thereof.
23. The gene therapy of claim 22, wherein the non-native secretory signal peptide comprises a TPA signal peptide or a modified TPA signal peptide.
24. The gene therapy of any one of claims 20-23, wherein the engineered therapeutic protein is an antibody, antibody fragment, scFv-Fc, cytokine, chemokine, TNFSF ligand, TGFp trap, tumor lysis agent, pore-forming protein, protease- activated toxin, single-chain IL- 12, IL- 15 fusion, or any fusion thereof.
25. The gene therapy of any one of claims 20-24, wherein the gene therapy encodes two or more therapeutic agents comprising the same secretory signal peptide amino acid sequence encoded by different nucleic acid sequences to reduce homologous recombination.
26. A gene therapy or vector system comprising one or more isolated nucleic acid molecules encoding two or more therapeutic agents, wherein the two or more therapeutic agents are selected from at least two of the following:(i) an immune checkpoint inhibitor;(ii) a chemokine;(iii) a cytokine;(iv) a co-stimulatory ligand (optionally, a TNFSF protein or a variant thereof or a TNFRSF agonist);(v) a TGF-P trap; and(vi) a tumor antigen release or tumor lysis agent;wherein the at least one of the therapeutic agents is expressed under the control of an immediate promoter and at least one of the therapeutic agents is expressed under the control of a delayed promoter; and / orwherein at least one of the therapeutic agents is a fusion protein comprising two or more therapeutic proteins, optionally, each separated by a proteolytic cleavage site; and / or465FH30035011.1Attorney Docket No: FTE-00125 wherein one or more, or each, of the two or more therapeutic agents is capable of being secreted from a target cell, optionally wherein one or more of the two or more therapeutic agents comprises a non-native secretory signal peptide.
27. The gene therapy or vector system of claim 26, wherein the two or more therapeutic agents are at least three, four, five or six therapeutic agents selected from three, four, five or six of items (i) to (vi).
28. The gene therapy or vector system of claim 26 or 27, wherein the at least one of the therapeutic agents is expressed under the control of an immediate promoter and at least one of the therapeutic agents is expressed under the control of a delayed promoter; optionally wherein the immediate promoter is a tumor- specific or a ubiquitous promoter, and the delayed promoter is an immune activation sensing promoter (optionally, a pGAS promoter or a CIITA pIV promoter or a variant thereof).
29. The gene therapy or vector system of any one of claims 26-28, wherein at least one of the therapeutic agents is a fusion protein comprising two or more therapeutic proteins, optionally, each separated by a proteolytic cleavage site; wherein the proteolytic cleavage site is a furin cleavage site, a variant thereof, or a site cleaved by a tumor-enriched protease.
30. The gene therapy or vector system of any one of claims 26-29, wherein one or more, or each, of the two or more therapeutic agents is engineered to be secreted from a target cell, wherein said engineered therapeutic agent comprises a non-native secretory signal peptide.
31. The gene therapy or vector system of claim 30, wherein the non-native secretory signal peptide is selected from TPA, IGK, IL2, PSA and HSA secretory signal peptides and variants thereof.
32. The gene therapy or vector system of claim 31, wherein the non-native secretory signal peptide is a TPA secretory signal peptide or a variant thereof, optionally wherein the variant is selected from spTPAvA, spTPAvG, spTPAvS, spTPAvAA, spTPAvGA, spTPA2, spTPA3,466FH30035011.1Attorney Docket No: FTE-00125 spTPA4, spTPA5, and spTPA6 as set forth in any of amino acid SEQ ID NOs: 62-68, or the secretory signal peptide is encoded by a nucleic acid sequence set forth in any of SEQ ID NOs: 69-75, or a variant thereof.
33. The gene therapy or vector system of any one of claims 26-32, wherein the two or more therapeutic agents comprise therapeutic agents (i), (ii), (iii) and (iv).
34. The gene therapy or vector system of any one of claims 26-33, which comprises the tumor antigen release or tumor lysis agent.
35. The gene therapy or vector system of claim 34, wherein the tumor antigen release or tumor lysis agent comprises a non-native secretory signal peptide, optionally wherein the nonnative secretory signal peptide is a TPA secretory signal peptide, PSA secretory signal peptide, or a variant of any thereof.
36. A gene therapy or vector system comprising one or more isolated nucleic acid molecules encoding two or more therapeutic agents, wherein the two or more therapeutic agents are selected from at least two of the following:(i) an immune checkpoint inhibitor molecule, optionally wherein the immune checkpoint inhibitor molecule comprises an antibody antigen binding fragment or scFv that specifically binds to PD-1 or PD-L1, and further optionally wherein the immune checkpoint inhibitor molecule is a fusion protein comprising an immune checkpoint inhibitor fused to a TNFSF protein or a variant thereof or a TNFRSF agonist;(ii) a TNFSF protein or a variant thereof or a TNFRSF agonist that optionally agonizes CD40, 0X40, 4- IBB, GITR, EIGHT, or CD27;(iii) a toxin, an antibody antigen binding fragment or an scFv that specifically binds to a tumor antigen fused to an IgG Fc domain or a variant thereof, a fusion protein comprising an antibody antigen binding fragment or an scFv that specifically binds to a tumor antigen fused to an antigen binding fragment467FH30035011.1Attorney Docket No: FTE-00125 or an scFv that specifically binds to CD3, a transmembrane IgG, or another agent mediating tumor lysis;(iv) an antibody antigen binding fragment or an scFv that specifically binds to CTLA4 fused to an IgG Fc domain or a variant thereof, or a fusion protein comprising an antigen binding fragment or an scFv that specifically binds to CTLA4 fused to a TGF-beta trap protein;(v) a TGF-beta trapping domain, optionally a fusion protein comprising the TGF- beta trapping domain fused to a TNFSF protein or a variant thereof or a TNFRSF agonist;(vi) an IL 12 or a variant thereof, optionally a single chain fusion protein comprising alpha chain of IL 12 fused to a truncated variant of beta chain of IL 12, further optionally comprising a fusion protein comprising an IL 12 or a variant thereof fused to a CXCR3 agonist chemokine, optionally wherein the CXCR3 agonist chemokine is CXCL9, CXCL10 or CXCL11;(vii) a CXCR3 agonist chemokine, optionally wherein the CXCR3 agonist chemokine is CXCL9, CXCL10 or CXCL11;(viii) at least one of an FLT3 ligand and / or an XCL1 protein, optionally a fusion protein comprising FLT3 ligand fused to XCL1 protein, or a fusion protein comprising at least one of an FLT3 ligand and an XCL1 protein fused to IFN- gamma or TGF-beta trap protein; and(ix) a cytokine selected from IL 15 or a variant thereof, IL21, IL7, and IL 18, optionally a fusion protein comprising the cytokine fused to a TNFSF protein or a variant thereof or a TNFRSF agonist;wherein the at least one of the therapeutic agents is expressed under the control of an immediate promoter at least one of the therapeutic agents is expressed under the control of a delayed promoter; and / orwherein at least one of the therapeutic agents is a fusion protein comprising two or more therapeutic proteins, optionally, each separated by a proteolytic cleavage site; and / or wherein one or more, or each, of the two or more therapeutic agents is capable of being secreted from a target cell, optionally wherein one or more of the two or more therapeutic agents comprises a non-native secretory signal peptide.468FH30035011.1Attorney Docket No: FTE-0012537. The gene therapy or vector system of claim 36, which comprises three or more therapeutic agents selected from at least three of items (i)-(ix).
38. The gene therapy or vector system of claim 36, which comprises four or more therapeutic agents selected from at least four of items (i)-(ix).
39. The gene therapy or vector system of claim 36, which comprises five or more therapeutic agents selected from at least five of items (i)-(ix).
40. The gene therapy or vector system of claim 36, which comprises six or more therapeutic agents selected from at least six of items (i)-(ix).
41. The gene therapy or vector system of claim 36, which comprises seven or more therapeutic agents selected from at least seven, eight or nine of items (i)-(ix).
42. The gene therapy or vector system of any of claims 36-41, wherein the at least one of the therapeutic agents is expressed under the control of an immediate promoter at least one of the therapeutic agents is expressed under the control of a delayed promoter; and optionally wherein the immediate promoter is a tumor- specific or a ubiquitous promoter, and the delayed promoter is an immune activation sensing promoter (optionally, a pGAS promoter or a CIITA pIV promoter or a variant thereof).
43. The gene therapy or vector system of any one of claims 36-42, wherein one or more, or each, of the two or more therapeutic agents is engineered to be secreted from a target cell, wherein said engineered therapeutic agent comprises a non-native secretory signal peptide.
44. The gene therapy or vector system of claim 43, wherein the secretory signal peptide is selected from TPA, IGK, IL2, PSA and HSA secretory signal peptides or variants thereof.469FH30035011.1Attorney Docket No: FTE-0012545. The gene therapy or vector system of claim 44, wherein the secretory signal peptide is a TPA secretory signal peptide or a variant thereof, optionally wherein the variant is selected from spTPAvA, spTPAvG, spTPAvS, spTPAvAA, spTPAvGA, spTPA2, spTPA3, spTPA4, spTPA5, and spTPA6 as set forth in any of amino acid SEQ ID NOs: 62-68, or the secretory signal peptide is encoded by a nucleic acid sequence set forth in any of SEQ ID NOs: 69-75, or a variant thereof.
46. The gene therapy or vector system of any one of claims 36-45, wherein at least one of the therapeutic agents is a fusion protein comprising two therapeutic proteins separated by a protease cleavage site; wherein the protease cleavage site is a furin cleavage site, a variant thereof, or a site cleaved by a tumor-enriched protease.
47. The gene therapy or vector system of any one of claims 36-46, wherein at least one of the therapeutic agents is an immune checkpoint inhibitor molecule that specifically binds PD-1, PD-Ll, CTLA-4, LAG-3, TIM-3, TIGIT, CD47, B7-H3, or EGFR, optionally wherein the immune checkpoint inhibitor molecule comprises an antibody antigen binding fragment or an scFv.
48. The gene therapy or vector system of claim 47, wherein the immune checkpoint inhibitor molecule comprises an antibody antigen binding fragment or scFv that specifically binds to PD- 1 or PD-L1.
49. The gene therapy or vector system of any one of claims 36-48, wherein at least one of the therapeutic agents is an immune checkpoint inhibitor molecule that is a fusion protein comprising an immune checkpoint inhibitor fused to a TNFSF protein or a variant thereof or a TNFRSF agonist that agonizes CD40, 0X40, 4-1BB, GITR, or CD27.
50. The gene therapy or vector system of claim 49, wherein the fusion protein comprises an anti-PD-1 scFv or an anti-PD-Ll scFv fused to a CD40 agonist selected from: an agonist anti-CD40 scFv, monomeric CD40L, and single-chain trimeric CD40L, optionally wherein the anti-CD40 scFv comprises the amino acid sequence set forth in SEQ ID NO: 225, the monomeric470FH30035011.1Attorney Docket No: FTE-00125CD40L comprises the amino acid sequence set forth in SEQ ID NO: 223, and / or the single-chain trimeric CD40L comprises the sequence set forth in SEQ ID NO: 224, or variants thereof.
51. The gene therapy or vector system of claim 49, wherein the fusion protein comprises an anti-PD-1 scFv or an anti-PD-Ll scFv fused to a single-chain trimeric OX40L and / or a singlechain trimeric 4-1BBL, optionally wherein the single-chain trimeric OX40L comprises the amino acid sequence set forth in SEQ ID NO: 253, and / or the single-chain trimeric 4-1BBL comprises the amino acid sequence set forth in SEQ ID NO: 252, or variants thereof.
52. The gene therapy or vector system of any one of claims 36-51, wherein at least one of the therapeutic agents is or comprises a TNFSF protein or a variant thereof or a TNFRSF agonist that agonizes CD40, 0X40, 4- IBB, GITR, or CD27.
53. The gene therapy or vector system of claim 52, wherein TNFRSF agonist is an agonistic antibody, antigen binding fragment or scFv that specifically binds CD40, 0X40, 4- IBB, GITR, or CD27; and a TNFSF protein or a variant thereof is an extracellular domain of CD40 ligand, 0X40 ligand, 4- IBB ligand, GITR ligand, or LIGHT ligand.
54. The gene therapy or vector system of claim 52 or 53, wherein the TNFSF protein or a variant thereof is an extracellular domain of the TNFSF protein in a single-chain trimeric format selected from sctriCD40L, sctriOX40L, sctri4-lBBL, sctriGITRL, and sctriLIGHT, optionally wherein the TNFSF protein is selected from an amino acid sequence set forth in any one of SEQ ID NOs: 224 and 256-259, and variants thereof.
55. The gene therapy or vector system of any one of claims 36-54, wherein at least one of the therapeutic agents is or comprises an antibody antigen binding fragment or an scFv that specifically binds to CTLA-4 (anti-CTLA4) fused to an IgG Fc domain, optionally wherein the anti-CTLA4 comprises the amino acid sequence set forth in SEQ ID NO: 226 or 227, or a variant thereof.471FH30035011.1Attorney Docket No: FTE-0012556. The gene therapy or vector system of claim 55, wherein at least one of the therapeutic agents is a fusion protein comprising the anti-CTLA-4 fused to an IgG Fc domain and further fused to a TGF-P trapping domain, optionally wherein the anti-CTLA-4 fused to an IgG Fc domain and further fused to a TGF-P trapping domain comprises the amino acid sequence set forth in SEQ ID NO: 374 or is encoded by the nucleic acid set forth in SEQ ID NO: 375, or a variant thereof.
57. The gene therapy or vector system of any one of claims 36-56, wherein at least one of the therapeutic agents is or comprises XCL1 and / or FLT3L, optionally wherein at least one of the therapeutic agents is a fusion protein comprising XCL1 fused to FLT3L, optionally wherein the fusion protein further comprises a CD40 agonist, optionally wherein the fusion protein comprises the amino acid sequence set forth in any one of SEQ ID NO: 478, 480, 482, 484, 513, 515, and 517 or a variant thereof, or is encoded by the nucleic acid set forth in any one of SEQ ID NO: 479, 481, 483, 485, 514, 516, and 518, or a variant thereof.
58. The gene therapy or vector system of any one of claims 36-57, wherein at least one of the therapeutic agents is or comprises a single-chain IL- 12 fusion, optionally wherein the singlechain IL- 12 fusion comprises a truncated IL- 12 p40 (P) subunit and an IL- 12 p35 (a) subunit, optionally wherein the single-chain IL- 12 fusion is selected from IL12V2, IL12V3, IL12V3_2Ct2S, and IL12V4, optionally wherein the IL- 12 fusion comprises an amino set forth in any one of SEQ ID NOs: 237-241 and 245, or a variant thereof.
59. The gene therapy or vector system of any one of claims 36-58, wherein at least one of the therapeutic agents is or comprises a CXCR3 agonist chemokine selected from CXCL9, CXCL10, and CXCL11.
60. The gene therapy or vector system of any one of claims 36-59, wherein at least one of the therapeutic agents is or comprises a single-chain IL- 12 fusion fused to the CXCR3 agonist chemokine, optionally wherein the CXCR3 agonist chemokine comprises an amino acid sequence set forth in any one of SEQ ID NOs: 206, 208, 210, 213, and 214, or a variant thereof.472FH30035011.1Attorney Docket No: FTE-0012561. The gene therapy or vector system of any one of claims 36-60, wherein at least one of the therapeutic agents is or comprises a TGF-P trapping domain comprising TGF-P receptor II extracellular domain (TGFpRII ECD) or a variant thereof that binds TGF-P, optionally wherein the TGF-P trapping domain comprises the amino acid sequence set forth in SEQ ID NO: 263, or a variant thereof.
62. The gene therapy or vector system of any one of claims 36-61, wherein at least one of the therapeutic agents is or comprises a cytokine, wherein the cytokine is selected from: IL-15, an IL-15 variant, IL-7, IL-21, or IL-18, optionally wherein the cytokine comprises an amino acid sequence selected from any one of SEQ ID NOs: 260-262, or a variant thereof.
63. The gene therapy or vector system of claim 62, wherein an IL-15 variant comprises an IL- 15 receptor alpha sushi domain, optionally wherein the IL- 15 receptor alpha sushi domain comprises the amino acid sequence set forth in SEQ ID NO: 683, or a variant thereof.
64. The gene therapy or vector system of claim 62, wherein the cytokine is a fusion protein comprising IL-15 fused to IL-21, IL-15 fused to IL-7, or IL-21 fused to IL-7, optionally wherein the fusion protein comprises any amino acid sequence set forth in any one of SEQ ID NO: 638, 640, 642, 644, 646, 648, 650, 652, 654, and 656, or a variant thereof.
65. The gene therapy or vector system of any one of claims 36-64, wherein at least one of the therapeutic agents is a fusion protein comprising the cytokine fused to a TNFSF protein or a variant thereof or a TNFRSF agonist that agonizes CD40, 0X40, 4- IBB, GITR, or CD27, optionally which is a single-chain trimeric OX40L or a single-chain trimeric 4-1BBL, optionally wherein the TNFSF protein is selected from an amino acid sequence set forth in any one of SEQ ID NOs: 223, 224, 252-259, and variants thereof.
66. The gene therapy or vector system of any one of claims 36-65, wherein at least one of the therapeutic agents is an agent that mediates tumor lysis selected from: (i) a cytotoxic polypeptide; (ii) a pore-forming polypeptide; (iii) a tumor-specific protease-gated cytotoxic polypeptide; (iv) an oncolysis-inducing factor; (v) a tumor-targeting antibody antigen binding473FH30035011.1Attorney Docket No: FTE-00125 fragment or scFv, optionally comprising an Fc that enables immune-mediated killing of tumor cells, or (vi) a transmembrane IgG molecule.
67. The gene therapy or vector system of claim 66, wherein at least one of the therapeutic agents is a tumor- selective protease-gated cytotoxic or pore-forming polypeptide, wherein the tumor- selective protease-gated cytotoxic or pore-forming polypeptide comprises: (i) a tumor-enriched protease-cleavable inhibitory domain fused to a masking domain; and (ii) a cytotoxic or pore-forming effector domain, wherein cleavage of the inhibitory domain by a tumor-enriched protease activates the cytotoxic or pore-forming effector domain.
68. The gene therapy or vector system of claim 66, wherein at least one of the therapeutic agents is a tumor-targeting scFv fused to an IgG Fc domain, optionally targeting PSMA, EGFR, HER2, B7-H3, or SIRPa / CD47, optionally wherein the tumor-targeting scFv comprises the amino acid sequence set forth in any one of SEQ ID NOs: 228-234, or a variant thereof.
69. The gene therapy or vector system of claim 66, wherein at least one of the therapeutic agents is a tumor-targeting antibody antigen binding fragment or scFv fused to an anti-CD3 antibody antigen binding fragment or scFv, optionally wherein the anti-CD3 antibody antigen binding fragment or scFv comprises the amino acid sequence set forth in SEQ ID NO: 273, or a variant thereof.
70. The gene therapy or vector system of any one of claims 26-69, wherein any one or more of the therapeutic agents comprises a multimerization domain, wherein the multimerization domain is a silenced Fc domain (optionally an IgGl comprising LALA-PG mutations), a hinge-CH3 domain that lacks a CH2 domain, an IgG4 Fc domain, a leucine zipper, a collagen-like trimerization domain, or a MATN 1 trimerization domain.
71. The gene therapy or vector system of any one of claims 26-70, wherein any one or more of the therapeutic agents is a fusion protein comprising a linker between the components of the fusion protein selected from: a flexible glycine- serine linker, a rigid alpha-helical linker, a hybrid474FH30035011.1Attorney Docket No: FTE-00125 flexible-rigid linker comprising one or more (GGGGS)n segments, and one or more (EAAAK)n segments.
72. The gene therapy or vector system of any one of claims 26-71, wherein any one or more of the therapeutic agents comprises a tumor retention domain fused to a C-terminus of the therapeutic agent, wherein the tumor retention domain is a decorin-derived peptide, a collagen-binding peptide, a glycosaminoglycan-binding peptide, an extracellular matrix-binding domain, or any combination thereof.
73. The gene therapy or vector system of claim 72, wherein the tumor retention domain is fused to a therapeutic agent selected from: IL-12, IL-15, IL-15 / IL-15Ra sushi, IL-21, IL-7, IL-18, a co- stimulatory TNFSF ligand, and an immune checkpoint binding domain, optionally wherein the therapeutic agent comprises an amino acid sequence selected from any one of SEQ ID NOs: 223-234, 236-246, 250-259, 260-262, and 683, and variants thereof.
74. The gene therapy or vector system of any one of claims 26-73, wherein at least one of the two or more therapeutic agents is expressed under the control of an immediate promoter, wherein the immediate promoter is a tumor-specific promoter or a ubiquitous promoter;wherein the at least one therapeutic agent under the control of the immediate promoter comprises: (i) CXCL9, CXCL10, CXCL11, and / or XCL1, (ii) FLT3L, (iii) LIGHT and / or TGF beta trap, (iv) anti-CTLA4 scFv, (v) IL12, and / or (vi) GITRL; andoptionally wherein at least one of the two or more therapeutic agents is expressed under the control of a delayed promoter configured as an immune-activation-responsive transcriptional control region (optionally activated after infiltration of immune effector cells and / or after induction of interferon-responsive transcription factors in the tumor microenvironment); and / or under the control of a constitutively active low-expressing promoter leading to continuous low-level expression of a therapeutic agent, optionally wherein the therapeutic agent expressed under the control of the delayed promoter or the constitutively active low-expressing promoter is an agent promoting tumor lysis;475FH30035011.1Attorney Docket No: FTE-00125optionally wherein the immediate promoter and / or the delayed promoter are in the forward orientation (non-reverse complement) or reverse complement orientation; optionally the immediate promoter is in the forward orientation and the delayed promoter is in the reverse complement orientation, or the immediate promoter is in the reverse complement orientation and the delayed promoter is in the forward orientation.
75. The gene therapy or vector system of claim 74, wherein the tumor-specific promoter is a prostate cancer-specific promoter, wherein the prostate cancer-specific promoter comprises a PSA promoter, a PSA enhancer, a PSMA promoter, a KLK2 promoter, or an androgen receptor (AR) response element-containing promoter, or any combination thereof, optionally comprising the nucleic acid sequence set forth in any one of SEQ ID NOs: 6-12 and 19, or a variant thereof.
76. The gene therapy or vector system of claim 74 or 75, wherein the tumor- specific promoter is or comprises a sequence of Pc_FIG_Pmtl, Pc_FIG_enhl, Pc_FIG_enh2, FIG_PSA Enh wl, or FIG_PSA Enh w2, or any combination thereof, optionally comprising the nucleic acid sequence set forth in any of SEQ ID NOs: 6-9 and 19, or a variant thereof.
77. The gene therapy or vector system of claim 74, wherein the tumor- specific promoter is a survivin promoter, an hTERT promoter, an AFP promoter, an EPCAM promoter, a HER2 promoter, an EGFR promoter, or an MSLN promoter.
78. The gene therapy or vector system of claim 74, wherein the tumor-specific promoter comprises a synthetic promoter comprising two or more transcription factor response elements for transcription factors enriched in tumor cells relative to normal tissue.
79. The gene therapy or vector system of claim 78, wherein the transcription factor response elements are selected from androgen receptor (AR) response elements, c-Myc response elements, hypoxia response elements (HREs), or NF-KB response elements, or any combination combinations thereof, optionally comprising a nucleic acid sequence selected from any of SEQ ID NOs: 28-30, and variants thereof.476FH30035011.1Attorney Docket No: FTE-0012580. The gene therapy or vector system of claim 74, wherein the ubiquitous promoter comprises an EFla promoter, optionally comprising the nucleic acid sequence set forth in SEQ ID NO: 18, or a variant thereof.
81. The gene therapy or vector system of any one of claims 26-80, wherein at least one of the two or more therapeutic agents is expressed under the control of a delayed promoter configured as an immune-activation-responsive transcriptional control region (optionally activated after infiltration of immune effector cells and / or after induction of interferonresponsive transcription factors in the tumor microenvironment); and / or under the control of a constitutively active low-expressing promoter leading to continuous low-level expression of a therapeutic agent, optionally a therapeutic agent promoting tumor lysis;optionally wherein the at least one therapeutic agent under the control of the delayed promoter or constitutively active low-expressing promoter comprises: (i) a tumor lysis agent, (ii) anti-PDLl scFv and / or anti-PD-1 scFv, (iii) IL21 and / or IL15, or (iv) 4-1BBL and / or OX40L.
82. The gene therapy or vector system of claim 81, wherein the delayed promoter is operably linked to a nucleic acid sequence encoding one or more of: (i) an agent mediating tumor lysis;(ii) an immune checkpoint inhibitor molecule; (iii) a TNFSF protein or a variant thereof or a TNFRSF agonist optionally agonizing CD40, 0X40, 4- IBB, GITR, or CD27; and (iv) a cytokine selected from IL 15 or a variant thereof, IL21, IL7, and IL18.
83. The gene therapy or vector system of claim 81 or 82, wherein the delayed promoter is or comprises a CIITA pIV promoter, a synthetic GAS promoter, a synthetic ISRE promoter, a modified PD-L1 promoter, a CXCL10 promoter, an IDO1 promoter, a GBP1 promoter, an NF-KB-responsive promoter, or any combination thereof, optionally comprising a nucleic acid sequence set forth in any one of SEQ ID NOs: 15-17, 20, 21, and 23, and variants thereof.
84. The gene therapy or vector system of claim 81 or 82, wherein the delayed promoter is an interferon-responsive promoter and / or a promoter comprising one or more Gamma Interferon477FH30035011.1Attorney Docket No: FTE-00125Activation Site (GAS) elements, optionally comprising the nucleic acid sequence of SEQ ID NO: 14, or a variant thereof.
85. The gene therapy or vector system of claim 81 or 82, wherein the delayed promoter is or comprises a CIITA pIV promoter, optionally comprising the nucleic acid sequence set forth in SEQ ID NO: 20, or a variant thereof.
86. The gene therapy or vector system of claim 81 or 82, wherein the delayed promoter comprises a synthetic 3xGAS promoter and a minimal promoter, optionally a minimal CMV promoter or a minimal EFla promoter, optionally wherein the CMV promoter comprises the nucleic acid sequence of SEQ ID NO: 22, optionally wherein the EFla promoter comprises the nucleic acid sequence of SEQ ID NO: 18, and variants thereof.
87. The gene therapy or vector system of claim 81 or 82, wherein the delayed promoter is or comprises a synthetic 5XNF-KB promoter and a minimal promoter, optionally a minimal CMV promoter, optionally comprising the nucleic acid sequence set forth in SEQ ID NO: 22, or a variant thereof.
88. The gene therapy or vector system of any one of claims 26-87, wherein the one or more nucleic acids are comprised in one polycistronic vector.
89. The gene therapy or vector system of claim 88, wherein the immediate promoter and the delayed promoter (or a low expressing promoter) in the polycistronic vector are oriented to drive transcription in opposite directions.
90. The gene therapy or vector system of claim 88 or 89, further comprising an insulator sequence positioned between the immediate promoter and the delayed promoter in the polycistronic vector, optionally wherein the insulator sequence comprises a cHS4 insulator or a core cHS4 insulator, optionally comprising the nucleic acid sequence set forth in SEQ ID NO: 25 or 26, or a variant thereof.478FH30035011.1Attorney Docket No: FTE-0012591. The gene therapy or vector system of any one of claims 88-90, wherein the immediate promoter and the delayed promoters in the polycistronic vector are separated by 50 bp to 2000 bp.
92. The gene therapy or vector system of any one of claims 74-91, wherein the immediate promoter comprises PSAEnhl and the delayed promoter comprises pGAS or CIITA pIV.
93. The gene therapy or vector system of claim 92, wherein the immediate promoter drives expression of XCL1-FLT3L, anti-CTLA4-Fc, TGFp trap-sctriLIGHT, and / or CXCL9-IL12V4, and wherein the delayed promoter drives expression of anti-PD-Ll-Hinge-CH3-sctriCD40L, IL21-furin-sIL15, and / or a tumor lysis agent.
94. The gene therapy or vector system of any one of claims 26-87, wherein the one or more nucleic acids are comprised in two or more vectors, optionally wherein at least one of the two or more vectors is a polycistronic vector.
95. The gene therapy or vector system of any one of claims 26-87, wherein the one or more nucleic acids are comprised in one polycistronic cassette within a vector.
96. The gene therapy or vector system of claim 95, wherein the polycistronic cassette encodes at least two therapeutic agents separated by one or more ribosome skipping sequences and / or internal ribosome entry sites (IRESs).
97. The gene therapy or vector system of claim 96, wherein the polycistronic cassette encodes at least two therapeutic agents separated by one or more ribosome skipping sequences, wherein the ribosome skipping sequence comprises a 2A peptide selected from P2A, T2A, E2A, F2A and nucleic acid variants encoding an identical amino acid 2A peptide sequence but having reduced nucleotide homology to one another, optionally wherein the 2A peptide comprises an amino acid sequence selected from any one of SEQ ID NOs: 144-146, and variants thereof.479FH30035011.1Attorney Docket No: FTE-0012598. The gene therapy or vector system of claim 97, wherein at least one 2A peptide is immediately preceded by a short flexible linker that improves cleavage efficiency, optionally a GSG linker, and wherein a furin cleavage site is positioned to remove a C-terminal 2A peptidederived remnant from an upstream polypeptide after translation, optionally comprising an amino acid sequence selected from an amino acid sequence set forth in any of SEQ ID NOs: 148, 150, 152, 153, 155, 157, 159, and 162, and variants thereof.
99. The gene therapy or vector system of any one of claims 26-98, wherein a tumor lysis agent is positioned downstream of a ribosome-skipping peptide or an internal ribosome entry site to tune expression of the tumor lysis agent relative to one or more upstream immunomodulatory therapeutic agents.
100. The gene therapy or vector system claim 99, wherein the tumor lysis agent is positioned immediately downstream of a T2A peptide, P2A peptide, E2A peptide, or F2A peptide to increase expression of the tumor lysis agent relative to expression from an internal ribosome entry site.
101. The gene therapy or vector system of claim 99, wherein the tumor lysis agent is positioned downstream of an internal ribosome entry site to attenuate expression of the tumor lysis agent relative to expression from a 2A peptide.
102. The gene therapy or vector system of any one of claims 88-101, wherein the vector (or vectors) is a plasmid vector.
103. The gene therapy or vector system of any one of claims 88-101, wherein the vector (or vectors) is a viral vector.
104. The gene therapy or vector system of claim 103, wherein the viral vector is selected from: adenovirus, helper-dependent adenovirus, adeno-associated virus, herpes simplex virus, lentivirus, vaccinia virus, and poxvirus, optionally the viral vector is from a helper-dependent adenovirus.480FH30035011.1Attorney Docket No: FTE-00125105. The gene therapy or vector system of claim 104, wherein the viral vector is a helperdependent adenoviral vector configured to express at least four therapeutic agents from one or more expression cassettes without expressing adenoviral genes required for viral replication in the transduced tumor cell.
106. The gene therapy or vector system of any one of claims 88-105, wherein the vector (or vectors) is comprised in a lipid nanoparticle or a phospholipid liposome.
107. A gene therapy comprising a nucleic acid sequence encoding a protein comprising a single-chain IL- 12 fusion, wherein the single-chain IL- 12 fusion comprises an IL- 12 p35 (a) subunit and an IL- 12 p40 (0) subunit, wherein the 0 subunit is truncated at residue S295 removing amino acid sequence SWSEWASVPCS, and variants thereof.
108. The gene therapy of claim 107, wherein the single-chain IL- 12 fusion is selected from IL12V2 of SEQ ID NO: 237, IL12V3 of SEQ ID NO: 239, IL12V3_2Ct2S of SEQ ID NO: 238, and IL12V4 of SEQ ID NO: 245, or a variant having at least 85%, 90%, 95%, or 98% sequence identity to any of SEQ ID NOs: 237, 238, 239, and 245.
109. The gene therapy of claim 107 or 108, wherein the protein is a fusion protein comprising the single-chain IL- 12 fusion and a CXCR3 agonist chemokine, optionally wherein the CXCR3 agonist chemokine is CXCL9, CXCL10 or CXCL11, optionally wherein the fusion polypeptide comprises a protease cleavage site between the IL- 12 domain and the chemokine domain, optionally wherein the protein further comprises a tumor retention domain, optionally wherein the fusion polypeptide comprises an amino acid sequence set forth in any of SEQ ID NOs: 454, 456, 458, and 460, or a variant having at least 85%, 90%, 95%, or 98% sequence identity to any of SEQ ID NOs: 454, 456, 458, and 460.
110. A gene therapy comprising a nucleic acid sequence encoding a fusion protein comprising a transmembrane domain from a first protein covalently linked to an extracellular domain from a second protein, wherein the extracellular domain comprises an immuno stimulatory molecule,481FH30035011.1Attorney Docket No: FTE-00125 and wherein the immuno stimulatory molecule is exposed extracellularly upon expression in a target cell, wherein the immuno stimulatory molecule is an IgG Fc or a fragment thereof, a Toll like receptor agonist, a complement protein, a phagocytosis stimulating factor, or an antigen specific to a chimeric T cell (optionally, wherein the immuno stimulatory molecule is an IgG Fc), optionally wherein the IgG comprises an amino acid sequence set forth in SEQ ID NO 180, 181, or 182, or a variant thereof.
111. The gene therapy of claim 110, wherein the immuno stimulatory molecule is an IgG Fc or a fragment thereof, and wherein the transmembrane domain is PSMA transmembrane domain, EGFR transmembrane domain or HER2 transmembrane domain, optionally wherein the transmembrane domain comprises an amino acid sequence set forth in any one of SEQ ID NOs: 177-179, or a variant having at least 85%, 90%, 95%, or 98% sequence identity thereto.
112. A gene therapy comprising a nucleic acid sequence encoding a fusion protein comprising:(a) an antibody antigen binding fragment or scFv that specifically binds to PD-1 or PD-L1; and(b) a single-chain trimeric TNFSF ligand, optionally wherein the TNFSF ligand is a CD40 ligand, 0X40 ligand, 4- IBB ligand, GITR ligand, or CD27 ligand, optionally wherein the fusion protein comprises an amino acid sequence selected from SEQ ID NOs: 346, 348, 350, 352, 330, 332, and 334, or a variant having at least 85%, 90%, 95%, or 98% sequence identity thereto.
113. The gene therapy of claim 112, wherein the fusion protein comprises an anti-PDl scFv or anti-PD-Ll scFv fused to a single-chain trimeric CD40L, single-chain trimeric OX40L, or single-chain trimeric 4-1BBL, optionally wherein the fusion protein comprises an amino acid sequence selected from SEQ ID NOs: 346, 348, 350, 352, 330, 332, and 334, or a variant having at least 85%, 90%, 95%, or 98% sequence identity thereto.
114. The gene therapy of claim 112 or 113, which further comprises a multimerization domain, optionally wherein the multimerization domain comprises a hinge-CH3 domain or an effector- silenced Fc domain, optionally wherein the multimerization domain comprises an amino acid sequence selected from any one of SEQ ID NOs: 127, 129, 131, 133, and 181, or a variant having at least 85%, 90%, 95%, or 98% sequence identity thereto.482FH30035011.1Attorney Docket No: FTE-00125115. A gene therapy comprising a nucleic acid sequence encoding a fusion protein comprising an XCL1 domain and a FLT3L domain, optionally further comprising a multimerization domain and / or a CD40 agonist domain, optionally wherein the fusion protein comprises an amino acid sequence set forth in any one of SEQ ID NOs: 478, 480, 482, 484, 513, 515, and 517, or a variant having at least 85%, 90%, 95%, or 98% sequence identity thereto.
116. A gene therapy comprising a nucleic acid sequence encoding a fusion protein comprising an antibody antigen binding fragment or an scFv that specifically binds to CTLA4 fused to a TGF-beta trapping domain, optionally comprising the amino acid sequence set forth in SEQ ID NO: 374 or SEQ ID NO: 376, or a variant having at least 85%, 90%, 95%, or 98% sequence identity thereto.
117. A gene therapy comprising a nucleic acid sequence encoding a fusion protein comprising a TGF-beta trapping domain fused to a TNFSF protein or a variant thereof or a TNFRSF agonist, (optionally, wherein TNFSF protein is LIGHT, and wherein the TGF-beta trapping domain is fused to any LIGHT agonist described herein), optionally comprising the amino acid sequence set forth in any one of SEQ ID NOs: 547, 548, 550, and 552, or a variant having at least 85%, 90%, 95%, or 98% sequence identity thereto.
118. A gene therapy comprising a nucleic acid sequence encoding a fusion protein comprising IL 15 or a variant thereof, fused to a collagen-binding peptide, and optionally fused to one or more of: IL21, IL7, or a TNFSF protein or a variant thereof or a TNFRSF agonist (optionally, fused to any 4- IBB agonist described herein), optionally comprising the amino acid sequence set forth in any one of SEQ ID NOs: 638, 640, 642, 644, 646, 648, 650, 652, 658, 660, 662, 664, 666, 668, 670, 672, 684, 685, and 703, or a variant having at least 85%, 90%, 95%, or 98% sequence identity thereto.
119. A gene therapy or vector system comprising one or more isolated nucleic acid molecules encoding two or more therapeutic agents (optionally, three, four, five, six, or more therapeutic483FH30035011.1Attorney Docket No: FTE-00125 agents), wherein the two or more therapeutic agents are selected from at least two, three or four of the following:(i) an immune checkpoint inhibitor molecule;(ii) an antigen release or tumor lysis facilitating agent;(iii) an agent facilitating recruitment of dendritic cells;(iv) an agent facilitating recruitment of T cells and / or NK cells;(v) an agent facilitating expansion and / or activation of antigen-presenting cells;(vi) an agent facilitating expansion, activation, survival, and / or anti-exhaustion signaling of T cells and / or NK cells;(vii) an agent facilitating co-stimulatory receptor agonism;(viii) an agent facilitating depletion and / or functional attenuation of regulatory T cells;(ix) an agent facilitating neutralization of TGF-P and / or reversal of stromal immune exclusion; and(x) an agent facilitating induction of tertiary lymphoid structures and / or high endothelial venules;wherein the at least one of the therapeutic agents is expressed under the control of an immediate promoter and at least one of the therapeutic agents is expressed under the control of a delayed promoter; and / orwherein at least one of the therapeutic agents is a fusion protein comprising two or more therapeutic proteins, optionally, each separated by a proteolytic cleavage site; and / or wherein one or more, or each, of the two or more therapeutic agents is capable of being secreted from a target cell, optionally wherein one or more of the two or more therapeutic agents comprises a non-native secretory signal peptide.
120. The gene therapy or vector system of claim 26 or 36, wherein the gene therapy comprises one or more expression cassettes as set forth in c06t3, c06i3, g06i3, g06t73, g05t73, or g04t73 (see, e.g., figures).484FH30035011.1Attorney Docket No: FTE-00125121. A pharmaceutical composition comprising a gene therapy or vector system of any one of claims 1-120, and a pharmaceutically acceptable carrier; optionally wherein the gene therapy or vector system is in a lipid nanoparticle formulation or a viral vector formulation.
122. An isolated fusion polypeptide comprising two or more therapeutic domains selected from: an immune checkpoint binding domain, a TNFSF ligand domain, a TNFRSF agonist domain, a TGFp trapping domain, a CXCR3 agonist chemokine domain, a single-chain IF-12 domain, an XCF1 domain, an FFT3F domain, an IF-15 domain, an IF-15Ra sushi domain, an IF-21 domain, an IF-7 domain, a collagen-binding domain, a tumor-retention domain, and a tumor-targeting antibody or antigen-binding fragment.
123. The isolated fusion polypeptide of claim 122, comprising an anti-CTFA4 scFv-Fc fused to a TGFp trapping domain.
124. The isolated fusion polypeptide of claim 122, comprising an anti-PD-1 or anti-PD-Fl binding domain fused to a CD40, 0X40, 4- IBB, GITR, or CD27 agonist domain.
125. The isolated fusion polypeptide of claim 122, comprising a TGFp trapping domain fused to sctriFIGHT.
126. The isolated fusion polypeptide of claim 122, comprising IF-15 or IL-15 / IF-15Ra sushi fused to a collagen-binding peptide, IL-21, IL-7, a 4- IBB agonist, or any combination thereof.
127. The isolated fusion polypeptide of claim 122, comprising CXCL9, CXCL10, or CXCL11 fused to a single-chain IL- 12 variant.
128. The isolated fusion polypeptide of claim 122, comprising XCL1 fused to FLT3L, optionally further comprising a multimerization domain, Hinge-CH3 domain, silenced Fc domain, IgG4 Fc domain, CD40 agonist, or TGFp trapping domain.
129. Any isolated fusion polypeptide or protein described herein.485FH30035011.1Attorney Docket No: FTE-00125130. A pharmaceutical composition comprising the isolated fusion polypeptide of any one of claims 122-129, and a pharmaceutically acceptable carrier.
131. A method of treating cancer, inhibiting tumor growth, inhibiting one or more symptoms of cancer, inducing tumor antigen release, or preventing recurrence or progression of cancer in a subject in need thereof, comprising administering to a subject an effective amount of the gene therapy or vector system of any one of claims 1-120, the pharmaceutical composition of claim 121, the isolated fusion polypeptide or protein of any one of claims 122-129, or the pharmaceutical composition of claim 130.
132. The method of claim 131, wherein administering is local, regional, systemic, intravenous, intraperitoneal, subcutaneous, or any combination thereof.
133. The method of claim 131, wherein the administering is intratumoral.
134. A method of treating cancer, inhibiting tumor growth, inhibiting one or more symptoms of cancer, inducing tumor antigen release, or preventing recurrence or progression of cancer in a subject in need thereof, comprising administering to a tumor or tissue surrounding a tumor of a subject an effective amount of the gene therapy or vector system of any one of claims 1-120, the pharmaceutical composition of claim 121, the isolated fusion polypeptide or protein of any one of claims 122-129, or the pharmaceutical composition of claim 130.
135. The method of claim 134, wherein administering comprises intratumoral injection, peritumoral injection, electroporation into the tumor or surrounding tissue, image-guided injection, lipid nanoparticle delivery, viral vector delivery, or any combination thereof.
136. The method of claim 135, wherein administering is by injection into the tumor and / or the tissue surrounding the tumor, optionally electroporation into the tumor.486FH30035011.1Attorney Docket No: FTE-00125137. The method of claim 135, wherein administering is by electroporation into the tumor and / or the tissue surrounding the tumor, optionally electroporation into the tumor.
138. The method of any one of claims 131-137, wherein the gene therapy is delivered in a lipid nanoparticle.
139. The method of any one of claims 131-138, wherein the cancer is a solid tumor.
140. The method of any one of claims 131-139, wherein the cancer is characterized by an immunosuppressive tumor microenvironment and / or low tumor mutational burden.
141. The method of claim 139 or 140, wherein the cancer is prostate cancer, pancreatic cancer, ovarian cancer, breast cancer, lung cancer, melanoma, colorectal cancer, head and neck cancer, or glioblastoma; optionally wherein the cancer is a prostate cancer.
142. The method of any one of claims 131-141, wherein the method is performed as a neoadjuvant therapy before surgical resection of the tumor.
143. The method of any one of claims 131-142, wherein the gene therapy is administered in two or more doses, optionally separated by 1 day to 6 weeks.
144. The method of any one of claims 131-143, wherein the subject is a human.
145. A kit comprising: (a) the gene therapy or vector system of any one of claims 1-120, the pharmaceutical composition of claim 121, the isolated fusion polypeptide or protein of claims 122-129, or the pharmaceutical composition of claim 130; and (b) instructions for intratumoral administration to treat cancer.
146. A method of treating cancer, inhibiting tumor growth, inhibiting one or more symptoms of cancer, inducing tumor antigen release, or preventing recurrence or progression of cancer in a subject in need thereof, comprising intratumorally administering to a subject (e.g., a human) an487FH30035011.1Attorney Docket No: FTE-00125 effective amount of a gene therapy, wherein the gene therapy comprises one or more vectors, wherein at least one of the one or more vectors is a polycistronic vector or a vector comprising a polycistronic cassette, wherein the one or more vectors encode at least 2, 3, 4, 5, 6, or 7 (optionally, at least 3, 4, 5, or 6 agents) therapeutic agents selected from at least two or three of the following:(i) an immune checkpoint inhibitor;(ii) a chemokine;(iii) a cytokine;(iv) a co-stimulatory ligand (optionally, a TNFSF protein or a variant thereof or a TNFRSF agonist);(v) a TGF-P trap; and(vi) a tumor antigen release or tumor lysis agent;wherein the at least one of the therapeutic agents is expressed under the control of an immediate promoter and at least one of the therapeutic agents is expressed under the control of a delayed promoter; and / orwherein at least one of the therapeutic agents is a fusion protein comprising two or more therapeutic proteins, optionally, each separated by a proteolytic cleavage site; and / or wherein at least one, at least two, at least three, at least four, at least five, at least six, or all of the therapeutic agents are secreted from the tumor upon expression in the tumor; optionally wherein at least one, at least two, at least three, at least four, at least five, at least six, or all of the therapeutic agents comprise a non-native secretory signal peptide; and optionally wherein at least one therapeutic agent is secreted, membrane-bound, cell-associated, intracellular, tumor-retained, protease- activated, or any combination thereof.
147. A method of treating cancer, inhibiting tumor growth, inhibiting one or more symptoms of cancer, inducing tumor antigen release, or preventing recurrence or progression of cancer in a subject in need thereof, comprising intratumorally administering to a subject (e.g., a human) an effective amount of a gene therapy, wherein the gene therapy comprises one or more vectors, wherein at least one of the one or more vectors is a polycistronic vector or a vector comprising a polycistronic cassette, wherein the one or more vectors encode at least 2, 3, 4, 5, 6, or 7488FH30035011.1Attorney Docket No: FTE-00125(optionally, at least 3, 4, 5, or 6 agents) therapeutic agents selected from at least two or three of the following:(i) an immune checkpoint inhibitor molecule, optionally wherein the immune checkpoint inhibitor molecule comprises an antibody antigen binding fragment or scFv that specifically binds to PD-1 or PD-L1, and further optionally wherein the immune checkpoint inhibitor molecule is a fusion protein comprising an immune checkpoint inhibitor fused to a TNFSF protein or a variant thereof or a TNFRSF agonist;(ii) a TNFSF protein or a variant thereof or a TNFRSF agonist that optionally agonizes CD40, 0X40, 4- IBB, GITR, LIGHT, or CD27;(iii) a toxin, an antibody antigen binding fragment or an scFv that specifically binds to a tumor antigen fused to an IgG Fc domain or a variant thereof, a fusion protein comprising an antibody antigen binding fragment or an scFv that specifically binds to a tumor antigen fused to an antigen binding fragment or an scFv that specifically binds to CD3, a transmembrane IgG, or another agent mediating tumor lysis;(iv) an antibody antigen binding fragment or an scFv that specifically binds to CTLA4 fused to an IgG Fc domain or a variant thereof, or a fusion protein comprising an antigen binding fragment or an scFv that specifically binds to CTLA4 fused to a TGF-beta trap protein;(v) a TGF-beta trapping domain, optionally a fusion protein comprising the TGF- beta trapping domain fused to a TNFSF protein or a variant thereof or a TNFRSF agonist;(vi) an IL 12 or a variant thereof, optionally a single chain fusion protein comprising alpha chain of IL 12 fused to a truncated variant of beta chain of IL 12, further optionally comprising a fusion protein comprising an IL 12 or a variant thereof fused to a CXCR3 agonist chemokine, optionally wherein the CXCR3 agonist chemokine is CXCL9, CXCL10 or CXCL11;(vii) a CXCR3 agonist chemokine, optionally wherein the CXCR3 agonist chemokine is CXCL9, CXCL10 or CXCL11;489FH30035011.1Attorney Docket No: FTE-00125(viii) at least one of an FLT3 ligand and / or an XCL1 protein, optionally a fusion protein comprising FLT3 ligand fused to XCL1 protein, or a fusion protein comprising at least one of an FLT3 ligand and an XCL1 protein fused to IFN- gamma or TGF-beta trap protein; and(ix) a cytokine selected from IL 15 or a variant thereof, IL21, IL7, and IL 18, optionally a fusion protein comprising the cytokine fused to a TNFSF protein or a variant thereof or a TNFRSF agonist;wherein the at least one of the therapeutic agents is expressed under the control of an immediate promoter and at least one of the therapeutic agents is expressed under the control of a delayed promoter; and / orwherein at least one of the therapeutic agents is a fusion protein comprising two or more therapeutic proteins, optionally, each separated by a proteolytic cleavage site; and / or wherein at least one, at least two, at least three, at least four, at least five, at least six, or all of the therapeutic agents are secreted from the tumor upon expression in the tumor; optionally wherein at least one, at least two, at least three, at least four, at least five, at least six, or all of the therapeutic agents comprise a non-native secretory signal peptide; and optionally wherein at least one therapeutic agent is secreted, membrane-bound, cell-associated, intracellular, tumor-retained, protease- activated, or any combination thereof.
148. A method of treating cancer, inhibiting tumor growth, inhibiting one or more symptoms of cancer, inducing tumor antigen release, or preventing recurrence or progression of cancer in a subject (e.g., a human) in need thereof, comprising intratumorally administering to a subject an effective amount of a gene therapy, wherein the gene therapy comprises one or more vectors, wherein at least one of the one or more vectors is a polycistronic vector or a vector comprising a polycistronic cassette, wherein the one or more vectors encode at least 2, 3, 4, 5, 6, or 7 (optionally, at least 3, 4, 5, or 6 agents) therapeutic agents selected from at least two or three of the following:(i) an immune checkpoint blocker agent;(ii) an agent facilitating antigen release and / or tumor lysis;(iii) an agent facilitating recruitment of dendritic cells;(iv) an agent facilitating recruitment of T cells and / or NK cells;490FH30035011.1Attorney Docket No: FTE-00125(v) an agent facilitating expansion and / or activation of antigen-presenting cells;(vi) an agent facilitating expansion, activation, survival, and / or anti-exhaustion signaling of T cells and / or NK cells;(vii) an agent facilitating co-stimulatory receptor agonism;(viii) an agent facilitating depletion and / or functional attenuation of regulatory T cells;(ix) an agent facilitating neutralization of TGF-P and / or reversal of stromal immune exclusion; and(x) an agent facilitating induction of tertiary lymphoid structures and / or high endothelial venules;wherein the at least one of the therapeutic agents is expressed under the control of an immediate promoter and at least one of the therapeutic agents is expressed under the control of a delayed promoter; and / orwherein at least one of the therapeutic agents is a fusion protein comprising two or more therapeutic proteins, optionally, each separated by a proteolytic cleavage site; and / or wherein at least one, at least two, at least three, at least four, at least five, at least six, or all of the therapeutic agents are secreted from the tumor upon expression in the tumor; optionally wherein at least one, at least two, at least three, at least four, at least five, at least six, or all of the therapeutic agents comprise a non-native secretory signal peptide; and optionally wherein at least one therapeutic agent is secreted, membrane-bound, cell-associated, intracellular, tumor-retained, protease- activated, or any combination thereof.491FH30035011.1
